CURRICULUM VITAE

**MATTHEW RYAN WEIR, M.D.**

Professor and Director

Division of Nephrology

University of Maryland School of Medicine

**Date** October 6, 2016



### Contact Information

Matthew R. Weir, M.D.

Professor and Director

Division of Nephrology

University of Maryland Medical Center

22 S. Greene Street, Room N3W143

Baltimore, Maryland 21201

Phone: 410.328.5720

Fax: 410.328.5685

Email: [mweir@medicine.umaryland.edu](mailto:mweir@medicine.umaryland.edu)

**Education**

1974 B.A. University of Virginia

Charlottesville, Virginia

1978 M.D. University of Virginia

Charlottesville, Virginia

**Internship**

1978-1979 The Waterbury Hospital and Yale-New Haven Hospital

Yale University School of Medicine

New Haven, CT

**Residency**

1979-1980 Junior Assistant Resident in Medicine, The Waterbury Hospital and Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT

1980-1981 Senior Assistant Resident in Medicine, The Waterbury Hospital and Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT

**Research Fellowships:**

1981-1982 Clinical Nephrology Fellow, Harvard Medical School and The Brigham and Women's Hospital, Boston, MA

1982-1983 Laboratory of Immunogenetics and Transplantation, Renal Division, Harvard Medical School and The Brigham and Women's Hospital, Boston, MA

**POSTGRADUATE CLINICAL EXPERIENCE**

1981-1983 General Practice Clinic

The Brigham and Women's Hospital

Boston MA

1981-1983 Medical Consultant

Parker Hill Hospital

Boston, MA

1981-1983 Medical Consultant, Intensive Care Unit

Marlborough Hospital

Marlborough, MA

1983-Present Attending Physician

University of Maryland Hospital,

Baltimore, MD

# LICENSURE AND CERTIFICATION

1979 Diplomate of the National Board of Medical Examiners

1980 Connecticut License Registration

1981 Massachusetts License Registration

1981 Diplomate of the American Board of Internal Medicine

1983 Maryland License Registration (#D29710)

1984 Diplomate of the American Board of Internal Medicine for the Subspecialty of Nephrology

**MAJOR RESEARCH INTERESTS**

▪ Immunobiology of tolerance in allograft transplantation

▪ Hypertensive nephropathy in blacks

▪ Hypertension - Impact of antihypertensive agents on renal hemodynamics, end-organ protection, and modulation of renal-adrenal responses

▪ The influence of dietary sodium on insulin sensitivity, blood pressure, renal hemodynamics and proteinuria in

hypertensive patients

▪ Mechanisms and treatment of allograft nephropathy

▪ Cardiovascular disease associated with chronic kidney disease

**FACULTY POSITIONS**

1983-1989 Assistant Professor of Medicine

University of Maryland School of Medicine

Baltimore, MD

1989-1994 Associate Professor of Medicine

University of Maryland School of Medicine

Baltimore, MD

1994-Present Professor of Medicine

University of Maryland School of Medicine

Baltimore, MD

1994-Present Director, Division of Nephrology

University of Maryland School of Medicine

Baltimore, MD

**MAJOR ACADEMIC TASKS**

1983-1990 Medical Director, Transplantation Service

University of Maryland Hospital

Baltimore, MD

1983-1990 Medical Director, Transplantation Clinic

University of Maryland Hospital

Baltimore, MD

1986-Present Task Force on Hypertensive Emergencies

University of Maryland Hospital

Baltimore, MD

1988-Present Medical Director, Clinical Research Unit

University of Maryland Hospital

Baltimore, MD

1990-Present Director, Nephrology Fellowship Training Program

University of Maryland Hospital

Baltimore, MD

1991-Present Associate Director, Organ Transplantation Services

University of Maryland Hospital

Baltimore, MD

**PROFESSIONAL MEMBERSHIPS**

1980 Member, American College of Physicians

1982 Member, International Society of Nephrology

1983 Member, American Federation of Clinical Research

1984 Member, American Society of Nephrology

1984 Member, Baltimore City Medical Society

1984 Member, Medical & Chirurgical Faculty of Maryland

1985 Member, The Transplantation Society

1986 Member, American Society of Transplant Physicians

1986 Member, National Kidney Foundation

1986 Member, Renal Physicians Association

1987-88 Co-Director, Program Committee of the Third International

Interscience Conference on Hypertension in Blacks.

1988 Member, American Society of Hypertension

1988 Fellow, American College of Physicians

1988-91 Member, Scientific Review Committee, American Society of Transplant Physicians

1991-Present Reviewer of Abstracts for American Society of Transplantation Meeting

1992,1995,1997-present Reviewer of Abstracts for American Society of Nephrology

1993-1997 Member, Kidney-Pancreas Committee, American Society of Transplant Physicians

1993-1996 Member, Program Committee, American Society of Transplant Physicians

1993-1996 Member, Scientific Advisory Board, United Network of Organ Sharing (UNOS)

1994-1998 Member, American Society of Hypertension CME Committee

1994-1998 Member, Physicians Manpower and Training Committee,

American Society of Transplant Physicians

1998-present Member, Editorial Board of American Journal of Kidney Diseases

2004-present Journal of Clinical Hypertension, Hypertension, Transplantation, and many others

2004-2008 Associate Editor, American Journal of Kidney Diseases

2004-present Section Editor Current Hypertension Reports

2004-present Section Editor, Current Opinion of Hypertension and Nephrology

2009-present Associate Editor, Clinical Nephrology

2010-present Associate Editor, American Journal of Nephrology

**HONORS, AWARDS**

1974 Phi Beta Kappa

1982 National Kidney Foundation Fellowship Award

1984 Traveling Fellowship Award, IX International Congress of Nephrology

1986 Traveling Fellowship Award, XI International Congress of the Transplantation Society

1987 Traveling Fellowship Award, X International Congress of Nephrology

1991 Volunteer Service Award, National Kidney Foundation

1994 Alpha Omega Alpha

1998 Distinguished Research Award, International Society of Hypertension in Blacks

**COMMITTEE AND SERVICE ACTIVITIES**

1983-1984 Housestaff Selection Committee

1983-1988 Member, Scientific Advisory Committee of Dr. John Warren's Program Project Entitled: "Complications of Long-Term Urinary Catheters in the Aged."

1986-present Housestaff Selection Committee

1984-1989 Department of Medicine Education Committee

1984-1986 Faculty Practice Offices Operations Committee

1984-1989 Task Force for Peer Review of Sophomore Pathology Medical School

1984,1985,1993 Judge, Medical School Research Day

1988-Present Student Appeals Committee

1985-1989 Clinical Years Curriculum Committee, Advisor for Senior Medical Students

1985-1989 Member, Baltimore Physicians for Social Responsibility

1986-present Chairman, Fund-Raising/Committee, National Kidney Foundation-Maryland

1986-present Department of Medicine Research Committee

1986-present Department of Medicine Benefits Committee

1987-present Board of Trustees, National Kidney Foundation - Maryland

1987-1990 Maryland Organ Procurement Center, Medical Advisory Board

1987-present Medical Advisory Board, National Kidney Foundation of Maryland

1987-present Reviewer of manuscripts for: Transplantation, American Journal of Kidney Diseases, Chest, New York State, Journal of Medicine, American Journal of Hypertension, Journal of Human Hypertension, Life Sciences, Journal of the American Society of Nephrology, Archives of Internal Medicine, American Journal of Cardiology, Kidney International, Hypertension

1988-1990 Board of Directors, Maryland Organ Procurement Center

1991-present Medical Advisory Board, Transplant Resource Center

1992- Member, Selection and Program Committee, Short-Term Research Training Program for Minority Undergraduate Students

1992- Preceptor, Short-Term Research Training Program for Minority Undergraduate Students

1993- Preceptor, Short-Term Research Training Program for Medical Students

Maryland State Advisory Council on HBP and Related Cardiovascular Risk Factors

1996-2000 Cardiorenal Study Section, NHLBI, National Institutes of Health

1997-present NIDDK Special Grants Review Committee, National Institutes of Health, R21,R33

2002-present NIDDK Grants Review Committee for Organ Transplantation

2007-presnet Grant Review Committee, VA Merit Review, Nephrology

**TEACHING ACTIVITIES**

1983-present 4-6 months attending transplant service

1-2 months attending consultative service

1983-present 1-2 months attending medical service

1983-84, 1987-91 Sophomore physical diagnosis

1983-present Multiple didactic talks to medical housestaff, shock-trauma, second, third and fourth year medical students, pharmacology department, clinical chemistry department. Lecturer of sophomore medical school nephrology course.

1986-92 Preceptor, Medical Clerkship of third year Medical Students

**RESEARCH GRANTS AND AWARDS**

**Peer Review Grants**

1984 American Red Cross, $20,325. "Evaluation of HLA-typed apheresis byproducts as alloenhancing agents in prospective renal transplant recipients." Principal Investigator.

1984 Bressler Research Fund, $3,000. "Evaluation of HLA-typed apheresis byproducts as alloenhancing agents". Principal Investigator.

1985 American Red Cross, $20,325. "Evaluation of HLA-typed apheresis byproducts as alloenhancing in prospective renal transplant recipients." Principal Investigator.

1987 Designated Research Initiative Funds, State of Maryland, $8,500. "The role of calcium in lymphocyte activation and function." Principal Investigator.

1987 National Kidney Foundation of Maryland, $4,500. "Additive effects of calcium channel blockers and cyclosporine on lymphocyte function." Principal Investigator.

1988 National Kidney Foundation of Maryland, $2500. "Additive effects of calcium channel blockers and cyclosporine on lymphocyte activation and function. Principal Investigator

1989 National Kidney Foundation of Maryland, $2500. "Additive effects of calcium channel blockers, prostaglandin metabolites and cyclosporine on lymphocyte activation and function."

Principal Investigator.

1990 National Kidney Foundation of Maryland, $2500. "Additive effects of calcium channel blockers, prostaglandin metabolites and cyclosporine on lymphocyte activation and function."

Principal Investigator.

1991 National Kidney Foundation of Maryland, $2500. "Additive effects of calcium channel blockers, prostaglandin metabolites and cyclosporine on lymphocyte activation and function."

Principal Investigator.

1992 National Kidney Foundation of Maryland, $2500. "Effects of calcium channel blockers of potassium channel blockers on lymphocyte activation and function." Principal Investigator.

1994 American Heart Association Grant-In-Aid, $44,000. "Exercise, Insulin and Sodium in Black Hypertensives." Principal Investigator.

1994 SERCA Award, $418,652. "Insulin action, sodium and exercise in the hypertension of Aging."

Co-Investigator.

2001 NIDDK 1U01DK61022-01(NIH) – Appel (PI) $1,639,923 9/28/2001 – 8/31/2008

Johns Hopkins Medical Institutions, Chronic Renal Insufficiency Cohort Study, Site Co-Investigator

The main goal of this project is to identify risk for factors associated with accelerated loss of renal function in patients with chronic renal insufficiency and to identify risk factors for cardiovascular disease associated with this condition.

2002 NHLBI HL67031-01A(NIH) B. Howard (PI) $211,546 4/1/2002 – 3/31/2008

Medstar Research Institute, Stop Atherosclerosis in Natives Diabetes Study (SANDS). This project is an interventional trial with lower levels of blood pressure and LDL-cholesterol reduction in Native Americans with type II diabetes and microalbuminuria. Outcome is based on carotid intimal plaque thickening. Site Principal Investigator.

2002 NHLBI UO1HL72515(NIH) Shuldiner (PI) $197,547 9/30/2002 – 9/29/2006

University of Maryland School of Medicine, Genome-Wide Search for CVD Gene Environment Interaction. The major goal of this project is to identify genes that interact with the environment in shaping the risk of cardiovascular disease. Site Co-Investigator

2002 NIDDK UO1 DK61700-01(NIH) Bostom (PI) $140,000 2/12/2002 – 1/31/2007

Lifespan, Rhode Island Hospital, Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT), Site Principal Investigator.

2005 R01/DK066013 Kasiske (PI) $228,519 9/15/2005-5/31/2012

University of Minnesota, Live Unrelated Kidney Donor and Sibling Follow-up Study. To investigate

biomeasures of cardiovascular risk in kidney donors. Site Principal Investigator .

2007 NIDDK UO2 DK61700-06 (NIH) Bostom (PI) $535,175 2/1/2007 – 1/31/2012

Lifespan, Rhode Island Hospital, Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT), Site Principal Investigator.

2007 No project number (Wilson) $50,000 7/1/2007-6/30/2008

University of Maryland Statewide Health Network Other Tobacco Related Diseases Research

The major goal of this project is to understand the effects of smoking on the graft function and explore the success of effectiveness of the smoking cessation in these patients with multiple co-morbidities. Role: PI

2008 NIDDK R21 AG033791 Mullins(PI) $200,00 11/2008-10/2010

Response to Medicare Reimbursement Policy Change by Minority and all ESRD patients, with regard

to access to renal transplantation.

2010 0468E5-4544 Weir $3,152,993 1/1/2010 – 3/30/2014

Spare the Nephron (STN) Continuation of Yearly Follow-up for another three years (a total of five-year study period). The plan is to evaluate change in measured GFR over time.

Principal Investigator

2010 R01 PA07-070 Fink $1,025,000 7/1/2010 – 6/30/2015

Does under-recognition of kidney disease affect patient safety?

The major goal of this study is to test the hypothesis that patients with chronic kidney disease (CKD) have a high frequency of both general and disease-specific safety events that account for a significant proportion of their adverse outcomes. An intervention (*structural measure*) that increases the recognition of CKD will reduce the occurrence of disease-specific unsafe practices and errors (*process measures*), and in turn, reduce the incidence of disease-specific adverse events (*outcome measures*).

2010 100255 Weir $148,504 4/26/2010 – 5/25/2013

A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients. The major goal of this study is to better understand the evolution of HPT (Hyperparathyroidism) in people during the first 12 months after receiving a kidney transplant.

Principal Investigator

**RESEARCH GRANTS AND AWARDS**

**Industry**

1984 Marion Laboratories, $90,000. "Comparison study of Diltiazem vs Atenolol in the treatment of mild to moderate hypertension." Co-Investigator.

1984 Miles Laboratories, $8,000. "Pharmacokinetic study of the renal excretion of Ciprofloxacin in patients with impaired renal function." Co-Investigator.

1985 Upjohn Co., $32,400. "The effects of topical Minoxidil in untreated hypertensives." Co-Investigator.

1985 Ayerst Laboratories. $55,728. "Hydrochlorothiazide dose finding study with Inderal LA." Co-Investigator.

1985 Syntex Laboratories. $60,000. "Nicardipine vs Propranolol in Mild to Moderate Hypertension."

Co-Investigator.

1986 American Cyanamid, Lederle Laboratories. $63,365.76. "Safety and Dose-Finding study of Nilvadipine in Hypertension." Principal Investigator.

1986 Merck, Sharp & Dohme. $18,000. "Vasotec-therapy in Mild to Moderate Hypertension."

Co-Investigator.

1986 Miles Laboratories, $6,000. "Pharmacokinetic Study of the renal excretion of intravenous ciprofloxacin in patients with impaired renal function." Co-Investigator.

1986 Syntex Laboratories, $48,211.20. "Nicardipine vs Captopril for Hypertension in the Elderly."

Co-Investigator.

1986 Marion Laboratories, $77,544. "A comparative Study of Urapidil vs Placebo in Mild to Moderate Hypertension." Principal Investigator.

1986 Merck, Sharp & Dohme. $63,936. "Comparison of the antihypertensive efficacy and tolerability of Vasotec and Hydrochlorothiazide and their Effects on Serum Lipids in Patients with Mild Uncomplicated Essential Hypertension." Principal Investigator.

1986 CIBA-GEIGY, $72,000. "CGS 13080: Thromboxane Synthetase Inhibition Effect on Renal Function and Blood Pressure." Principal Investigator.

1987 E.R. Squibb & Sons, Co., $33,000. "Capozide vs Tenoretic in Mild to Moderate Hypertension."

Principal Investigator.

1987 Pfizer Pharmaceuticals, $58,980. "Oral Nifedipine vs IV Labetalol in Hypertensive Urgencies." Co-investigator.

1987 Abbott Laboratories, $39,366. "Terazosin vs Propranolol in Elderly Hypertensives. " Co-principal Investigator.

1987 Searle Laboratories, $48,000. "Calan vs Tenormin vs Capoten in Black Hypertensives."

Co-principal Investigator.

1987 Dupont Critical Care, $70,000. "IV Nicardipine in hypertensive urgencies." Co-investigator.

1987 American Cyanamid Company, $72,072.00. "Efficacy of Nilvadipine in Hypertension." Principal Investigator.

1987 Merck, Sharpe & Dohme, $100,200. "Vasotec vs. Verapamil SR in Hypertension." Principal Investigator.

1987 A.H. Robins, $133,200. "Bopindolol in black hypertensives." Co-Principal Investigator.

1987 Marion Laboratories, $38,400. "Diltiazem SR vs HCTZ in Hypertension." Principal Investigator.

1987 Searle Laboratories $24,000. Unrestricted Educational Grant.

1988 Searle Laboratories $40,000. Unrestricted Education Grant.

1988 E.R. Squibb & Sons, $46,476.00. "Effect of Zofenopril in Hypertension." Principal Investigator."

1988 Marion Laboratories, $72,560.00. "Effect of Antihypertensive Therapy on Quality of Life in Elderly Females." Principal Investigator.

1988 Marion Laboratories, $54,000.00. "Efficacy of Diltiazem/Captopril Combination in Hypertension."

Principal Investigator.

1988 Syntex Laboratories, $57,552.00. "Once Daily Dose of RS-10085 in Essential Hypertension." Co-Investigator.

1988 Syntex Laboratories, $66,009.00. "Comparison of Nicardipine and HCTZ in the Treatment of Hypertension in Blacks." Principal Investigator.

1988 Merck, Sharpe & Dohme, $122,000. "Lisinopril vs. verapamil SR in the treatment of older hypertensives."

Principal Investigator.

1988 Merck, Sharpe & Dohme, $40,000. "Lisinopril vs verapamil SR in the treatment of black hypertensives.” Principal Investigator.

1988 Sandoz Research Institute, $9,200. Educational Grant. Principal Investigator.

1988 Marion Laboratories, $52,416. "Dose evaluation of Diltiazem SR/HCTZ in combination vs single agents and placebo in the treatment of hypertension." Principal Investigator.

1989 Searle Laboratories, $85,536.00. "Open label study of cytotec in the prevention of NSAID-induced renal dysfunction in the elderly." Principal Investigator.

1989 1989 Marion Laboratories, $35,550.00. "Diltiazem QD dose response hypertension trial." Principal Investigator.

1989 1989 Sandoz Research Institute, $82,917.00. "A clinical study to determine the efficacy and safety of cyclosporine and its effect on renal function in patients with rheumatoid arthritis." Co-Investigator.

1989 1989 Hoffman-LaRoche, $61,200. "Efficacy of cilazapril and/or HCTZ in hypertension." Co-Principal Investigator.

1989 1989 Merck, Sharp & Dohme, $49,900. "Evaluation of Vaseretic in mild to moderate hypertension."

1989 Principal Investigator.

1989 1989 Merck, Sharp & Dohme, $79,200. "Vasotec vs Cardizem SR for treatment of hypertension."

1989 Principal Investigator.

1989 1989 Rorer Pharmaceuticals, $61,500. "Comparative study of Lozol as add-on therapy to Calan SR."

1989 Co-Principal Investigator.

1989 1989 Knoll Pharmaceuticals, Inc., $84,600. "The safety and efficacy of Trandolapril in black hypertensives." Principal Investigator.

1989 1989 CIBA-GEIGY, 61,296.00. "The safety and tolerability of CGS 12970 in renal allograft recipients."

1989 Principal Investigator.

1989 1989 American Cyanamid, $64,920. "Randomized double-blind comparative study of

1989 bisoprolol in combination with HCTZ." Principal Investigator.

1989 Burroughs Welcome Co., $190,000. Retrovir in the treatment of HIV-infected patients in renal failure."

Co-Investigator.

1989 Parke-Davis, $204,000. "Evaluation of once vs twice daily dosing of Quinapril on renal function in patients with congestive heart failure." Co-Principal Investigator.

1990 Marion Laboratories, Inc. $68,500. "Dose response characteristics to TA-3090 in hypertensives." Principal Investigator.

1990 Glaxo, Inc. $104,300. "Isradipine vs HCTZ in the regression of left ventricular hypertrophy." Co-Principal Investigator.

1990 Glaxo, Inc. $156,000. "Impact of salt sensitivity on the effects of isradipine on blood pressure and renal hemodynamics. Principal Investigator.

1990 ICI Pharma. $31,200. "Lisinopril vs diltiazem SR in the treatment of moderate to severe hypertension." Principal Investigator.

1990 Bristol Myers Squibb, Inc. $68,900. "A comparison of fosinopril and verapamil SR on blood pressure and protein excretion in hypertensive patients with Type II diabetes mellitus." Principal Investigator.

1990 Knoll Pharmaceuticals, $58,000. "Open-label study of the long-term safety of oral trandolapril therapy in patients with mild to moderate essential hypertension." Principal Investigator.

1990 Roerig, $203,100. "A multicenter evaluation of the efficacy and side effect profile of doxazosin vs enalapril as initial antihypertensive therapy in patients with mild-to-moderate primary hypertension.” Principal Investigator.

1990 Hoffman-LaRoche, $32,100. "Multicenter, placebo controlled study evaluating the antihypertensive effect and safety of the cilazapril/hydrochlorothiazide combination. Principal Investigator.

1990 Knoll Pharmaceuticals, $60,500. "Double-blind, randomized, placebo-

controlled, factorial study to evaluate the safety and efficacy of oral trandolapril combination with verapamil." Principal Investigator.

1990 Merck, Sharpe & Dohme, $201,600. "Comparison of the efficacy and tolerability of lisinopril and extended-release nifedipine in mild to moderate uncomplicated essential hypertension."

Principal Investigator

1991 Lederle Laboratories, $26,200. "Isolated systolic hypertension in the elderly: a randomized, double- blind, placebo controlled trial of once-a-day Verelan verapamil 120 mg and 240 mg capsules in the treatment of isolated systolic hypertension in patients age 60 years and older." Principal Investigator

1991 ICI Pharma, $62,300. "Controlled clinical trial comparing Zestoretic 10-12.5 and Zestoretic 10-25 (lisinopril/hydrochlorothiazide) to each of the monocomponents and placebo in the treatment of mild to moderate essential hypertension." Principal Investigator.

1991 Knoll Pharmaceuticals, $55,200. "Open-label study of the long-term safety of oral trandolapril in combination with verapamil." Principal Investigator.

1991 Knoll Pharmaceuticals, $59,600. "Double-blind, randomized, placebo-controlled, five-way parallel dose-ranging study to evaluate the safety and efficacy of oral trandolapril therapy (4,8,12,16 mg/day) in black patients with mild to moderate essential hypertension." Principal Investigator.

1991 Knoll Pharmaceuticals, $56,700. "Evaluation of the safety and efficacy of oral trandolapril in

combination with verapamil (Isoptin SR) in patients with severe essential hypertension.

Principal Investigator.

1991 Marion Merrell Dow, $19,200. "Assessment of the safety and efficacy of diltiazem QD in patients whose hypertension is controlled by Cardizem SR. Principal Investigator.

1991 CIBA-GEIGY, $50,600. "A randomized, double-blind, placebo controlled, parallel-group comparison of monotherapy and combined therapy of benazepril 5 mg once daily and amlodipine 2.5 mg once daily for the treatment of patients with essential hypertension. Co-Principal Investigator.

1992 Merck, Sharp & Dohme, $12,000. "Efficacy and tolerability of extended release felodipine in adult patients with mild to moderate uncomplicated hypertension." Principal Investigator.

1992 CIBA Geigy, $47,712. "A randomized, double-blind, placebo controlled, parallel-group comparison of monotherapy and combined therapy of benazepril 20 mg once daily and amlodipine 5 mg once daily in black patients with essential hypertension." Co-Principal Investigator.

1992 Warner Lambert Company, $167,100. "The safety and efficacy of once daily quinapril for the treatment of mild, uncomplicated hypertension. Principal Investigator."

1992 R.W. Johnson Pharmaceutical Research Institute, $57,400. "A phase II double-blind titration comparison of perindopril erbumine and enalapril maleate in patients with mild to moderate hypertension." Principal Investigator.

1992 Merck, Sharpe Dohme, $12,000. "Efficacy and tolerability of simvastatin in the treatment of primary hypercholesterolemia." Principal Investigator

1992 Marion Merrell Dow, $22,700. "A comparative trial of the safety and efficacy of Cardizem CD and felodipine in elderly hypertensive patients." Principal Investigator.

1992 Hoechst-Roussel Pharmaceuticals, Inc. $135,000. "The impact of ramipril and nifedipine gits and high and low sodium intake on blood pressure, proteinuria, and renal hemodynamics in black hypertensives with renal dysfunction." Principal Investigator.

1992 Wyeth-Ayerst Laboratories, $42,000. "A multicenter, randomized, double-blind, placebo-controlled study to determine the effect of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with mild to moderate hypertension controlled by verelan." Principal Investigator.

1992 Hoffman-LaRoche, Inc, $33,912. "A comparison of RO 40-5967 versus Diltiazem CD and placebo for the treatment of essential hypertension.” Principal Investigator

1992 Bristol Myers Squibb U.S. Pharmaceutical Division, $25,416. "A double- blind, randomized trial comparing once daily combination Captopril plus Hydrochlorothiazide versus Nifedipine GITS in black patients with mild-to-moderate essential hypertension." Co-Investigator.

1993 Sandoz Pharmaceuticals Corporation, $20,300. "Impact of Isradipine and sodium intake on blood pressure proteinuria and renal hemodynamics in hypertensive renal transplant patients." Principal Investigator

1993 Parke-Davis, $16,800. Impact of Quinapril and high and low sodium intake on blood pressure, proteinuria, and renal hemodynamics in hypertensive renal transplant recipients." Principal Investigator

1993 Merck & Co., Inc, $21,200. "A multicenter, prospective, double-blind, randomized, parallel, comparison study of the quality of life and the efficacy and tolerability of 40 mg of Lovastatin versus 40 mg Pravastatin in male patients with primary hypercholesterolemia (types IIa and IIb)." Principal Investigator.

1993 Merck & Co., $24,000. "A multicountry, double-blind study to evaluate the quality of life of

hypercholesterolemic patients treated with simvastatin or pravastatin." Principal Investigator.

1993 Advanced Metabolic Systems, $193,136. "Anti-nephropathic effects of chronic intermittent intravenous insulin therapy in type I diabetics." Principal Investigator.

1993 Sandoz Pharmaceuticals, $92,280. "Dietary salt and blood pressure control with isradipine or enalapril." Principal Investigator.

1993 Lederle Laboratories, $58,320. "Efficacy and safety of verelan vs cardizem in hypertension."

Principal Investigator.

1993 Bristol-Myers Squibb, $46,368. "A multicenter 8-week study of the antihypertensive activity and safety of BMS-186295/SR 47436 in mild to moderate hypertensives. Principal Investigator.

1993 Sankyo U.S.A. Corporation, $36,800. Efficacy and safety of temocapril alone and in combination with hydrochlorothiazide. Principal Investigator.

1993 Hoffmann LaRoche, Inc., #76,800. "Long term safety and efficacy of Ro-40-5967 in hypertension. Principal Investigator.

1993 Marion Merrell Dow Inc., $22,410. "A comparative trial of the safety and efficacy of cardizem CD and amlodipine in older patients." Principal Investigator.

1993 Knoll Pharmaceuticals, $108,432. "Antihypertensive/antiproteinuric effects of verapamil and trandolapril." Principal Investigator.

1993 Bristol-Myers Squibb, $75,408. "A multicenter 8-week study of the antihypertensive activity and safety of BMS-186295 in mild to moderate hypertension." Principal Investigator.

1994 Bristol-Myers Squibb, $45,548. "Dose-ranging study II: A multicenter trial of the antihypertensive activity and safety of 100, 200, and 300 mg SR 47436 (BMS-186295) in mild-to-moderate hypertension." Principal Investigator.

1994 Marion Merrell Dow Inc., $57,960. "Diltiazem ER/Enalapril combination therapy in hypertensive patients not responding adequately to diltiazem CD (Cardizem CD) monotherapy." Principal Investigator.

1994 ZENECA, $35,616. "A placebo-controlled study assessing the treatment effects of lisinopril versus hydrochlorothiazide (HCTZ) in obese patients with hypertension - Trophy 1262US/0004." Principal Investigator

1994 Wyeth-Ayerst, $56,640. "A randomized, double-blind, placebo-controlled, multicenter, dose titration trial of ANA-756 in patients with essential hypertension." Principal Investigator

1994 CIBA-GEIGY, $47,910. "Randomized, double-blind, placebo-controlled, parallel-group trial comparing valsartan 20 mg, 80 mg, 160 mg, and 320 mg to placebo in patients with essential hypertension followed by an open-label extension of 52 weeks duration." Principal Investigator.

1994 Parke-Davis, $47,140. "A double-blind, randomized, comparative study to examine the single agent efficacy and tolerability of Accupril (quinapril), versus placebo for the treatment of mild to moderate hypertension in black and white subjects. (Protocol 906-379). Accupril in minorities (AIM) project." Co-Investigator.

1995 Bristol-Meyers Squibb/Medex, $55,200. "Metformin hydrochloride vs. placebo in non-insulin dependent diabetics." Co-Investigator

1995 Merck, $13,980. "COZAAR and HYZAAR vs. Procardia XL in patients with hypertension." Principal Investigator.

1995 Merck, 11,050. "COZAAR and HYZAAR vs. Procardia XL in elderly patients with hypertension." Principal Investigator.

1995 Lederle/Medex,$40,320. "Verelan vs Norvasc in Women with Hypertension." Principal Investigator.

1995 Wyeth-Ayerst, $75,650. "A randomized, double-blind, placebo-controlled, multicenter, dose titration trial of ANA-756 in patients with essential hypertension." Principal Investigator.

1995 Bristol-Myers Squibb, $14,730. Antihypertensive activity and Safety of Irbesartan in patients with hypertension. Principal Investigator.

1995 Medex, $16.667. Multicenter Trial of HCTZ (12.5mg). Principal Investigator.

1995 Bristol-Myers Squibb, $83,333. Phase II study of the treatment of Acute Renal Graft Rejection. Principal Investigator.

1995 Wyeth Ayerst, Direct $114,812/Indirect $28,628. ANA‑756 (304) vs Atenolol in Hypertensives. Principal Investigator

1995 Merck & Co, Direct $15,401/Indirect $3,715. Simvastatin and Fluvastatin(Zocor). Principal Investigator.

1995 Merck & Co, Direct $6,200/Indirect $1,550. Losartan effectiveness and tolerability (LET). Principal Investigator.

1995 Bristol-Myers Squibb, Direct $28,280/Indirect $7,070. Irbesartan in Hypertensives-050. Principal Investigator.

1996 Bristol-Myers Squibb, Direct $28,750/Indirect $5,750.Dual Metalloprotease Inhibitor, BMS‑186716. Principal Investigator.

1996 Forest Laboratories, Inc. Direct $27,083/Indirect $5,167. Calcium Channel Blockers in reducing Proteinuria. Principal Investigator.

1996 Merck & Co, Direct $33,178/ Indirect $8,294. Losartan Intervention for Endpoint Reduction (LIFE). Principal Investigator.

1996 Bristol-Myers Squibb, Direct $57,760/ Indirect $14,440. Irbesartan in Type II Diabetics with Nephropathy. Principal Investigator.

1996 Merck & Co, Direct $71,250/Indirect $14,250. Losartan in patients with Diabetes Mellitus.

Principal Investigator.

1996 Bristol-Myers Squibb, Direct $43,639/ Indirect $10,909. Irbesartan in Mild to Moderate

Hypertensives. Principal Investigator.

1996 Astra Merck, Direct $55,373 Indirect $13,843. Fixed Combination of Candesartan and HCTZ. Principal Investigator.

1996 Bristol-Myers Squibb, Direct $29,167 Indirect $5,833. Multicenter, randomized, forced titration trial antihypertensive efficacy and safety Irbesartan compared with losartan for treatment of mild to moderate hypertensives-088. Principal Investigator.

1996 Merck & Co, Direct $45,625 Indirect $9,125. Study of the effects of the non-steroidal anti-inflammatory drug indomethacin on the anti-hypertensive response to losartan versus captopril in essential hypertension. Principal Investigator.

1996 Searle, Direct $24,000 Indirect $6,000. Revised clinical protocol for controlled onset verapamil investigation of cardiovascular endpoints. Principal Investigator.

1996 Merck & Co, Direct $51,067 Indirect $10,213. African-American ECHO substudy for LIIFE. Principal Investigator.

1997 Roche, Direct $181,940 Indirect $36,388. Cooperative Clinical Trials in Adult Transplantation (CCTAT) Hoffman LaRoche steroid sparing trial. Principal Investigator.

1997 Roche, Direct $150,000 Indirect $30,000. MMF rescue therapy in chronic rejection. Principal Investigator.

1997 Merck & Co, Direct $29,167 Indirect $5,833. The influence of losartan and enalapril on blood pressure and proteinuria in hypertensives with normal renal function. Principal Investigator.

1997 Merck & Co, Direct $29,167 Indirect $5,833. The influence of dietary salt and losartan therapy on blood pressure and proteinuria in hypertensives with normal renal function. Principal Investigator.

1997 Novartis, Direct $14,350 Indirect $2,870. A randomized, double blind, placebo-controlled, forced-titration parallel safety efficacy of Lotrel 5/20 mg to Lotrel 10/20 mg once daily in patients with hypertension. Co-principal Investigator.

1997 ISHIB/Bayer, Direct $33,340 Indirect $6,660. Calcium antagonists in Blacks. Co-principal Investigator.

1997 Hoffman-La Roche, Direct $86,792 Indirect $17,358. Immunosuppression Withdrawal in Stable Renal Allograft Recipients Treated with Triple Therapy. Principal Investigator.

1997 Covance, Direct $45,500 Indirect $9,100. Placebo Controlled Study of Moxonidine in Stage 1 and Stage 2 Hypertension. Co-principal Investigator.

1997 Novartis, Direct $117,000 Indirect $23,400. Comparative Effects of Diuretics and Ace Inhibitors to Alleviate Ankle Edema Due to Calcium Antagonist. Principal Investigator.

1997 Novartis, Direct $106,425 Indirect $21,285. The influence of dietary salt and valsartan therapy on blood pressure and proteinuria in hypertensive African Americans. Principal Investigator.

1998 Astra Merck, Direct $55,090 Indirect $11,018. The ABC Study of Hypertension: Protocol 140."

Co-principal Investigator.

1998 Smith Kline Beecham, Direct $31,967 Indirect $6,393. A Double Blind Efficacy and Safety Study of Baycol (cerivastatin) & Pravacol (pravastatin) in treatment of hypercholesterolemia. Co-principal Investigator.

1998 Merck & Co., Direct $31,302 Indirect $6,260. Losartan in African American Patients with Mild-to-Moderate Hypertension. Co-principal Investigator.

1998 Novartis, Direct $65,494 Indirect $13,099. VALUE (Diovan Antihypertensive Long-term Use Evaluation). Co-principal Investigator.

1998 Covance, Direct $36,000 Indirect $7,200. Open Label Study of Neoral as Primary Immunosuppressant Therapy in Transplant Patients Who are Unable to Maintain Immunosuppression. Co-principal Investigator.

1998 Merck & Co., Direct $11667 Indirect $2,333. A Triple-Blind, Randomized, Parallel, Efficacy Study of Losartan Versus Irbesartan in Patients With Mild to Moderate Essential Hyperten. Coz442. Principal Investigator.

1998 Smith Kline Beecham, Direct $71,250 Indirect $14,250. Forced Titration Study of Teveten (Eprosartan mesylate; SK&F 108566-J) at Doses of 600 mg and 1200 mg Once Daily in African Americans. Principal Investigator.

1998 Bristol-Myers Squibb, Direct $29,167 Indirect $5,833. A Study of the antiproteinuric Effects of Omapatrilat and Amlodipine in Type II Diabetic with Hypertension and Microalbuminuria. Principal Investigator.

1999 Merck-Sharpe and Dohme, Direct $26,220. Losartan and enalapril alone in combination on blood pressure and proteinuria in hypertensive-normal renal function. Principal Investigator.

1999 Fujisawa Healthcare, Direct $100,000. Prograf as secondary intervention in chronic allograft nephropathy. Prinicipal Investigator.

1999 Hoechst Marion Roussel, Direct$23,760. Dose response with intravenous HMR396 in Anemic Patients. Principal Investigator.

1999 Astra Pharmaceuticals Products, $94,500. A comparison of angiotensin receptor blockade vs calcium channel blockade on allograft nephropathy. Principal Investigator.

1999 Novartis. Tolerability of ERL080A.

2000 Fujisawa, 100,000 Direct, 20,000 Indirect. Prograf vs cyclosporine in patients with renal failure. Principal Investigator

2000 Hoffmann-LaRoche Company, 129,167 Direct, 25,8333 Indirect. Treatment for chronic allograft nephropathy. Principal Investigator

2000 Hoffmann-LaRoche Company, 86,500 Direct, 17,300 Indirect. Immunosuppression in renal allograft triple therapy. Principal Investigator

2000 Merck, Sharp and Dohme, 10.662 Direct, 2,133 Indirect. Losartan intervention for endpoint reduction in hypertension. Principal Investigator

2000 Merck, Sharp and Dohme, 9,510 Direct, 1,902 Indirect. Losartan in patients with non-insulin dependent diabetes.

2001 Biovail Laboratories. Diltiazem HCL Extended Release Capsules.

2001 Novartis. Enalapril in Treatment of Hypertension in Type 2 Diabetics.

2001 Novartis Pharmaceuticals, University of Maryland School of Medicine, The National Living Renal Transplant Registry, Co-Medical Director. 7/1/2001 – 6/30/2003. The major goal of this project is to conduct a multi-center Web-based registry to track the longitudinal outcome of living renal transplant recipients who are treated with or without basiliximab (Simulect).

1996-2000 Bristol-Myers Squibb, IDNT Study

1996-2000 Merck Sharp & Dohme, RENAAL Study

1996-2001 Novartis Pharmaceuticals VALUE Study

1996-2000 Merck Sharp & Dohme, LIFE Study

2006-2009 Roche Pharmaceuticals, STN Trial

**PUBLICATIONS - (REFEREED)**

1. Kirkman RL, Strom TB, Weir MR, Tilney NL. Late mortality and morbidity in recipients of long-term renal allografts. Transplantation 1982;34:347-351.
2. Weir MR, Thornton GF. Extrapulmonary tuberculosis. Experience of a community hospital and review of the literature. American Journal of Medicine 1985;79:467-478.
3. Weir MR, Kirkman RL, Strom, TB, Tilney NL. Liver disease in recipients of long-functioning renal allografts. Kidney International 1985;28:839-844.
4. Shen SY, Weir MR, Kosenko A, Revie DR, Ordonez JV, Dagher FJ, Chretien P, Sadler JH. Reevaluation of T cell subset monitoring in cyclosporine-treated renal allograft recipients. Transplantation 1985;40:620-623.
5. Shen SY, Weir MR, Litkowski LJ, Anthony RL, Welik RA, Kosenko A, Light PD, Dagher FJ, Sadler JH. Enzyme- linked immunosorbent assay for serum renal tubular antigen in kidney transplant patients. Transplantation 1985;40:642-647.
6. Weir MR. Kirkman RL, Strom TB. Long-term effects of hepatitis B virus in renal transplant recipients: analysis of morbidity and mortality. Transplant Proc 1985;XVII:163-164.
7. Weir MR, Hall-Craggs M, Shen SY, Posner JN, Alongi SV, Dagher FJ, Sadler JH. The prognostic value of the eosinophil in acute renal allograft rejection. Transplantation 1986;41:709-712.
8. Weir MR, Irwin BC, Maters AW, Genemans G, Shen SY, Charache P, Williams GM. Incidence of cytomegalovirus disease in cyclosporine-treated renal transplant recipients based on donor/recipient pretransplant immunity. Transplantation 1987;43:187-193.
9. Josselson J, Kyser BA, Weir MR, Sadler JH. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. AJKD 1987;9:456-461.
10. Drusano GL, Weir MR, Forrest A, Plaisance K, Emm T, Standiford HC. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrobial Agents and Chemotherapy 1987; 31:860-864.
11. Shen SY, Weir MR, Revie DR, Dagher FJ, Bentley FR, Chretien PB, Sadler JH. Differentiation of acute rejection from acute cyclosporine nephrotoxicity in renal transplants peripheral T cell subset counts. Transplant Proc 1987; 19:1776-1779.
12. Weir MR, Josselson J, Giard MJ, Warren JB, Posner JN, Lam YWF, Zaske DE, Saunders E. Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension. American Journal of Cardiology 1987; 60:36I-41I.
13. Weir MR, Shen SY, Dagher FJ, Bentley FR, Lesko L, Sadler JH. Evaluation of the effects of cyclosporine and HLA-typed source leukocyte transfusions (apheresis by-products) on the immune systems of highly sensitized prospective renal allograft recipients. Transplant Proc 1987;19(1):735-737.
14. Shen SY, Zemel SM, Weir MR, Dagher FJ, Bentley FR. Conversion of cyclosporine to azathioprine in renal transplant patients. Transplant Proc 1987;19:2032-2036.
15. Zemel SM, Shen SY, Weir MR, Dagher FJ, Bentley FR. Effects of HLA matching and panel reactive antibodies in the development of rejection after conversion of cyclosporine to azathioprine. Transplant Proc 1987; 19:2029-2031.
16. Weir MR, Irwin BC, Maters AW, Genemans G, Shen SY, Charache P, Williams GM. Morbid outcome of cytomegalovirus-negative transplant recipients receiving cytomegalovirus-positive kidneys. Transplant Proc 1987; 19:2137-2141.
17. Plaisance K, Drusano G, Forrest A, Weir M, Standiford H. The effect of renal function on the bioavailability of ciprofloxacin. Clin Pharmacol Ther 1987; 41:195-200.
18. Weir MR, Henry ML, Blackmore M, et al. Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor-specific transfusion and living-related donor transplantation. A multi-center evaluation. Transplantation 1988;45:111-116.
19. Weir MR, Saunders E. Pharmacologic management of systemic hypertension in blacks. American Journal of Cardiology 1988; 61:46H-52H.
20. Weir MR, Sowers JR. Physiologic and hemodynamic considerations in blood pressure control while maintaining organ perfusion. American Journal of Cardiology 1988; 61:60H-66H.
21. Forrest A, Weir MR, Plaisance KI, Drusano GL, Leslie J, Standiford HC. Relationships between renal function and disposition of oral ciprofloxacin. Antimicrobial Agents and Chemotherapy 1988; 32:1537-1540.
22. Weir MR, Salomon DR, Cohen DJ, Carpenter CB. Lack of secondary suppressor response in enhanced allografted rats with endogenous suppressor activity in spleen and diminished cytotoxic T cell response. Transplantation 1988;46:731-739.
23. Weir MR, Shen SY, Dagher FJ, Bentley FR, Lesko LJ, Sadler JH. Effects of allostimulation and cyclosporine therapy on cytotoxic antibody production in highly sensitized prospective renal transplant recipients. Transplantation 1988;46:591-594.
24. Weir MR, Josselson J. Prevention of end-stage renal disease: a focus of antihypertensive therapy. Maryland Medical Journal 1988; 37:369-372.
25. Weir MR, Peppler R, Gomolka D, Handwerger BS. Additive effect of cyclosporine and verapamil on the inhibition of activation and function of human peripheral blood mononuclear cells. Transplant Proc 1988; 20(Suppl 2):240-244.
26. Weir MR, Krichten C, Urick A, Saunders E, Lavin PT. Comparison of enalapril and hydrochlorothiazide in mild hypertension and changes in plasma lipid concentrations during therapy. Clinical Therapeutics 1988; 10:712-724.
27. Weir MR, Peppler R, Gomolka D, Handwerger BS. Additive inhibitory effect of cyclosporine and verapamil may occur through different mechanisms which may be dependent or independent of the slow calcium channel. Transplant Proc 1989; 21:866-870.
28. Weir MR, Klassen DK, Shen SY, Sullivan D, Buddemeyer EU, Handwerger, BS. Acute effects of intravenous cyclosporine on renal function in healthy humans. Transplant Proc 1989; 21:915-917.
29. Shen SY, Weir MR, Coughlin TR. Renal allograft biopsy and conversion from cyclosporine to azathioprine. Transplantation 1989;47:223-229.
30. Weir MR, Klassen DK, Hoover N, Douglas FL. Preliminary observations of the acute effects of selective serum /thromboxane inhibition and angiotensin converting enzyme inhibition on blood pressure and renal hemodynamics in hypertensive humans. J Clin Pharmacol 1989;29:1108-1116.
31. Weir MR. The effects of enalapril on blood pressure, renal hemodynamics, and renal function. Clin Ther 1989;11:685-700.
32. Shen SY, Wood C, Amin AN, Papadimitriou JC, Weir MR, Coughlin TR. Cyclosporine nephrotoxicity and dermal vascular alterations in renal transplants. Transplant Proc 1989; 21:1508-1510.
33. Weir MR, Vlachkis ND, DeQuattro V, Douglas J, Svetkey LP, Singh S, Wiedl SC, Chen CF, Woodward DL, Saunders E. Evaluation of the clinical pharmacology of nilvadipine in patients with mild to moderate essential hypertension. J Clin Pharmacol 1990;30:425-437.
34. Burris JF, Weir MR, Oparil S, Weber M, Cady WJ. An innovative approach to clinical trials of combination therapy: multifactorial assessment of diltiazem and hydrochlorothiazide in hypertension. JAMA 1990;263:1507-1512.
35. Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, Stewart WH. An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. Comment in: JAMA 1990;264:971-973.
36. Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a -blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990;150:1707-1713.
37. Croog SH, Kong BW, Levine S, Weir MR, Baume RM, Saunders E. Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Black Hypertension Quality of Life Multicenter Trial Group. Arch Intern Med 1990;150:1733-1741.
38. Weir MR, Klassen DK, Shen SY, Sullivan D, Buddemeyer EU, Handwerger BS. Acute effects of intravenous cyclosporine on blood pressure, renal hemodynamics, and urine prostaglandin production of healthy humans. Transplantation 1990;49:41-47.
39. Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC. Effect of renal function on the bioavailability of ciprofloxacin. Antimicrobial Agents and Chemotherapy 1990;34:1031-1034.
40. Weir MR. Calcium channel blockers in organ transplantation: Important new therapeutic modalities. J Am Soc Nephrol 1990;1:S28-S38.
41. Li XW, Weir MR. Radix Tripterygium Wilfordii–a Chinese herbal medicine with potent immunosuppressive properties. Transplantation 1990;50:82-86.
42. Gottlieb SS, Weir MR. Renal effects of angiotensin-converting enzyme inhibition in congestive heart failure. Am J Cardiol 1990;66:14D-20D; discussion 20D-21D.
43. Weir MR, Cassidy CA, Hall PS, Lancaster A, Schubert C, Urick A, Saunders E, Kong BW, Jenkins P, Lavin PT. Efficacy and tolerability of enalapril and sustained-release verapamil in older patients with mild to moderate essential hypertension. Clin Ther 1990;12:139-148.
44. Weir MR. Mycobacterium tuberculosis: a disease of growing importance in urban population groups. NY State J Med 1990;90:585-586. Comment in: N Y State J Med 1990; 90:588-591.
45. Weir MR, Peppler R, Gomolka D, Handwerger BS. Additive inhibition of afferent and efferent immunological responses of human peripheral blood mononuclear cells by verapamil and cyclosporine. Transplantation 1991;51:851-857
46. Weir MR, Josselson J, Ekelund LG, Korc M, Pool JL, Stein GH, Wohlbach RA, Champion D. Nicardipine as antihypertensive monotherapy: positive effects on quality of life. J Hum Hypertens 1991;5:205-213.
47. Weir MR, Klassen DK, Hall PS, Schubert C, Voss TE, Stromatt SC, Brown JA. Minimization of indomethacin-induced reduction in renal function by misoprostol. J Clin Pharm 1991;31:729-735.
48. Muluk SC, Clerici M, Via CS, Weir MR, Kimmel PL, Shearer GM. Correlation of in vitro CD4+ T helper cell function with clinical graft status in immunosuppressed kidney transplant recipients. Transplantation 1991;52:284-291.
49. Weir MR Impact of age, race, and obesity on hypertensive mechanisms and therapy. Am J Med 1991;90(5A):3S-14S.
50. Weir MR. Therapeutic benefits of calcium channel blockers in cyclosporine-treated organ transplant recipients: blood pressure control and immunosuppression. Am J Med 1991; 90(5A):32S-36S.
51. Weir MR, Li XW, Gomolka D, Peppler R, O'Bryan-Tear CG, Moran MA. The immunosuppressive properties of enisoprost and a 5-lipoxygenase inhibitor (SC-45662). Transplantation 1991;52:1053-1057.
52. Muluk SC, Clerici M, Via CS, Weir MR, Kimmel PL, Shearer GM. A new approach for analysis of the mixed lymphocyte reaction that is predictive for human renal allograft rejection. Transplant Proc 1991:23; 1274-1276.
53. Weir MR, Kong BW, Jenkins P, Lavin PT. Comparison of the efficacy and tolerability of lisinopril and sustained-release verapamil in black patients with hypertension. Clin Ther 1991; 13:409-416.
54. Weir MR, Lavin PT. Comparison of the efficacy and tolerability of lisinopril and sustained-release verapamil in older patients. Clin Ther 1991; 13:401-408.
55. Weir MR, Klassen DK, Burdick JF. A pilot study to assess the ability of an orally available selective thromboxane synthase inhibitor to improve renal function in cyclosporine-treated renal transplant recipients. J Am Soc Neph 1992; 2:1285-1290
56. Weir MR, Bakris GL. Risk for renal injury in diabetic hypertensive patients. The physiologic basis for blood pressure control. Postgraduate Medicine 1992; 91(3): 77-80,83-84.
57. Weir MR, Bakris GL. Risk for renal injury in diabetic hypertensive patients. Pharmacologic approaches. Postgraduate Medicine 1992; 91(3):87-91,94-95.
58. Gottlieb SS, Robinson S, Weir MR, Fisher ML, Krichten CM. Determinants of the renal response to ACE inhibition in patients with congestive heart failure. Am Heart J 1992; 124:131-136.
59. Burnett HW, Friedman R, Perell F, Weir MR, Klassen DK. The impact of chronic corticosteroid administration on intraocular pressure in renal transplant recipients. J Clin Transplantation 1992; 6:199-201.
60. Weir MR, Weber MA, Punzi HA, Serfer HM, Rosenblatt S, Cady WJ. A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension. J Hum Hypertens 1992;6:133-138.
61. Felicetta JV, Serfer HM, Cutler NR, Comstock TJ, Huber GL, Weir MR, Hafner K, Park GD. A dose-response trial of once-daily diltiazem. Am Heart J 1992; 123:1022-1026.
62. Weir MR, Peppler R, Gomolka D, Handwerger BS. Evidence that the antiproliferative effect of verapamil on afferent and efferent immune responses is independent of calcium channel inhibition. Transplantation 1992; 54:681-685.
63. Weir MR. Hypertensive nephropathy: is a more physiologic approach to blood pressure control an important concern for the preservation of renal function? Am J Med 1992; 93(2A): 27S-37S.
64. Klassen DK, Weir MR, Buddemeyer EU. Simultaneous measurements of glomerular filtration rate by two radioisotopic methods in patients without renal impairment. J Am Soc Neph 1992; 3:108-112.
65. Weir MR, Wright JT Jr., Ferdinand KC, Cook CA, Champion D, Wong S, Jenkins PA, Kong BW. Comparison of the efficacy and metabolic effects of nicardipine and hydrochlorothiazide in hypertensive black men and women. J Hum Hypertens 1993; 7:141-147.
66. Weir MR, Peppler R, Gomolka D, Handwerger BS. Calcium channel blockers inhibit cellular uptake of thymidine, uridine, and leucine: the incorporation of these molecules into DNA, RNA and protein in the presence of calcium channel blockers is not a valid measure of lymphocyte activation. Immunopharmacology 1993; 25:75-82.
67. Weir MR, Bakris GL. Albuminuria in hypertensive diabetics: Is it an important variable in treatment? Postgraduate Medicine 1993;92(S):23-32.
68. Weir MR, Tuck ML. Essential hypertension in blacks: is it a metabolic disorder? AJKD 1993; 21(Suppl 1):58-67.
69. Schulick RD, Weir MR, Miller MW, Cohen DJ, Bermas BL, Shearer GM. Longitudinal study of in vitro CD4+ T helper cell function in recently transplanted renal allograft patients undergoing tapering of their immunosuppressive drugs. Transplantation 1993;56:590-596.
70. Weir MR, Fagan T, Chrysant S, Flamenbaum W, Kaihlanen PM, Leug M, Anzalone D. Comparison of the efficacy and tolerability of an angiotensin converting enzyme inhibitor (lisinopril) versus a calcium channel antagonist (diltiazem SR) in the treatment of moderate to severe hypertension. J Hum Hypertens 1994; 8:531-537.
71. Riley DJ, Weir MR, Bakris GL. Renal adaptation to the failing heart. Understanding the cascade of responses. Postgraduate Med 1994; 95:141-146,149-150.
72. Riley DJ, Weir MR, Bakris GL. Renal adaptation to the failing heart. Avoiding a therapeutic misadventure. Postgraduate Med 1994;95:153-156.
73. Schulick RD, Muluk SC, Clerici M, Bermas BL, Via CS, Weir MR, Shearer GM. Value of in vitro CD4+ T helper cell function test for predicting long-term loss of human renal allografts. Transplantation 1994; 57:480-482.
74. Weir MR. Speed and duration of dose titration with the angiotensin converting enzyme inhibitor quinapril: relationship with efficacy in patients with moderate hypertension. J Hum Hypertens 1994; 8:725-730.
75. Simpson LL, Standley PR, Zhang F, Ram JL, Weir MR, Sowers JR. Role of calcium in vascular smooth muscle proliferation: antiproliferative effects of verapamil enantiomers in vascular smooth muscle cells. J Vasc Biol Med 1994
76. Weir MR, Suthanthiran M. Supplementation of immunosuppressive regimens with calcium channel blockers: rationale and clinical efficacy. Clinical Immunother 1994; 2:458-467.
77. Weir MR, Messerli, FH. Optimal titration of ACE inhibitors. J Hum Hypertens 1994;8:153-162.
78. Hoelscher DD, Weir MR, Bakris GL. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharmacol 1995; 35:73-80.
79. Weir MR. Diltiazem: ten years of clinical experience in the treatment of hypertension. J Clin Pharm 1995;35:220-232.
80. Houston MC, Weir MR, Gray J, Ginsberg D, Szeto C, Kaihlenen PM, Sugimoto D, Runde M. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Int Med 1995;155:1049-1054.
81. Weir MR. Salt intake and hypertensive renal injury in African-Americans: a therapeutic perspective. Am J Hypertens 1995;8(6): 635-644.
82. Weir MR, Dengel DR, Behrens MT, Goldberg AP. Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. Hypertension 1995; 25:1339-1344.
83. Prisant LM, Weir MR, Papademetriou V, Weber MA, Adegbile IA, Alemayehu D, Lefkowitz MP, Carr AA. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J 1995;130:359-366.
84. Moy E, Bartman BA, Weir MR. Access to hypertensive care. Effects of income, insurance, and source of care. Arch Intern Med 1995;155:1497-1502.
85. Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 1995; 26(1):124-130.
86. Weir MR**.** Pharmacologic antagonism of the renin-angiotensin-aldosterone system: a focus on angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. Cardiovascular Reviews and Reports 1995;9:37-42.
87. Frishman WH, Burris JF, Mroczek WJ, Weir MR, Alemayehu D, Simon JS, Chen SY, Bryzinski BS. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. Journal of Clinical Pharmacology 1995; 35(2):182-188.
88. Weir MR, Hanes DS. Hypertension in African Americans: a paradigm of metabolic disarray. Seminars in Nephrology 1996;16(2):102-109.
89. Pirsch JD, Andrews C, Hricik DE, Josephson MA, Leichtman AB, Lu CY, Melton LB, Rao VK, Riggio RR, Stratta RJ,Weir MR,. Pancreas transplantation for diabetes mellitus. AJKD 1996; 27(3):444-450.
90. Weir MR, Berger ML, Weeks ML, Liss CL, Santanello NC. Comparision of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. The Quality of Life Multicenter Group. Am J Cardiol 1996;77:475-479.
91. Klassen DK, Hoehn-Saric EW, Weir MR, Papadimitriou JC, Drachenberg CB, Johnson LB, Schweitzer EJ, Bartlett ST. Isolated pancreas rejection in combined kidney pancreas transplantation: results of percutaneous pancreas biopsy. Transplantation 1996; 61:974-977.
92. Weir MR, Sugimoto D, Gray J, Black H, Saunders E, Applegate W, Davidson J, Ginsberg D, Marbury T, Moser M, Cziner D, deSilva J, Mills D, Rosenblum J, Hall WD. Safety and efficacy of once-daily captopril plus hydrochlorothiazide versus nifedipine gastrointestinal therapeutic system in black patients with mild to moderate hypertension. Am J Therapeutics 1996;3:811-817.
93. Weir MR, Prisant LM, Papademetriou V, Weber MA, Adegbile IA, Alemayehu D, Lefkowitz MP. Antihypertensive therapy and quality of life: influence of blood pressure reduction, adverse events, and prior antihypertensive therapy. Am J Hypertens 1996;9:854-859.
94. Walker JA, Klassen DK, Hooper FJ, Hoehn-Saric EW, Schweitzer EJ, Johnson LB, Bartlett ST, Weir MR. Late pancreas allograft rejection. Preliminary experience with factors predisposing to rejection. Transplantation 1996;62:539-543.
95. Franklin SS, Weir MR, Smith DHG, Codispoti J, Stokes A, McNally C, Weber MA. Combination treatment with sustained-release verapamil and indapamide in the treatment of mild-to-moderate hypertension. Am J Therapeutics 1996; 3:506-514.
96. Weir MR. Angiotensin-II receptor antagonists: a new class of antihypertensive agents. American Family Physician 1996;53:589-594.
97. Hanes DS, Nicholson PG, Raval DD, Behrens MT, Weir MR. A cross-over comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients. Am J Therapeutics 1996; 3:1-7.
98. Johnson LB, Kuo PC, Dafoe DC, Schweitzer EJ, Alfrey EJ, Klassen DK, Hoehn-Saric EW, Weir MR, Bartlett ST. Double adult renal allografts: a technique for expansion of the cadaveric kidney donor pool. Surgery 1996; 120:580-583.
99. Schweitzer EJ, Drachenberg CB, Anderson L, Papadimitriou JC, Kuo PC, Johnson LB, Klassen DK, Hoehn-Saric EW, Weir MR, Bartlett ST. Significance of the Banff borderline biopsy. AJKD 1996; 28(4);585-588
100. Malinow L, Walker J, Klassen D, Oldach D, Schweitzer E, Bartlett ST, Weir MR. Antilymphocyte induction immuno-suppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience. Clin Transplantation 1996;10(3):237-242.
101. Weir MR. Differing effects of antihypertensive agents on urinary albumin excretion. American Journal of Nephrology 1996; 16(3):237-245.
102. Dengel DR, Goldberg AP, Mayuga RS, Kairis GM, Weir MR. Insulin resistance, elevated glomerular filtration fraction, and renal injury. Hypertension 1996; 28(1):127-132.
103. Bakris GL, Weir MR. Salt intake and reductions in arterial pressure and proteinuria: Is there a direct link? Am J Hypertens 1996; 9:200S-206S.
104. Weir MR. Insulin resistance and salt sensitivity: A renal hemodynamic abnormality? Am J Hypertens 1996; 9:193S-199S.
105. Johnson LB, Kuo PC, Schweitzer EJ, Ratner LE, Klassen DK, Hoehn-Saric EW, de la Torre A, Weir MR, Strange J, Bartlett ST. Double renal allografts successfully increase utilization of kidneys from older donors within a single organ procurement organization. Transplantation 1996;62(11):1581-1583.
106. Bartlett ST, Schweitzer EJ, Johnson LB, Kuo PC, Papadimitriou JC, Drachenberg CB, Klassen DK, Hoehn-Saric EW,Weir MR,, Imbembo AL. Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. Ann Surg 1996;224:440-449; discussion 449-452.
107. Sowers JR, Weir MR. Introduction: a reappraisal of therapeutic issues in hypertension. Am J Med 1996;101(suppl 3A):1S-2S.
108. Hanes DS, Weir MR, Sowers JR. Gender considerations in hypertension pathophysiology and treatment. Am J Med 1996;101(suppl 3A):10S-21S.
109. Bakris GL, Weir MR, Sowers JR. Therapeutic challenges in the obese diabetic patient with hypertension. Am J Med 1996; 101(suppl 3A):33S-46S.
110. Weir MR, Flack JM, Applegate WB. Tolerability, safety, and quality of life and hypertensive therapy: the case for low-dose diuretics. Am J Med 1996;101(suppl 3A):83S-92S.
111. Drachenberg CB, Papadimitriou JC, Weir MR, Klassen DK, Hoehn-Saric E, Bartlett ST. Histologic findings in islets of whole pancreas allografts: lack of evidence for recurrent cell-mediated diabetes mellitus. Transplantation 1996;62:1770-1772.Weir MR,. Can hypertension be prevented? Is salt reduction important in hypertension? Ethnicity & Disease 1996;6:321-325.
112. Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996; 18(3):411-428.
113. Weir MR. The calcium channel blocker debate: Dr. Weir’s opinion. J Myocardial Ischemia 1996; 8:129-130.
114. Drachenberg CB, Klassen DK, Bartlett ST, Hoehn-Saric EW, Schweitzer EJ, Johnson LB, Weir MR, Papadimitriou JC. Histologic grading of pancreas acute allograft rejection in percutaneous needle biopsies. Transplant Proc 1996 ;28:512-513.
115. Papadimitriou JC, Drachenberg CB, Anderson L, Bartlett ST, Johnson LB, Klassen DK, Hoehn-Saric EW, Weir MR, Schweitzer EJ. Follow-up of patients with borderline changes in renal allograft biopsies: clinical outcome and evaluation of other histological features in addition to tubulitis. Transplant Proc 1996; 28:517-518.
116. Schweitzer EJ, Anderson L, Kuo PC, Johnson LB, Klassen DK, Hoehn-Saric EW, Weir MR, Bartlett ST. Safe pancreas transplantation in patients with coronary artery disease. Transplantation 1997; 63:1294-1299.
117. Schweitzer EJ, Yoon S, Hart J, Anderson L, Barnes R, Evans D, Hartman K, Jaekels J, Johnson LB, Kuo PC, Hoehn-Saric EW, Klassen DK, Weir MR, Bartlett ST. Increased living donor volunteer rates with a formal recipient family education program. AJKD 1997;29:739-745.
118. Weir MR. The influence of dietary salt on the antiproteinuric effect of calcium channel blockers. AJKD 1997; 29:800-805.
119. Reisin E, Weir MR, Falkner B, Hutchinson HG, Anzalone DA, Tuck ML. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Hypertension 1997; 30:140-145.
120. Kuo PC, Johnson LB, Schweitzer EJ, Klassen DK, Hoehn-Saric EW, Weir MR, Drachenberg CB, Papadimitriou JC, Bartlett ST. Solitary pancreas allografts. The role of percutaneous biopsy and standardized histologic grading of rejection. Arch Surg 1997; 132:52-57.
121. Massie BM, Chrysant SG, Jain A, Weir MR, Weiss R, Kobrin I. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD. Clin Cardiol 1997; 20:562-568.
122. Drachenberg CB, Papadimitriou JC, Klassen DK, Racusen LC, Hoehn-Saric EW, Weir MR, Kuo PC, Schweitzer EJ, Johnson LB, Bartlett ST. Evaluation of pancreas transplant needle biopsy: reproducibility and revision of histologic grading system. Transplantation 1997; 63:1579-1586.
123. Weir MR. Population characteristics and the modulation of the renin-angiotensin system in the treatment of hypertension. J Hum Hypertens 1997; 11:17-21.
124. Weir MR, Hall PS, Behrens MT, Flack JM. Salt and blood pressure responses to calcium antagonism in hypertensive patients. Hypertension 1997; 30:422-427.
125. Dengel DR, Mayuga RS, Kairis GM, Goldberg AP, Weir MR. Effect of dietary sodium on insulin sensitivity in older, obese, sedentary hypertensives. Am J Hypertens 1997 10:964-970.
126. Messerli FH, Schmieder RE, Weir MR. Salt: a perpetrator of hypertensive target organ disease? Arch Int Med 1997; 57:2449-2452.
127. Schweitzer EJ, Yoon S, Fink J, Wiland A, Anderson L, Kuo PC, Lim JW, Johnson LB, Farney AC, Weir MR, Bartlett ST. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients. Transplantation 1998; 65:242-248.
128. Chrysant SG, Weir MR, Weder AB, McCarron DA, Canossa-Terris M, Cohen JD, Mennella RF, Kirkegaard LW, Lewin AJ, Weinberger MH. There are no racial, age, sex, or weight differences in the effect of salt on blood pressure in salt-sensitive hypertensive patients. Arch Int Med 1997; 157:2489-2494.
129. Weir MR. Non-diuretic-based antihypertensive therapy and potassium homeostasis in elderly patients. Coronary Artery Disease 1997; 8:499-504.
130. Weir MR. Hypertension in elderly African-Americans. Am J Geri Cardiol 1997; 6:13-20.
131. Weir MR, Anderson L, Fink JC, Gabregiorgish K, Schweitzer EJ, Hoehn-Saric E, Klassen DK, Cangro CB, Johnson LB, Kuo PC, Lim JY, Bartlett ST. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64:1706-1710.
132. Weir MR, Saunders E for the Trandolapril Multicenter Study Group. Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African-Americans. J Human Hypertens 1998; 12:189-194.
133. Pool JL, Guthrie RM, Littlejohn TW III, Raskin P, Shephard AMM, Weber MA, Weir MR, Wilson TW, Wright J, Kassler-Taub KB, Reeves RA. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11:462-470.
134. Weir MR, Chrysant SG, McCarron DA, Canossa-Terris M, Cohen JD, Gunter PA, Lewin AJ, Mennella RF, Kirkegaard LW, Hamilton JH, Weinberger MH, Weder AB. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension 1998; 31:1088-1096.
135. Weir MR, Reisin E, Falkner B, Hutchinson HG, Sha L, Tuck ML, for the Trophy Study Group. Nocturnal Reduction of Blood Pressure and the Antihypertensive Response to A Diuretic or Angiotensin Converting Enzyme Inhibitor in Obese Hypertensive Patients. Am J of Hypertens 1998; 11(8) Part I:914-920.
136. Weir MR, Dworkin LD. Antihypertensive Drugs, Dietary Salt, and Renal Protection: How low should you go and with which therapy? AJKD 1998; 32(1):1-22.
137. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54:1283-1289.
138. Prisant LM, Neutel JM, Papademetriou V, DeQuattro V, Hall WD, Weir MR. Low-dose combination treatment for hypertension versus single-drug treatment-bisoprolol/hydrochlorothiazide versus amlodipine, enalapril, and placebo: Combined analysis of comparative studies. American Journal of Therapeutics 1998; 5:313-321.
139. Weir MR. The rationale for combination versus single-entry therapy in hypertension. American Journal of Hypertension 1998:11:163S-169S.
140. Papadimitriou JC, Drachenberg CB, Wiland A, Klassen DK, Fink J, Weir MR, Cangro C, Schweitzer EJ, Bartlett ST. Histologic grading of acute allograft rejection in pancreas needle biopsy. Transplantation 1998; 66:1741-1745.
141. Weir MR,Tolchin N, Toth P, Reeves RA. Addition of hydrochlorothiazide to irbesartan produces further dose-related reductions in blood pressure within two weeks. J Hypertens 1998; 16(suppl 2):S130.
142. Weir, MR. Impact of salt intake on blood pressure and proteinuria in diabetes: Importance of the renin-angiotensin system. Miner and Electrolyte Metab 1998; 24:438-445.
143. Papademetriou V, Prisant LM, Neutel JM, Weir MR. Efficacy of low-dose combination of bisoprol/hydrochlorothiazide compared with amlodipine and enalapril in men and women with essential hypertension. Am J Cardiol 1998; 81:1363-1365.
144. Weir MR. Obesity-related hypertension: Many factors affect response to Tx. Am J Hypertens 1998; 12:29-30.
145. Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Disease 1999 34 (1): 1-13.
146. Prisant LM, Weir MR, Frishman WH, Neutel JM, Davidov ME, Lewin AJ. Self reported sexual dysfunction in men and women treated with bisoprolol, hydrochlorothiazide, enalapril, amlodipine, placebo, or bisoprolol/hydrochlorothiazide. J Clin Hypertension 1999:1(1)22-26.
147. Weir MR. How low should we treat blood pressure and why? J Clin Hypertens 1999; 1:199-208.
148. Jacobs S, Cho E, Philosophe B, Bartlett ST, Weir MR. A Comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. J Urol; 2004, 162:963-964.
149. Prisant LM, Neutel JM, Ferdinand K, Papademetriou V, DeQuattro V, Hall WD, Weir MR. Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks. J Natl Med Assoc 1999;91:40-48.
150. Drachenberg CB, Papadimitriou JC, Klassen DK, Weir MR, Cangro CB, Fink JC, Bartlett ST. Chronic pancreas allograft rejection: morphologic evidence of progression in needle biopsies and proposal of a grading scheme. Transplant Proc. 1999; 31:(1-2)614.
151. Weir MR, Fink JC, Hanes DS, Gardner J, Klassen DK, Cangro, Schweitzer E, Bartlett ST. Chronic allograft nephropathy: effect of cyclosporine reduction and addition of mycophenolate mofetil on progression of renal disease. Transplant Proceedings, 1999; 31:1296-1287.
152. Nogueira JM, Cangro CB, Fink JC, Klassen DK, Gardner J, Schweitzer E, Wiland A, Flowers J, Jacobs S, Cho E, Philosophe B, Bartlett ST, Weir MR. A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. Transplantation 1999; 67:722-728.
153. Hadley GA, Rostapshova EA, Gomolka DM, Taylor BM, Bartlett ST, Drachenberg CI, Weir, MR. Regulation of the epithelial cell-specific integrin, CD103, by human CD8+ cytolytic T lymphocytes. Transplantation 1999; 67(11)1418-1425.
154. Weir MR and Fink JC. Post-transplant Diabetes Mellitus: risks versus benefits with current immunosuppressive medications. Am J Kidney Dis 1999 34:1-14
155. Drachenburg CB, Beskow CO, Cangro CB, Bourquin PM, Simsir A, Fink J, Weir, MR, Klassen DK, Bartlett ST, Papadimitriou JC. Human Polyoma Virus in Renal Allograft Biopsies: Morphological findings and correlation with urine cytology. Human Pathology 1999:30(8)970-977
156. Drachenberg CB, Klassen DK, Weir, MR, Wiland A, Fink JC, Bartlett ST, Cangro CB, Blahut S, Papadimitriou JC. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68(3)396-402.
157. Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency? Am J Hypertens 1999;12:195S-203S.
158. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 12:1999:205S-213S.
159. Weir MR. Diabetes and hypertension: Blood pressure control and consequences. Am J Hypertension 1999:12(12):170S-178S.
160. Papadimitriou JC, Drachenberg CB, Wiland A, Klassen DK, Fink J, Weir MR, Cangro C, EJ Schweitzer, Bartlett ST. Histologic grading of acute allograft rejection in pancreas needle biopsy. Transplantation, 1999; 66:1741-1745.
161. Weir MR. Effects of low dose combination therapy with amlodipine/benazepril on systolic blood pressure. Cardiovascular Review and Reports 1999; 20(7)368-374.
162. Weir MR. Indicators and treatment of hypertensive heart disease. Hospital Practice 1999; 34 (9):93-107.
163. Weir MR. Hypertension: Goal systolic and diastolic blood pressure. Current Hypertension Reports 1999:1:411-413.
164. Wali RK, Weir MR. Hypertensive cardiovascular disease in African Americans. Current Hypertension Reports: 1999 (6)521-528.
165. Weir MR. The role of multiple drug therapy for controlling hypertension in African Americans. J Clin Hyperten 2000; 2:99-108,123
166. Weir MR, Bravo E, Robinson J, Harris S, Hardison JD, Michelson EL, Wang R for the ACTION Investigators. Effects of candesartan cilexetil alone or as add-on therapy in African-American patients with hypertension: a large clinical experience trial. Ethinicity & Disease 2000:10:298.
167. Weir MR, Smith DHG, Neutel JH, Bedigian MP. Valsartan alone and in combination with other antihypertensives on blood pressure control in African-American patients receiving a high salt diet. Ethnicity & Disease 2000:10:316.
168. Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J 2000; 139:174-183.
169. Weir MR, Maibach EW, Bakris GL, et al. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med 2000; 160(4):481-490.
170. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 2000; 160:685-693.
171. Hjelmesaeth J, Hartmann A, Fink JC, Weir MR. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Letter to the editor**.** Am J Kidney Dis 2000; 35(3):562.
172. Chrysant SG, Weder AB, McCarron DA, Canossa-Terris M, Cohen JD Gunter PA, Hamilton BP, Lewin AJ, Mennella RF, Kirkegaard LW, Weir MR, Weinberger MH. Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators. Am J Hypertens 2000; 13:1180-1188.
173. Weir MR. Preventing renal disease progression: is it the drug or the blood pressure reduction, or both? Curr Hypertens Rep 2000; 2:497-499.
174. Weir MR, Henrich WL. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Curr Opin Nephrol Hypertens 2000; 9:403-411
175. Weir MR. When initial antihypertensive monotherapy fails: potential benefits of fixed-dose angiotensin-converting enzyme inhibitor/calcium antagonist combination therapy. Southern Medical Journal 2000; 93:548-556.
176. Klassen DK, Drachenberg, CB, Papadimitriou JC, Cangro CB, Fink JC, Bartlett ST, Weir MR. CMV allograft pancreatitis: diagnosis, treatment, and histological features. Transplantation 2000; (9):1968-1971.
177. Neutel JM, Weir MR, Moser M, Harris S, Edwards D, Michelson EL, Wang R. The effects of candesartan cilexetil in isolated systolic hypertension: A clinical experience trial. J Clin Hypertens 2000; 2:181-186.
178. Weir MR. The role of multiple drug therapies for controlling hypertension in African Americans. J Clin Hypertens 2000; 123:99-108.
179. Bakris GL, Whelton P, Weir MR, et al for the Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Group. Clinical trials in chronic renal disease; what does the future hold? J Clin Pharmacol 2000;40:815-823.
180. Bakris GL, Williams M, Dworkin L Weir MR, et al for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kid Dis 2000; 36:646-661.
181. Dailey GE, Boden GH, Creech RH, Johnson DG, Gleason RE, Kennedy FP, Weinrauch LA, Weir MR, D’Elia JA. Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. Metabolism 2000; 49:1491-1495.
182. Weir MR, Blantz RC. Implications from the Heart Outcomes Evaluation Study. Curr Opin Nephrol and Hypertens 2001; 10:61-63.
183. Weir MR, Ward MT, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, Fink JC. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 591567-1571.
184. Weir MR. Diabetes and Hypertension: How Low Should You Go and With Which Drugs? Am J Hypertens 2001; 14:17S-26S.
185. Weir MR, Wei C. The role of angiotensin II and TGF-beta on the progression of chronic allograft nephropathy. JRAAS 2001; 2(suppl1): S188-S190.
186. Weir MR, Wang RY. Use of angiotensin II receptor blockers alone and in combination with other drugs: a large clinical experience trial. JRAAS 2001; 2(suppl1):S217-S222.
187. Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and angiotensin convertin enzyme inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001; 14:963-968.
188. Weir MR, Weber MA, Neutel JM, Vendetti J, Michelson EL, Wang RY for the ACTION Study Investigators. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. Am J Hypertens 2001; 14:567-572.
189. Weir MR, Smith DHG, Neutel JM, Bedigian MP. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens 2001:14:665-671.
190. Weber MA, Weir MR. Management of high-risk hypertensive patients with diabetes: potential role of angiotensin II receptor antagonists. J Clin Hypertens 2001; 3:225-235.
191. Hanes DS, Weir MR. The beta blockers: are they as protective in hypertension as in other cardiovascular conditions. J Clin Hypertens 2001; 3:236-243.
192. Nogueira JH, Fink JC, Weir MR. Recipient outcome after receiving a laparoscopically harvested kidney from a living donor. Transplantation 2001; 72:355-356.
193. Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, Rush DN, Vazques MA, Weir MR.for the American Society of Transplantation. The evaluation of renal transplant candidates: clinical practice guidelines. Am J Transplant 2001; (suppl 2):1-95
194. Hadley GA, Charandee C, Weir MR, Wang D, Bartlett ST, Drachenburg, CB. Cd103+ accumulate within the graft epithelium during clinical renal allograft rejection. Transplantation 2001:72:1548-155.
195. Fink JC, Salmanullah M, Blahut SA, Weir MR, Sawyer R, Henrich WL, Mise MK. The inevitability of renal function loss in patients with hypercreatinemia. Am J Nephrology 2001:21:386-389.
196. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104:2280-2288.
197. Drachenberg VC, Drachenberg CB, Papadimitriou MC, Ramos E, Fink JC, Wali R, Weir MR, Cangro CB, Klassen DK, Khaled A, Cunningham R,Bartlett S. Morphological spectrum of polyoma virus disease in renal allografts: Diagnostic Accuracy of urine cytology. American Journal of Transplantation 2001: 1; 373-381.
198. Wiland AM, Fink JC, Philosophe B, Farney AC, Schweitzer EJ, Colonna JO, Weir MR, Bartlett ST. Peripheral administration of thymoglobulin for induction therapy in pancreas transplantation. Transplant Proc 2001;33:1910.
199. Weir MR. Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation. Transplant Proc 2001;33 (Suppl 4A):19S-28S.
200. Weir MR. Impact of immunosuppressive regimes on posttransplant diabetes mellitus. Transplant Proc 2001;33(Suppl 5A):23S-26S.
201. Weir MR. Appropriate use of calcium antagonists in hypertension. Hosp Practice 2001:36(9):47-48,53-5.
202. Weir MR. Hypertension in patients with type II diabetes. Hosp Practice 2001;36(1):41-42,47-48,51-54.
203. Weir MR. Commentary: Renal effects of cyclooxygenase-2-selective inhibitors. J Pain and Symptom Management 2002;23:S21.S23.
204. Cunningham RM, Weir MR. Pros and cons of diuretic therapy for hypertension. Emergency Med 2002:34:14-20.
205. Ramos E, Drachenberg CB, Papadimitriou JC, Hamze O, Fink JC, Klassen DK, Drachenberg RC, Wiland A, Wali R, Cangro CB, Schweitzer E, Bartlett ST, Weir MR: Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol. 2002; 13:2145-2151.
206. Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, Rush DN, Vazquez MA, Weir MR: The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant. 2002; 1 Suppl 2:1-95.
207. Weir MR: Renal effects of nonselective NSAIDs and coxibs. Cleve.Clin J Med 2002; 69 Suppl 1:SI53-SI58.
208. Konstam MA, Weir MR: Current perspective on the cardiovascular effects of coxibs. Cleve.Clin J Med 2002; 69 Suppl 1:SI47-SI52.
209. Messerli FH, Weir MR, Neutel JM: Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens. 2002; 15:550-556.
210. Haririan A, Ramos ER, Drachenberg CB, Weir MR, Klassen DK: Polyomavirus nephropathy in native kidneys of a solitary pancreas transplant recipient. Transplantation 2002; 73:1350-1353.
211. Fink JC, Onuigbo MA, Blahut SA, Christenson RH, Mann D, Bartlett ST, Weir MR: Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case- control study. Am J Kidney Dis. 2002; 39:1096-1101.
212. Fink JC, Blahut SA, Weir MR: Optimal strategies for modeling the reciprocal of creatinine versus time in renal transplant recipients and patients with native chronic renal disease. Am J Kidney Dis. 2002; 39:753-761.
213. Klassen DK, Weir MR, Cangro CB, Bartlett ST, Papadimitriou JC, Drachenberg CB: Pancreas allograft biopsy: safety of percutaneous biopsy-results of a large experience. Transplantation 2002; 73:553-555.
214. Danovitch GM, Hariharan S, Pirsch JD, Rush D, Roth D, Ramos E, Starling RC, Cangro C, Weir MR: Management of the waiting list for cadaveric kidney transplants: report of a survey and recommendations by the Clinical Practice Guidelines Committee of the American Society of Transplantation. J Am Soc Nephrol. 2002; 13:528-535.
215. Weir MR. Progressive renal and cardiovascular disease: Optimal treatment strategies. Kidney Int 2002; 62:1482-1492.
216. Bakris GL, Weir MR. ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: What’s the evidence? J Clin Hypertens 2002; 4:420-423,440.
217. Weir MR. Microalbuminuria as a cardiovascular and renal risk factor in patients with type II diabetes. Am J Clin Proc 2002; 3:7-14.
218. Weir MR: Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers. Curr.Hypertens.Rep.2002; 4:333-335.
219. Papadimitriou JC, Drachenberg CB, Klassen DK, Gaber L, Racusen LC, Voska L, Cangro CB, Ramos E, Wali R, Weir MR, Bartlett ST: Histological Grading of Chronic Pancreas Alograft Rejection/Graft Sclerosis. Am J of Transplantation 2003; 3:599-605.
220. Onuigbo M, Weir MR. Evidence-based treatment of hypertension in patients with diabetes mellitus. Diabetes, Obesity and Metabolism 2003; 5:13-26.
221. Weir MR, Sperling RS, Reicin A, Gertz BJ: Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am.Heart J. 146:591-604, 2003
222. Weir MR. Is chronic calcineurin inhibitor toxicity responsible for long-term deterioration of renal function in transplant recipients? Transplantation Reviews 2003; 17:20-30.
223. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND, Weir MR, Henrich WL. Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. Clin Pharmacology & Therapeutics 2003; 5:427-434.
224. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch.Intern.Med. 2003; 163:1555-1565.
225. Weir MR: Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J.Clin.Hypertens.(Greenwich.) 2003; 5:330-335.
226. Mange KC, Weir MR: Preemptive renal transplantation: why not? Am.J.Transplant 2003;3:1336-1340.
227. Lakkis J, Lu WX, Weir MR: RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr.Hypertens.Rep. 2003; 5:408-417.
228. Weir MR: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or CCB vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Curr.Hypertens.Rep. 2003;5:405-407.
229. Weir MR: Clinical trials report. Chronic kidney disease: blood pressure, treatment goals, and cardiovascular outcomes. Curr.Hypertens.Rep.2003;5:405-407.
230. Bakris GL, Weir MR: Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J.Clin.Hypertens. V (III) (Greenwich.) 2003;5:202-209.
231. Lu WX, Lakkis J, Weir MR: Optimizing target-organ protection in patients with diabetes mellitus: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Curr.Hypertens.Rep.2003;5:192-198.
232. Haririan A, Hamze O, Drachenberg CB, Ramos E, Weir MR, Klassen DK: Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. Transplantation 2003;75:1186-1190.
233. DeMaria AN, Weir MR: Coxibs--beyond the GI tract: renal and cardiovascular issues. J.Pain Symptom.Manage. 2003;25:S41-S49.
234. Weir MR, Blantz RC: Blood pressure and cardiovascular risks: implications of the presence or absence of a nocturnal dip in blood pressure. Curr.Opin.Nephrol.Hypertens. 2003;12:57-60.
235. Weir MR. Commentary on CADI scoring for determining late graft survival: review and case study. The Am J of Urology Review 2004; 2(12) 614-615.
236. Lakkis J, Weir MR: Pharmacological strategies for kidney function preservation: Are there differences by ethnicity? Adv.Ren Replace.Ther. 2004;11:24-40.
237. Ramos E, Vincenti F, Lu WX, Shapiro R, Trofe J, Stratta RJ, Jonsson J, Randhawa PS, Drachenberg CB, Wali RK, Papadimitriou JC, Weir MR, Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation 2004;77:131-133.
238. Wiland AM, Fink JC, Weir MR, Philosophe B, Blahut S, Weir MR, Jr., Copenhaver B, Bartlett ST: Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation 2004;77:422-425.
239. Weir MR. Microalbuminuria in Type 2 Diabetics: An Important, Overlooked Cardiovascular Risk Factor. J Clin Hypertens 2004; 6:134-141.
240. Hanes DS, Nahar A, Weir MR: The Tissue Renin-Angiotensin-Aldosterone System in Diabetes Mellitus. Curr. Hypertens.Rep. 2004; 6:98-105.
241. Weir MR: Blood Pressure Management in the Kidney Transplant Recipient. Adv.Chronic Kidney Dis. 2004; 11:172-183.
242. Bakris GL, Weir MR, Secic M, Brett C, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991-2002.
243. Weir MR. Antiotensin II Receptor Blockers: The Importance of Dose in Cardiovascular and Renal Risk Reduction. J Clin Hypertens 2004; 6:315-323.
244. Weir MR, Blahut S, Drachenburg C, Young C, Papademitriou J, Klassen DK, Cangro CB, Bartlett ST, Fink JC. Late Calcineurin Inhibitor Withdrawal as a Strategy to Prevent Graft Loss in Patients with Suboptimal Kidney Transplant Function. Am J Nephrol 2004;24:379-386.
245. Wali RK, Drachenberg C, Hirsch HH, Papadimitriou J, Nahar A, Mohanlal V, Brisco MA, Bartlett ST, Weir MR, Ramos E. BK Virus-Associated Nephropathy in Renal Allograft Recipients: Rescue Therapy by Sirolimus-Based Immunosuppression. Transplantation 2004; 78:1069-1073.
246. Weir MR: Albuminuria predicting outcome in diabetes: Incidence of microalbuminuria in Asia-Pacific Rim. Kidney Int; 2004; 66:S38-S39.
247. Weir MR: Clinical trials report. Drug-induced Diabetes: Cardiovascular Implications. Curr. Hypertens. Rep. 2004; 6:365-366.
248. Blantz RC, Weir MR: Are the oxygen costs of kidney function highly regulated? Curr.Opin.Nephrol.Hypertens. 2004; 13:67-71.
249. Drachenberg CB, Papadimitriou JC, Wali R, Nogueira J, Mendley S, Hirsch HH, Cangro CB, Klassen DK, Weir MR, Bartlett ST, Ramos E: Improved outcome of polyoma virus allograft nephropathy with early biopsy. Transplant.Proc. 2004; 36:758-759.
250. Weir MR: Healthy diet and blood pressure. J.Clin.Hypertens.(Greenwich.) 2004; 6:381-382.
251. Weir MR: Dietary salt, blood pressure, and microalbuminuria. J.Clin.Hypertens.(Greenwich.) 2004; 6:23-26.
252. Weir MR: Editorial Commentary. Reduction in Microalbuminuria: A Biomeasure of Therapeutic Success?

Hypertension. 2005; 45:181-182.

1. Moser M, Weir MR: Commentary. Treatment of Diabetic Hypertensive Patients: Results of a National

Survey. J. Clin. Hypertens. 2005; 7:110-111.

1. Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CD: Selective Cyclooxygenase-2 Inhibition and

Cardiovascular Effects: An Observed Study of a Medicaid Population. Arch. Intern. Med. 2005; 2:165, 181- 188.

1. Weir MR, Fink JC. Salt intake and progression of chronic kidney disease: an overlooked modifiable exposure? A commentary. Am J Kidney Disease 2005; 45(1): 176-188.
2. Weir MR: The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. Am.J.Hypertens. 2005; 18:4 Pt 2:100S-105S.
3. Mimran A, Weir MR: Angiotensin-receptor blockers and diuretics--advantages of combination. Blood Press. 2005; 14:6-11.
4. Danovitch, GM., Cohen, DJ, Weir MR, Stock, PG, Bennett,WM, Christensen, LL, Sung, RS: Current status of kidney and pancreas transplantation in the United States, 1994-2003. Am.J.Transplant. 2005; 5:4 Pt 2, 904-915.
5. Weir MR, Blantz RC: The clinical utilization of albuminuria as a surrogate measure of cardiovascular disease burden and risk for events: are we there yet? Curr.Opin.Nephrol.Hypertens. 2005; 14:39-41.
6. Weir MR, Ferdinand KC, Flack JM, Jamerson KA, Daley W, Zelenofske, AADVANCE investigators: A Noninferiority Comparison of Valsartan/Hydrochlorothiazide Combinations Versus Amlodipine in Black Hypertensives. Hypertension. 2005; 46:508-513.
7. Wali,R.K.; Wang,G.S.; Gottlieb,S.S.; Bellumkonda,L.; Hansalia,R.; Ramos,E.; Drachenberg,C.; Papadimitriou,J.; Brisco,M.A.; Blahut,S.; Fink,J.C.; Fisher,M.L.; Bartlett,S.T.; Weir,M.R.: Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J.Am.Coll.Cardiol. 2005; 45:7, 1051-1060.
8. Mishra SI, Jones-Burton C, Fink JC, Brown JB, Bakris GL, Weir MR: Does Dietary Salt Increase the Risk for Progression on Kidney Disease? Curr Hypertension Reports. 2005; 7:385-391.
9. Weir MR. Blood pressure salt sensitivity: a biomeasure of kidney disease susceptibility in diabetics? Nephrology Dialysis Transplant 2005 20(10):2022-2024.
10. Gotto Jr AM, Blackburn GL, Dailey III GE, Garber AJ, Grundy SM, Sobel BE, Weir MR: The metabolic syndrome: a call to action. Coronary Artery Disease 2006, (1) 17:77-80.
11. Jones JM, Park JJ, Johnson J, Vizciano D, Brian H, Ferrell R, Weir M, Dowling T, Bobisean T, Brown M: Renin-angiotensin system genes and exercises training-induced changes in sodium excretion in African American hypertensives. Ethnicity & Disease 2006, 16: 666-674.
12. Jones-Burton C, Mishra SI, Fink JC, Brown J, Gossa W, Bakris GL, Weir MR. An In-Depth Review of the Evidence Linking Dietary Salt Intake and Progression of Chronic Kidney Disease. Am J Nephrol 2006;26:268-75.
13. Weir MR. Providing end-organ protection with renin-angiotensin system inhibition: the evidence so far. *J Clin Hypertens (Greenwich )* 2006 February;8(2):99-105.
14. Shaya FT, El Khoury AC, Mullins CD, Du D, Skolasky R, Fatodu H, Garber H, Weir MR. Drug therapy persistence and stroke recurrence. *Am J Manag Care* 2006 June;12(6):313-9.
15. Weir MR. Treatment of prehypertension: how soon is soon enough? What therapy should be used? *Curr Hypertens Rep* 2006 October;8(5):393-4
16. Russell M, Fleg JL, Galloway WJ, Henderson JA, Howard J, Lee ET, Poolaw B, Ratner RE, Roman MJ, Silverman A, Weir MR et al. Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in Native Diabetics Study (SANDS). *Am Heart J* 2006 November;152(5):867-75.
17. Weir MR. How Do You Define “Hypertension” in a Patient with Type 1 Diabetes? *Hypertension* 2007 January 49(1) 13-14.
18. Weir MR. Is it the low-protein diet or simply the salt restriction? *Kidney Int* 2007 February;71(3):188-90.
19. Weir MR. Crikelair N, Levy D, Rocha R, Kuturu V, Glazer R. Evaluation of the Dose Response With Valsartan and Valsartan/Hydrochlorothiazide in Patients With Essential Hypertension. *J Clin Hypertens (Greenwich )* 2007 February;9(2):103-12.
20. Bakris GL, Weir MR, Black HR. Improving blood pressure control rates: is there more we can do? *J Clin Hypertens (Greenwich )* 2007 February;9(2):134-42.
21. Goel R, Majeed F, Vogel R, Corretti MC, Weir M, Mangano C, White C, Plotnick GD, Miller M: Exercise-induced hypertension, endothelial dysfunction, and coronary artery disease in a marathon runner. Am J Cardiol 2007;99:743-744.
22. Hanes DS, Weir MR. Usefulness of ARBs and ACE Inhibitors in the Prevention of Vascular Dementia in the Elderly. *Am J Geriatr Cardiol* 2007;16(3):175-82.
23. Wali RK, Mohanlal V, Ramos E, Blahut S, Drachenberg C, Papadimitriou J, Dinits M, Joshi A, Philosophe B, Foster C, Cangro C, Nogueira J, Cooper M, Bartlett ST, Weir MR. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. *Am J Transplant* 2007 (6):1572-83.
24. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de ZD. Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial. *J Am Soc Nephrol* 2007;(5):1540-6.
25. Jones-Burton C., Seliger SL, Scherer RW, Mishra, SI, Vessal G, Brown J, Weir MR, Fink JC. Cigarette Smoking and Incident Chronic Kidney Disease: A Systemic Review. Am JNephrol 2007; 27:342-351.
26. Weir MR. Calcium Channel Blockers: Their Pharmacologic and Therapeutic Role in Hypertension. *Am J Cardiovasc Drugs* 2007; 7 Suppl. 1: 5-15.
27. Weir MR: Microalbuminuria and Cardiovascular Disease. *Clin J Am Soc Nephrol* 2: 581-590, 2007.
28. Vessal G, Wiland AM, Philosophe B, Fink JC, Weir, MR *et al*.: Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient survival compared with maintenance steroid therapy. *Clincal Transplantation* 2007:21: 491-497.
29. Weir MR, Levy D, Crikelair N *et al*.: Time to Achieve Blood-Pressure Goal: Influence of Dose of Valasartan Monotherapy and Valsartan and Hydrochlorothiazide Combination Therapy. *American Journal of Hypertension* 20:807-815, 2007.
30. Weir MR, Bush C, Anderson DR *et al*.: Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension. *Journal of American Society Hypertension* 1(4), 264-277. 2007.
31. Thoenes M, Bramlage Weir MR, *et al*: Albuminuria: pathophysiology, epidemiology and clinical relevance of an emerging marker for cardiovascular diseas. *Future Cardiology* 2007; 3 (5): 519-524.
32. Weir MR. Effects of Renin-Angiotensin System Inhibition on End-Organ Protection: Can We Do Better? *Clinical Therapeutics* 2007; 29 (9): 1803-1824.
33. Weir MR. Direct Renin Inhibitors: Where Will They Fit in for Antihypertensive Treatment? *Current Hypertension Reports 2007*, 9(5): 389-391.
34. Weir MR. Is Anemia a Predictor for Mortality and Loss of Graft in Kidney Transplant Recipients? *American Journal of Tranplantation* 2007; 7: 731-732.
35. Weir MR, Neutel JM, Bhaumik A, *et al*.:The Efficacy and Safety of Initial Use of Irbesartan/Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Patients with and Without High Cardiovascular Risk. *J Clin Hypertens* 2007; 12(5) 15-22.
36. Weber MA, Bakris GL, Dahlof B, Pitt B, Velaquez E, Gupte J, Weir MR, *et al*. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. *Blood Press* 2007;16:13-9.
37. Nogueira J, Weir MR. The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. *Clin J Am Soc Nephrol* 2007; 2: 766–785,.
38. Weir MR. Risk-Based Classification of Hypertension and the Role of Combination Therapy. *J Clin Hypertens* 2008; 1(1):4-8
39. Singh P, Deng A, Weir MR, Blantz R: The balance of angiotensin II and nitric oxide in kidney diseases. *Curr Opin Nephrol Hypertens* 2008; 17:51-56.
40. Howard BV, Roman M, Devereux RB, Weir MR, et al. Effects of Lower Target for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial. *JAMA* 2008 Apr 9;299(14):1678-89.
41. Bakris GL, Weir MR. Comparison of Dual RAAS Blockade and Higher-Dose RAAS Inhibition on Nephropathy Progression. *Postgraduate Medicine* 2008;120:33-42.
42. Weir MR, Bakris GL. Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come? *J Clin. Hypertens. (Greenwich.)* 2008;10:146-52.
43. Gradman AH, Weir MR, Bakris GL. Newer Combination Therapies in the Management of Hypertension: An Update. *J Clin Hypertens* 2008:10:398-405.
44. Bakris, GL, Weir MR, Davidai G, Koval S. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. *Kidney Int* 2008;74:364-9.
45. Mitchell BD, McArdle PF, Shen H, Rampersaud E, Pollin TI, Bielak LF, Jaquish C, Douglas JA, Roy-Gagnon MH, Sack P, Naglieri R, Hines S, Horenstein RB, Chang YP, Post W, Ryan KA, Brereton NH, Pakyz RE, Sorkin J, Damcott CM, O’Connell JR, Mangano C, Corretti M, Vogel R, Herzog W, Weir MR, et al. The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. *Am Heart J*. 2008 May; 155(5):823-8.
46. Weir MR. Is Activated Vitamin D Supplementation Renoprotective? *Hypertension* 2008;52:211-212.
47. Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, Wilkinson A. Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients. *Am J Transplant* 2008;8:1384-1392.
48. Nogueira J, Jacobs SC, Haririan A, Phelan MW, Weir MR, Seliger SL, Hurley HA, Cooper M. A single center comparison of long-term outcomes of renal allografts procured laparoscopically versus historic controls procured by the open approach. *Transplant International* 2008; 9:908-914.
49. Roy-Gagnon MH, Weir MR, Sorkin JD et al. Genetic influences on blood pressure response to the cold pressor test: results from the Heredity and Phenotype Intervention Heart Study. *J Hypertens* 2008;26: 729-736.
50. Weir MR. The Advantage of Single-Pill Combination Therapy Based on Recent Clinical Information. *The Journal of Medicine* 2008;1(1):72-78.
51. McArdle PF, Parsa A, Chang YP, Weir MR, etc. Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order amish. *Arthritis Rheum*. 2008 Sep; 58(9):2874-81.
52. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon, Powe NR, Fink NE, Sadler JH, Weir MR, *etc*. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. *Nat Genet*. 2008 Oct;40(10):1185-92.
53. Akinbamowo AO, Salzberg DJ, Weir MR. Renal consequences of prostaglandin inhibition in heart failure. *Heart Failure Clinics*. 2008 Oct;4(4):505-10.
54. Weir MR. Are we “ONTARGET” yet with regard to optimal antihypertensive regimens? *Curr Hypertens Rep*. 2008 Oct; 10(5):385-6.
55. Weir MR. Optimizing Early *De Novo* Immunosuppression With Sirolimus. *Transplantation Proceedings,* 2008;40:S29-S31.
56. Weir MR. Clinical Commentary: how to choose blood pressure goals and treatment: influence of estimated glomerular filtration rate and albuminuria. *Trans Am Clin Climatol Assoc*. 2008; 119:53-61; discussion 61-3.
57. Lewin AJ, Weir MR. Antihypertensive efficacy and tolerability of irbesartan / hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial. *Clin.Ther*. 2008 Dec:30 (12) : 2354-65.
58. Fleg, JL, Mete M, Howard BV, Umans JG, Roman MJ, Ratner RE, Silverman A, Galloway JM, Henderson JA, Weir MR, etc. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Arthrosclerosis in Native Diabetics Study) trial. *J AM Coll Cardiol*. 2008 Dec 16;52(25):2198-205.
59. Wali RK, Weir MR. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function? *Curr Opin Organ Transplant*. 2008 Dec; 13(6):614-21.
60. Bradbury BD, Critchlow CW, Weir MR, Stewart R, et al. Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients. *Nephrology Dialysis Transplantation* 2009 24(3):919-925.
61. Nogueira JM, Haririan A, Jacobs SC, Weir MR, Hurley A, Al-Qudah HS, Phelan M, Drachenberg CB, Bartlett ST, and Copper M. The Detrimental Effect of Poor Early Graft Function after Laparoscopic Live Donor Nephrectomy on Graft Outcomes. *Am J Transplant* 2009; 9:337-347.
62. Weir MR. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease. *Postgrad Med*. 2009 Jan; 121(1): 96-103.
63. Onukwugha E, Weir MR. The dual impact of rehabilitation admission and race/ethnicity on discharges against medical advice. *NeuroRehabilitation*. 2009;24(1): 67-74.
64. Shaya FT, Du D, Gbarayor CM, French-Tamas F, Lau H, Weir MR. Predictors of compliance will antihypertensive therapy in a high-risk medicaid population. *J Natl Med Assoc*. 2009 Jan;101(1):34-9.
65. Weir MR. Assessing the blood pressure-lowering efficacy of antihypertensive medications: which blood pressures should we use? *J Clin Hypertens* (Greenwhich). 2009 Mar;11 (3):155-8.
66. Weir MR, Wali RK. Minimizing the risk of chronic allograft nephropathy. *Transplantation*. 2009 April 27;87 (8 Suppl):S14-8.
67. Krum H, Swergold G, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, *et. al*. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. *J Hypertens*. 2009 Apr;27(4):886-93.
68. Weir MR. β Blockers in the Treatment of Hypertension: Are There Clinically Relevant Difference? *Postgrad Med.* 2009 May; 121(3): 90-98.
69. Mohamed MA, Weir MR. Renin angiotensin system inhibition in the older person: a review. *Clin Geriatr Med*. 2009 May;25(2):245-57.
70. Badowski M, Gurk-Turner C, Cangro C, Weir M, Philosophe B, *et. al.* The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. *Clin Transplant* 2009 July: 23: 930-937
71. Krum H, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, et al. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. *Eur J Heart Fail*. 2009 June;11 (6):542-50.
72. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL,Weir MR, Fink JC. The frequency of hyperkalemia and its significance in chronic kidney disease. *Arch Intern Med*. 2009 June 22;169(12):1156-62.
73. Weir MR. Hypertension and the Kidney: Perspectives on the Relationship of Kidney Disease and Cardiovascular Disease. *Clin J Am Soc Nephrol* 2009 July 16 (4): 2045–2050.
74. Onukwugha EC, Shaya FT, Saunders E, Weir MR. Ethnic disparities, hospital quality, and discharges against medical advice among patients with cardiovascular disease. Ethn Dis, 2009 Spring;19(2):172-8.
75. Weir MR, Townsend RR. What is left ventricular hypertrophy and is there a reason to regress left ventricular hypertrophy? *J Clin Hypertens*. 2009 Aug;11(8):407-10.
76. Weir MR, Anderson CA. Optimal Dietary Strategies for Reducing Incident Hypertension. *Hypertension*. 2009 ; 54:698-699
77. Weir MR. Wali RK. Optimizing immunosuppression with sirolimus in the first year posttransplantation: experience in the United States. *Transplant Proc.* 2009.Jul-Aug;41(6 Suppl):S13-7.
78. Manitpistkul W, McCann E, Lee S, Weir MR. Drug interactions in transplant patients: what everyone should know. *Curr Opin Nephrol Hypertens*. 2009 Sep;18(5):404-11.
79. Weir MR, Yeh F, Silverman A, Devereux RB, Galloway JM, Henderson JA, Howard WJ, *et. al*. Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial. *J Clin Hypertens* (Greenwich). 2009 Oct;11(10):540-8.
80. Weir MR, and Townsend R. Gauging adequacy of cardiovascular disease treatment: importance of estimating glomerular filtration rate and time-varying albuminuria. *J Am Soc Hypertens* 2009;3(4):277-285.
81. Blak BT, Mullins CD, Shaya FT, Simoni-Wastila L, Cooke CE, Weir MR. Prescribing Trends and Drug Budget Impact of the ARBS in the UK. *Value in Health* 2009; 12(2):302-308.
82. Nogueira JM, Weir MR, Jacobs S, Breault D, Klassen D, Evans DA, Bartlett ST, Cooper M. A study of Renal Outcomes in Obese Living Kidney Donors. Transplantation. 2009 Dec 27;88(12):1371-6.
83. Shaya FT, Lu Z, Sohn K, Weir MR. Thiazolidinediones and cardiovascular events in high-risk patients with type-2 diabetes mellitus: a comparison with other oral antidiabetic agents. *PT*. 2009 Sep;34(9): 490-501.
84. Weir MR, Hollenberg NK, Zappe DH, Meng X, Parving HH, Viberti G, Remuzzi G. Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. *J Hypertens*. 2010 Jan;28(1):186-93.
85. Weir MR, Bogle LL, Mackowiak PA. The Death of John Paul Jones and Resurrection as ‘Father of the US Navy’. *Am J Nephrol*. 2010;31(1):90-4.
86. Stevens LA, Schmid CH, Zhang YL, Coresh J, Manzi J, Landis R, Bakoush O, Contreras G, Genuth S, Klintmalm GB, Poggio E, Rossing P, Rule AD, Weir MR, *et. al*. Development and validation of GFR-estimating equations using diabetes, transplant and weight. *Nephrol Dial Transplant*. 2010 Feb;25(2):449-57.
87. Weir MR. Relative plasma volume monitoring and blood pressure control: an overlooked opportunity to achieve dry weight in the hemodialysis patient. *Hypertension*. 2010 Feb;55(2):226-7.
88. Weir MR, Rolfe M. Potassium hemeostasis and renin-angiotensin-aldosterone system inhibitors. *Clin J Am Soc Nephrol*. 2010 Mar;5(3):531-48.
89. Haririan A, Nogueira JM, Zandi-Nejad K, Aiyer R, Hurley H, Cooper M, Klassen DK, Weir MR. The independent association between serum uric acid and graft outcomes after kidney transplantation. *Transplantation*. 2010 Mar 15;89(5):573-9.
90. Townsend RR, Wimmer NJ, Chirinos JA, Parsa A, Weir M, Perumal K, *et al*. Aortic PWV in chronic kidney disease: a CRIC ancillary study. *Am J Hypertens*. 2010 Mar;23(3):282-9.
91. Weir MR. Hypertension: Endothelin-receptor antagonists for treating hypertension. *Nat Rev Nephrol*. 2010 Apr;6(4):192-4.
92. Bakris GL, Sarafidis PA, Weir MR, Dahlof B, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. *Lancet*. 2010 Apr 3;375(9721):1173-81.
93. Wilson C, Huang CC, Shara N. Howard BV, Fleg JL, Henderson JA, Howard WJ, Huentelman H, Lee ET, Mete M, Russell M, Galloway JM, Silverman A, Stylianou M, Umans J, Weir MR, Yeh F, Ratner RE. Cost-effectiveness of lower targets for blood pressure and LDL cholesterol in diabetes: the stop atherosclerosis in native diabetics study (SANDS). *J Clin Lipidol*. 2010 May;4(3):165-172.
94. mTOR inhibition: the learning curve in kidney transplantation. Weir MR, Diekmann F, Flechner SM, Lebranchu Y, Mandelbrot DA, et al. Transpl Int. 2010 May 1;23(5):447-60.
95. Szczech LA, Granger CB, Dasta JF, Amin A, Peacock WF, McCullough PA, Devlin JW, Weir MR, *et al*. Acute kidney injury and cardiovascular outcomes in acute severe hypertension. *Circulation*. 2010 May 25;121(20):2183-91.
96. Nogueira JM, Haririan A, Jacobs SC, Cooper M, Weir MR. Cigarette smoking, kidney function, and mortality after live donor kidney transplant. *Am J Kidney Dis*. 2010 May;55(5):907-15.
97. Weir MR, Bakris GL. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2010;31(5):469-70.
98. Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, O’Connor A, Perumal K, Rahman M, Steigerwalt S, Teal V, Townsend R, Weir MR, et al. Hypertension Awareness, Treatment, and Control in Adults With CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010 Mar;55(3):441-51.
99. Joffe, M, Hsu, C, Feldman, HI, Weir M, landis JR, et al. Variability of Creatinine Measurements in Clinical Laboratories: Results from the CRIC Study. *Am J Nephrol* 2010; 31:426-434. DOI: 10.1159/000296250.
100. Onukwugha E, Saunders E, Mullins CD, Pradel FG, Zuckerman M, Weir MR. Reasons for discharges against medical advice: a qualitive study. *Qual Saf Health Care*. 2010;19:420-424.
101. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, et. al. Cardiovascular events during differing hypertension therapies in patients with diabetes. *J Am Coll Cardiol*. 2010 Jun 29;56(1):77-85.
102. Agarwal R, Weir MR. Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients. *Clin J Am Soc Nephrol*. 2010 Jul;5(7):1255-60.
103. Weir MR, Zappe D, Orloski LA, Sowers JR. How early should blood pressure control be achieved for optimal cardiovascular outcomes? *J Hum Hypertens.* 2011 Apr;25(4):211-7.
104. Weir MR, Yadao AM, Purkayastha D, Charney AN. Effects of High-and Low-Sodium Diets on Ambulatory Blood Pressure in Patient With Hypertension Receiving Aliskiren. J Cardiovasc Pharmacol Ther. 2010 Dec;15 (4):356-63.
105. Townsend RR, Chirinos JA, Parsa A, Weir MR, Sozio SM, Lash JP, et al. Central pulse pressure in chronic kidney disease: a chronic renal insufficiency cohort ancillary study. *Hypertension*. 2010 Sep;56(3):518-24.
106. Lattanzio MR, Weir MR. Have we fallen off target with concerns surrounding dual RAAS blockade? *Kidney Int*. 2010 Sep;78(6):539-45.
107. Weir MR. Hypervolemia and blood pressure: powerful indicators of increased mortality among hemodialysis patients. *Hypertension*. 2010 Sep;56(3):341-3.
108. DeSilva L, Weir MR. Renin inhibition and microalbuminuria development: meaning predictor of kidney disease progression. *Curr Opin Nephrol Hypertens*. 2010 Sep;19(5):437-43.
109. Weir MR. Dietary fructose and elevated levels of blood pressure. *J Am Soc Nephrol*. 2010 Sept;21(9):1416-8.
110. Weir MR, Bakris GL. Optimal blood pressure for a patient with type 2 diabetes mellitus: insight from the ACCORD study. *Curr Hypertens Rep*. 2010 Oct;12(5):313-5.
111. Lattanzio MR, Weir MR. Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease? *Curr Hypertens Rep*. 2010 Oct;12(5):369-77.
112. Weinrauch LA, Sun J, Gleason RE, Boden GH, Creech RH, Dailey G, Kennedy FP, Weir MR, D’Elia JA. Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus. *Metabolism*. 2010 Oct;59(10):1429-34.
113. Russell M, Silverman A, Fleg JL, Lee ET, Mete M, Weir M, Wilson C, Yeh F, Howard BV, Howard WM. Achieving lipid targets in adults with type 2 diabetes: the Stop Atherosclerosis in Native Diabetics Study. *J Clin Lipidol*. 2010 Sep-Oct;4(5):435-43.
114. Wali RK, Lyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, Cooper C, Himmelfarb J, Weir MR, Berl T, Henrich WL, Cheung AK. Efficacy and Safety of Carvediolol in Treatment of Heart Failure in Chronic Kidney Disease: A Meta-Analysis of Randomized Trials. *Circ Heart Fail*. 2011 Jan;4(1):18-26.
115. Gradman AH, Weir MR, Wright M, Bush CA, Keefe DL. Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies. *J Hum Hypertens*. 2010 Nov;24(11):721-9.
116. Onukwugha E, Mullins CD, Loh FE, Saunders E, Shaya FT, Weir MR. Readmissions after unauthorized discharges in the cardiovascular setting. *Med Care*. 2011 Feb; 49(2):215-24.
117. Weir MR, Punzi HA, Flack JM, Stoakes KA, Chavanu KJ, et al. A Randomized, Double-Blind, Forced-Titration Study to Compare Olmesartan Medoxomil Versus Losartan Potassium in Patients with Stage 1 and 2 Hypertension. *Postgraduate Medicine*. 2011 Jan; 123(1):80-87.
118. Jamerson KA, Devereux R, Bakris GL, Dahlof B, Velazquez EJ, Weir M, et al. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. *Hypertension*. 2011 Feb; 57(2):174-9.
119. Weir MR, Mulgaonkar S, Chan L, Shidban H, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. *Kid Int*. 2011; (79) 897-907.
120. Seliger SL, Zhang AD, Weir MR, Walker L, Hsu VD, Parsa A, Diamantidis CJ, Fink JC. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. *Kidney Int.* 2011 Aug;80(3):288-94.
121. Weir MR, Bartlett ST, Drachenberg CB. Eosinophilia as an early indicator of pancreatic allograft rejection. *Clin Transplant.* 2012 Mar-Apr;26(2):238-41.
122. Weir MR, Aronson S, Avery EG, Pollack CV Jr. Acute kidney injury following cardiac surgery: role of perioperative blood pressure control. *Am J Nephrol.* 2011;33(5):438-52.
123. McMahon G, Weir MR, Li XC, Mandelbrot DA. The Evolving Role of mTOR Inhibition in Transplantation Tolerance. J AM Soc Nephrol 2011 (22): 408-415.
124. Sharma AM, Weir MR. The role of angiotensin receptor blockers in diabetic nephropathy. *Postgrad Med.* 2011 May;123(3):109-21.
125. Schmieder RE, Bakris G, Weir MR. Telmisartan in incipient and overt diabetic renal disease*. J Nephrol.* 2011 May-June;24(3):263-73.
126. Krum H, Swergold G, Gammaitoni A, Peloso PM, Smugar SS, Curtis SP, Brater DC, Wang H, Kaur A, Laine L, Weir MR, Cannon CP. Blood Pressure and Cardiovascular Outcomes in Patients Taking Nonsteroidal Antiinflammatory Drugs. *Cardiovasc Ther.* 2012 Dec;30(6):342-350.
127. Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, Selhub J, Jacques PF, Cole E, Gravens-Mueller L, House AA, Kew C, McKenney JL, Pacheco-Silva A, Pesavento T, Pirsch J, Smith S, Solomon S, Weir M. Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients: Primary Results From the Folic Acid for Vascular Outcome Reduction in Transplantation Trial. *Circulation*. 2011;123:1763-1770.
128. Weir MR, Hsueh WA, Nesbitt SD, Littlejohn TJ 3rd, Graff A, et. al. A Titrate-to-Goal Study of Switching Patients Uncontrolled on Antihypertensive Monotherapy to Fixed-Dose Combinations of Amlodipine and Olmesartan Medoxomil ± Hydrochlorothiazide. *J Clin Hypertens (Greenwich).* 2011 Jun;13(6):404-12.
129. Weir MR and Salzberg Daniel J. Management of hypertension in the transplant patient. JASH 2011 5(5):425-432.
130. Weir MR, Hollenberg NK, Remuzzi G, Zappe DH, Meng X, Parving HH. Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients. *J Hypertens*. October 2011, 29(10):2031-2037.
131. Weir MR. Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success? *Kidney Int.* 2011 Aug;80(3):235-7.
132. Weir MR, Townsend RR, Fink JC, Teal V, Anderson C, Appel L, et. al. Hemodynamic Correlates of Proteinuria in Chronic Kidney Disease. *Clin J Am Soc Nephrol*. October 2011;6:(10):2403-2410.
133. Weir MR, Izzo JL Jr. Angiotensin-converting enzyme inhibitors. *J Clin Hypertens (Greenwich)*. 2011 Sep;13(9):667-75.
134. Haririan A, Metireddy M, Cangro C, Nogueira JM, Rasetto F, Cooper M, Klassen DK, Weir MR. Association of serum uric Acid with graft survival after kidney transplantation: a time-varying analysis. *Am J Transplant*. 2011 Sept; 11(9):1943-50.
135. Hsu C, Propert K, Xie, D, Hamm L, He J, Miller E, Akinlolu O, Shlipak M, Townsend R, Weir M, et al. Measured GFR Does Not Outperform Estimated GFR in Predicting CKD-related Complications. *J Am Soc Nephrol* 2011(22):1931-1937.
136. Montasser ME, Douglas JA, Roy-Gagnon M, Van Hout CV, Weir MR, et. al. i Response to Low-Salt Intake in a Healthy Adult Population. *J Clin Hypertens* (Greenwich). 2011;13:795-800.
137. Weir MR. Short-term effects of vitamin D receptor activation on serum creatinine, creatinine generation, and glomerular filtration. *Kidney Int.* 2011 Nov;10(2):1016-1017.
138. Scialla J, Leonard MB, Townsend R, Appel L, Wolf M, Budoff MJ, Chen J, Lustigova E, Gadegbeku CA, Glenn M, Hanish A, Raj D, Rosas SE, Seliger SL, Weir MR, Parekh RS on behalf of the CRIC Study Group. Correlates of Osteoprotegerin and Association with Aortic Pulse Wave Velocity in Patients with Chronic Kidney Disease. *Clin J Am Soc Nephrol*. 2011;6:2612-2619.
139. Weir MR. Optimal Treatment Strategies for Patients with Hypertension and Diabetes Are Effects on Metabolism Important? *Hypertension*. 2011;58:789-759.
140. Weir MR. Recognizing the link between chronic kidney disease and cardiovascular disease. Am J Manag Care. 2011 Dec; 17 Suppl 15:S396-402.
141. Weir MR. Body mass index-mortality paradox in hemodialysis patients: blood pressure, blood volume, and nutritional status. *Hypertension*. 2011 Dec;58(6):989-90.
142. Weir MR. Recognizing the link between chronic kidney disease and cardiovascular disease. *Am J Manag Care*. 2011 Dec; Suppl 15:S396-402.
143. Greathouse MK and Weir MR. The Role of ARBs Alone or with HCTZ in the Treatment of Hypertension and Prevention of Cardiovascular and Renal Complications. *Postgrad Med*. 2012 Mar;124(2):40-52.
144. Jones H, Talwar M, Nogueira JM, Ugarte R, Cangro C, Rasheed H, Klassen DK, Weir MR, Haririan A. Anemia After Kidney Transplantation: Its Prevalence, Risk Factors, and Independent Association with Graft and Patient Survival: A Time-Varying Analysis. *Transplantation.* 2012 May 15;93(9):923-8.
145. Weir MR, Bakris GL, Weber MA, Dahlof B, Devereux RB, Kjeldsen SE, Pitt B, Wright JT, Kelly RY, Hua TA, Hester RA, Velazquez E, Jamerson KA. Renal Outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar;81(6):568-76.
146. Parsa A, Brown E, Weir MR, Fink JC, Shuldiner AR, Mitchell BD, McArdle PF. Genotype-based changes in serum uric acid affect blood pressure. Kidney Int. 2012 Mar;81(5):502-7.
147. Mohanlol V, Parsa A, Weir MR. Role of dietary therapies in the prevention and treatment of hypertension. *Nat Rev Nephrol*. 2012 May 15;8(7):413-22.
148. Weir MR, Agarwal R. Thiazide and thiazide-like diuretics: perspectives on individualization of drug and dose based on therapeutic index. *Hypertension*. 2012 Jun;59(6):1089-90.
149. Scialla JJ, Appel LJ, Wolf M, Yang W, Zhang X, Sozio SM, Miller ER 3rd, Bazzano LA, Cuevas M, Glenn MJ, Lustigova E, Kallem RR, Porter AC, Townsend RR, Weir MR, Anderson CA; Chronic Renal Insufficiency Cohort (CRIC) Study Group. *J Ren Nutr*. 2012 Jul;22 (4):379-388.
150. Onukwugha E, Saunders E, Mullins CD, Pradel FG, Zuckerman M, Loh FE, Weir MR. A qualitative study to identify reasons for discharges against medical advice in the cardiovascular setting. *BMJ Open*. 2012 Jul 30;2(4).
151. Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, Carithers RL, Ragosta M, Bolton K, Auerbach AD, Eagle KA; on behalf of the American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Peripheral Vascular Disease. *Circulation*. 2012 Jul 31; 126 (5):617-663.
152. Carpenter MA, Weir MR, Adey DB, House AA, Bostom AG, Kusek JW. Inadequacy of cardiovascular risk factor management in chronic kidney transplantation – evidence from the FAVORIT study. *Clin Transplant*. 2012 Jul;26(4):E438-46.
153. Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, Carithers RL, Ragosta M, Bolton K, Auerbach AD, Eagle KA; American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Peripheral Vascular Disease. Cardiac disease evaluation and management among kidney disease and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cariology Foundation. *J Am Coll Cardiol*. 2012 Jul 31;60(5): 434-80.
154. Weir MR. Improving the estimating equation for GFR-a clinical perspective. *N Engl J Med*. 2012 Jul 5;367 (1):75-6.
155. Weir MR, Drachenberg CB. A 72-year-old woman with several months of weight loss and generalized weakness. *Am J Med Sci*. 2012 Aug; 344(2):142-5.
156. Patel K, Diamantidis C, Zhan M, Hsu VD, Walker LD, Gardner J, Weir MR, Fink JC. Influence of Creatinine versus Glomerular Filtration Rate on Non-Steroidal Anti-Inflammatory Drug Prescriptions in Chronic Kidney Disease. *Am J Nephrol*. 2012; 36(1): 19-26.
157. Anderson AH, Yang W, Hsu CY, Joffe MM, Leonard MB, Xie D, Chen J, Greene T, Jaar BG, Kao P, Kusek JW, Landis JR, Lash JP, Townsend RR, Weir MR, Felman; CRIC Study Investigators. Estimating GFR Among Participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. *Am J Kidney Dis*. 2012 Aug (2):250-61.
158. Karadsheh F, Weir MR. Thiazide-like Diuretics: An opportunity to Reduce Blood Pressure in Patients with Advanced Kidney Disease. *Curr Hypertens Rep*. 2012 Oct;14(5):416-20.
159. Weir MR, Townsend RR, Fink JC, Teal V, Sozio SM, Anderson CA, Appel LJ, Turban S, Chen J, He J, Litbarg N, Ojo A, Rahman M, Rosen L, Steigerwalt S, Strauss L, Joffee MM. Urinary Sodium Is a Potent Correlate of Proteinuria: Lessons from the Chronic Renal Insuffficiency Cohort Study. Am J Nephrol. 2012 Oct 12; 36(5):397-404.
160. Weir MR. Debate from the 2012 ASH Annual Scientific Sessions: should blood pressure be reduced in hemodialysis patients? con position. J Am Soc Hypertens. 2012 Nov/Dec; 6(6):443-447
161. Nesbitt SD, Shojaee A, Maa J-F, and Weir MR. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). *J of Human Hypertens*. 2013 Jul;27(7):445-52.
162. Papadimitriou JC, Drachenberg CB, Ramos E, Kukuruga D, Klassen DK, Ugarte R, Nogueira J, Cangro C, Weir MR, Haririan A. Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and cause for biopsies. *Transplantation*. 2013 Jan 15;95(1):128-36.
163. Mullins CD, Jain R, Weir MR, Franey CS, Shih YC, Pradel FG, Bikov K, Bartlett ST. Benefits improvement and protection act’s impact on transplantation rates among elderly MEDICARE beneficiaries with end-stage renal disease. *Transplantation*. 2013 Feb 15;95(3):463-9.
164. Townsend RR, Weir MR. Angiotensin II blockade after kidney transplantation. *J Am Soc Nephrol*. 2013 Feb;24(2):167-8.
165. Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013 Feb 16; 381(9866):537-45.
166. Weir MR, Shojaee, Maa JF. Efficacy of amlodipine/olmesartan medoxomil ± hydrochlorothiazide in patients aged ≥ 65 or & lt; 65 years with uncontrolled hypertension on prior monotherapy. *Postgrad Med*. 2013 Mar; 125(2): 124-34.
167. Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, Sanders PW, Textor SC, Weir MR, Townsend RR. KDOQI US commentary on the 2012 KDIGO clinical practice guidelines for management of blood pressure in CKD. *Am J Kidney Dis*. 2013 Aug;62(2):201-13.
168. Agarwal R, Weir MR. Treated hypertension and the white coat phenomenon: office readings are inadequate measures of efficacy. *J Am Soc Hypertens*. 2013 May-June;7(3):236-43.
169. Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, Velazquez EJ, Pitt B, Jamerson K. Systolic Blood Pressure and Cardiovascular Outcomes During Treatment and Hypertension. *Am J Med*. 2013 Jun;126(6):501-8.
170. Agarwal R, Weir MR. Blood pressure response with fixed-dose combination therapy: comparing hydrochlorothiazide with amlodipine through individual-level meta-analysis. *J Hypertens*. 2013 Aug;31(8):1692-701.
171. Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, Sanders PW, Textor SC, Weir MR, Townsend RR. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD. *Am J Kidney Dis*. 2013 Aug;31(8):1692-701.
172. Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, Velazquez EJ, Pitt B, Jamerson K. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. *Am J Med*. 2013 June;126(6):501-8.
173. Weber MA, Bakris GL, Weir MR, Jamerson K. Obesity, blood pressure, and cardiovascular outcomes – Author’s reply. *Lancet*. 2013 Jun 8;381(9882):1982-3.
174. Nesbitt SD, Shojaee A, Maa JF, Weir MR. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). *J Hum Hypertens*. 2013 Jul;27(7):445-52.
175. Kasiske BL, Anderson-Haag T, Ibrahim HN, Pesavento TE, Weir MR, Nogueira JM, Cosio FG, Kraus ES, Rabb HH, Kalil RS, Posselt AA, Kimmel PL, Steffes MW. A Prospective Controlled Study of Kidney Donors: Baseline and 6-Month Follow-up. *Am J Kidney Dis*. 2013 Sept;62(3):577-86.
176. Mindikoglu AL, Weir MR. Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. *Am J Nephrol*. 2013;38(4):345-54.
177. Salzberg DJ, Karadsheh FF, Haririan A, Reddivari V, Weir MR. Specific Management of Anemia and Hypertension in Renal Transplant Recipients: Influence of Renin-Angiotensin System Blockade. *Am J Nephrol*. 2013 Dec 19;39(1):1-7.
178. Weir MR, Townsend RR. Refractory Hypertension: An Important Clinical Phenotype. *Hypertension*. 2014. Mar; 63(3):447-8.
179. Weir MR, Townsend RR. Vascular Stiffness as a Surrogate Measure of Mortality in Patients with Chronic Kidney Disease. *J Hypertens*. 2014 Apr; 32 (4):744-5.
180. Mindikoglu AL, Dowling TC, Weir MR, Seliger SL, Christenson RH, Magder LS. Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. *Hepatology*. 2014 Apr; 59(4):1532-42.
181. Weir MR, Fink JC. Safety of Medical Therapy in Patients with Chronic Kidney Disease and End-Stage Renal Disease. *Curr Opin Nephrol Hypertens*. 2014 May;23(3):306-13.
182. Carpenter MA, John A, Weir MR, Smith SR, Hunsicker L, Kasiske BL, Kusek JW, Bostom A, Ivanova A, Levey AS, Solomon S, Pesavento T, Weiner DE. *J AM Soc Nephrol*. 2014 Mar 13. [Epub ahead of print]
183. Weir MR. Salt, hypertension, and proteinuria in diabetic nephropathy. *Lancet Diabetes Endocrinol*. 2014 May;2(5):351-2.
184. Mindikoglu AL, Dowling TC, Wong-You-Cheong JJ, Christenson RH, Magder LS, Hutson WR, Seliger SL, Weir MR. A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. *Am J Nephrol*. 2014;39(6):543-52.
185. DeSilva L, Diamantidis CJ, Prakash D, Zuckerman M, Weir MR. Usability of Mobile Technology to Screen for Drug-Drug Interactions in Kidney Transplant Patients. *Am J Nephrol*. 2014 Jul 19;40(2):97-104.
186. Carpenter MA, John A, Weir MR, Smith SR, Hunsicker L, Kasiske BL, Kusek JW, Bostom A, Ivanova A, Levey AS, Solomon S, Pesavento T, Weiner DE. BP, cardiovascular disease , and death in the folic acid for vascular outcome reduction in transplantation trial. *J Am Soc Nephrol*. 2014 Jul;25(7):1554-62.
187. Agarwal R, Flynn J, Pogue V, Rahman M, Reisin E, Weir MR. Assessment and Management of Hypertension in Patients on Dialysis. *J Am Soc Nephrol*. 2014 Aug;25(8):1630-46.
188. Weir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (epGFR). *Curr Med Res Opin*. 2014 Sep;30(9):1759-68.
189. Weir MR, Januszewicz A, Gilbert RE, Vijapurkar U, Kline I, Fung A, Meininger G. Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients with Type 2 Diabetes Mellitus. *J Clin Hypertens (Greenwhich)*. 2014 Dec;16(12):875-82.
190. Lakkis JI, Weir MR. Treatment-Resistant Hypertension in the Transplant Recipient. *Semin Nephrol*. 2014;34(5):560-570.
191. Weir MR, Gravens-Muller L, Costa N, Ivanova A, Manitpisitkul W, Bostom AG, Diamantidis CJ; on behalf of the FAVORIT Study Investigators. Safety Events in Kidney Transplant Recipients: Results from the Folic Acid for Vascular Outcome Reduction in Transplant Trial. *Transplantation*, 2014 Nov 12. [Epub ahead of print].
192. Weir MR. Hypertension and kidney disease. *J AM Soc Hypertens*. 2014 Nov;8(11):855-7;quiz 858-9.
193. Weir MR. In the clinic: hypertension. *Ann Intern Med*. 2014 Dec 2;161(11):ITC1-15;quiz ITC16.
194. Karadsheh F, Weir MR. The use of thiazides in chronic kidney disease. *Curr Hypertens Rev*. 2014;10(2):81-5.
195. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv, Wittes J, Christ-Schmidt H, Berman L, Pitt B; the OPAL-HK Investigators. Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. N Engl J Med. 2015 Jan 15;372(3):211-21.
196. Anderson AH, Yang W, Townsend RR, Pan Q, Chertow GM, Kusek JW, Charleston J, He J, Kallem R, Lash JP, Miller ER 3rd, Rahman M, Steigerwalt S, Weir M, Wright JT Jr, Feldman HI; Chronic Renal Insufficiency Cohort Study Investigators. Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study. Ann Intern Med. 2015 Feb 17;162(4):258-65.
197. Liu KD, Yang W, Go AS, Anderson AH, Feldman HI, Fischer MJ, He J, Kallem RR, Kusek JW, Master SR, Miller ER 3rd, Rosas SE, Steigerwalt S, Tao K, Weir MR, Hsu CY; CRIC Study Investigators. Urine Neutrophil Gelatinase-Associated Lipocalin and Risk of Cardiovascular Disease and Death in CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2015 Feb;65(2):267-74.
198. Hart A, Weir MR, Kasiske BL. Cardiovascular risk assessment in kidney transplantation. Kidney Int. 2015 Mar;87(3):527-534.
199. Weir MR, Burgess ED, Cooper JE, Fenves AZ, Goldsmith D, McKay D, Mehrotra A, Mitsnefes MM, Sica DA, Taler SJ. Assessment and Management of Hypertension in Transplant Patients. *J Am Soc Nephrol*. 2015 Feb 4.
200. Weir MR. Is There an Optimal Strategy for Pretransplant Cardiovascular Screening? Transplantation. 2015 April;99(4):656-7.
201. Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications and controversies. *Nat Rev Endocrinol*. 2015 Apr;11(4):242-252.
202. Weir MR, Bakris GL, Pit B. New agents for hyperkalemia. N Engl J Med. 2015 Apr 16; 372(16):1570-1.
203. Hart A, Weir MR, Kasiske BL. The authors reply. Kidney Int. 2015 Apr;87(4):863-4.
204. Wolf M, Weir MR, Kopyt N, Mannon RB, Von Visger J, Deng H, Yue S, Vincenti F. A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. *Transplantation*. 2015 Jun 14. [Epub ahead of print].
205. Weir MR, Espaillat R. Clinical perspectives on the rationale for potassium supplementation. Postgrad Med. 2015 Jun; 127(5):539-48.
206. Mindikoglu AL, Dowling TC, Magder LS, Christenson RH, Weir MR, Seliger SL, Hutson WR, Howell CD. Estimation of Glomerular Filtration Rate in Patients With Cirrhosis by Using New and Conventional Filtration Markers and Dimethylarginines. Clin Gastroenterol Hepatol. 2015 Jun 29. Pii:S1542-3565(15)00845-9.[Epub ahead of print]
207. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA; AMETHYST-DN Investigators. Effect of Patiromer on Serum Potassium Level in Patients with Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. Jama 2015 July 14;314(2):151-61.
208. Kasiske BL, Anderson-Haag T, Israni AK, Kalil RS, Kimmel PL, Kraus ES, Kumar R, Posselt AA, Pesavento TE, Rabb H, Steffes MW, Snyder JJ, Weir MR. A prospective controlled study of living kidney donors: three-year follow-up. Am J Kidney Dis. 2015 Jul;66(1):114-24.
209. Campbell D, Weir MR. Defining, Treating, and Understanding Chronic Kidney Disease – A Complex Disorder. J Clin Hypertens (Greenwich). 2015 Jul;17(7):514-27.
210. Rubin MF, Weir MR. Access to Kidney Transplantation: Is There a Potential Conflict of Interest? Am J Nephrol. 2015;41(6):502-3. [Epub 2015 Aug 6]
211. Weir MR. CCR2 inhibition: a panacea for diabetic kidney disease? Lancet Diabetes Endocrinol. 2015 Sep; 3(9):663-7.
212. He J, Mills KT, Appel LJ, Yang W, Chen J, Lee BT, Rosas SE, Porter A, Makos G, Weir MR, Hamm LL, Kusek JW; Chronic Renal Insufficiency Cohort Study Investigators. Urinary Sodium and Potassium Excretion and CKD Progression. J AM Soc Nephrol. 2015 Sep 17. [Epub ahead of print]
213. Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015 Oct;17(10):1057-65.
214. Mindikoglu AL, Dowling TC, Schaub DJ, Hutson WR, Potosky DR, Christenson RH, Barth RN, LaMattina JC, Hanish SI, Weir MR, Raufman JP. Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child-Turcotte-Pugh Class C Cirrhosis and Renal Dysfunction. Dig Dis Sci. 2015 Nov;60(11):3491-4.
215. Thomas B, Weir MR. The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient. Curr Cardiol Rep. 2015 Nov;17(11):95.
216. Bushinsky DA, Williams GH, Pitt B, Weir MR, Freeman MW, Garza D, Stasiv Y, Li E, Berman L, Bakris GL. Kidney Int. 2015 Dec; 88(88)6:1427-1433.
217. Weir MR. Diabetic nephropathy: Nonsteroidal MRA added to RAS blockade reduces albuminuria. Nat Rev Nephrol. 2015 Dec; 11(12):691-2.
218. Wang Z, Zeng C, Villar VA, Chen SY, Konkalmatt P, Wang X, Asico LD, Jones JE, Yang Y, Sanada H, Felder RA, Eisner GM, Weir MR, Armando I, Jose PA. Human GRK4y142V Variant
219. Thomas G, Xie D, Chen HY, Anderson AH, Appel LJ, Bodana S, Brecklin CS, Drawz P, Flack JM, Miller ER 3rd , Steigerwalt SP, Townsend RR, Weir MR, Wright JT Jr. Rahman M. Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study. Hypertension. 2016 Feb; 67(2):387-96.
220. Weir MR, Blantz RC. Noteworthy observations in hypertension from 2015. Curr Opin Nephrol Hypertens. 2016 Jan;25(1):1-2.
221. Pitt B, Weir MR. Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment? Eur J Heart Fail. 2016 Feb;18(2):216.
222. Drawz PE, Alper AB, Anderson AH, Brecklin CS, Charleston J, Chen J, Deo R, Fischer MJ, He J, Hsu CY, Huan Y, Keane MG, Kusek JW, Makos GK, Miller ER 3rd, Soliman EZ, Steigerwalt SP, Taliercio JJ, Townsend RR, Weir MR, Wright JT Jr, Xie D, Rahman M; and the Chronic Renal Insufficiency Cohort Study Investigators. Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage. Clin J Am Soc Nephrol. 2016 Apr 7; 11(4):642-52.
223. Weir MR. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. Postgrad Med. 2016; 128(3):290-8.
224. Ahmad SB, Inouye B, Phelan MS, Kramer AC, Sulek J, Weir MR, Barth RN, LaMattina JC, Schweitzer EJ, Leeser DB, Niederhaus SV, Barlett ST, Bromberg JS. Live Donor Renal Transplant With Simultaneous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease Is Feasible and Satisfactory at Long-Term Follow-Up. Transplantation. 2016 Feb;100(2):407-15.
225. Weber MA, Bloch M, Bakris GL, Weir MR, Zappe DH, Dahlof B, Velazquez EJ, Pitt B, Basile JN, Jamerson K, Hua TA. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr;18(4):299-307.
226. Weir MR. Current and future treatment options for managing hyperkalemia. Kidney Int Supp 2016 (6):29-34.
227. Kasiske BL, Kumar R, Kimmel PL, Pesavento TE, Kalil RS, Kraus ES, Rabb H, Posselt AM, Anderson-Haag TL, Steffes MW, Israni AK, Snyder JJ, Singh RJ, Weir MR. Abnormalities in biomarkers of mineral and bone metabolism in kidney donors.Kidney Int. 2016 Jun 28. pii: S0085-2538(16)30203-4. [Epub ahead of print]
228. Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, Yuan J, Berman L, Williams GH. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016 Jun 24. pii: S0085-2538(16)30186-7. [Epub ahead of print]
229. Dias C, Moore KT, Murphy J, Ariyawansa J, Smith W, Mills RM, Weir MR. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis. Am J Nephrol. 2016;43(4):229-36.
230. Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract. 2016 Jun;22(6):753-62.
231. Gilbert RE, Weir MR, Fioretto P, Law G, Desai M, Kline I, Shaw W, Meininger G. Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. Can J Diabetes. 2016 Jun;40(3):247-57.
232. Narayan P, Duan B, Jiang K, Li J, Paka L, Yamin MA, Friedman SL, Weir MR, Goldberg ID. Late intervention with the small molecule BB3 mitigates postischemic kidney injury. Am J Physiol Renal Physiol. 2016 Aug 1;311(2):F352-61.
233. Palmer BF, Clegg DJ, Taylor SI, Weir MR. Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. J Diabetes Complications. 2016 Aug;30(6):1162-6.
234. Lentine KL, Villines TC, Axelrod D, Kaviratne S, Weir MR, Costa SP. Evaluation and Management of Pulmonary Hypertension in Kidney Transplant Candidates and Recipients: Concepts and Controversies. Transplantation. 2016 Mar 16. [Epub ahead of print]
235. Weir MR, Pearson TC, Patel A, Peddi VR, Kalil R, Scandling J, Chan L, Baliga P, Melton L, Mulgaonkar S, Waid T, Schaefer H, Youssef N, Anandagoda L, McCollum D, Lawson S, Gordon R. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. Transplantation. 2016 Mar 4.
236. Dias C, Moore KT, Murphy J, Ariyawansa J, Smith W, Mills RM, Weir MR. Rivaroxaban in Chronic Hemodialysis Patients: Clarification of an Editorial Error. Am J Nephrol. 2016;44(2):169. Epub 2016 Aug 23.
237. Ravichandran B, Weir MR. The Tyranny of Generic Immunosuppressants. Am J Nephrol. 2016;44(3):204-5. Epub 2016 Aug 31.
238. Weir MR. Biomarkers for Predicting Improved Outcomes With Renal Artery Stenting. Hypertension. 2016 Sep 19. [Epub ahead of print].
239. Bushinsky DA, Spiegel DM, Gross C, Benton WW, Fogli J, Hill Gallant KM, Du Mond C, Block GA, Weir MR, Pitt B. Effect of Patiromer on Urinary Ion Excretion in Healthy Adults. Clin J Am Soc Nephrol. 2016 Sep 27.
240. Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, Yuan J, Berman L, Williams GH. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016 Sep;90(3):696-704.
241. Liu X, Foster MC, Tighiouart H, Anderson AH, Beck GJ, Contreras G, Coresh J, Eckfeldt JH, Feldman HI, Greene T, Hamm LL, He J, Horwitz E, Lewis J, Ricardo AC, Shou H, Townsend RR, Weir MR, Inker LA, Levey AS; CRIC (Chronic Renal Insufficiency Cohort) Study Investigators. Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD. Am J Kidney Dis. 2016 Sep 20. pii: S0272-6386(16)30374-2.
242. Kasiske BL, Kumar R, Kimmel PL, Pesavento TE, Kalil RS, Kraus ES, Rabb H, Posselt AM, Anderson-Haag TL, Steffes MW, Israni AK, Snyder JJ, Singh RJ, Weir MR. Abnormalities in biomarkers of mineral and bone metabolism in kidney donors. Kidney Int. 2016 Oct;90(4):861-8.

**PUBLICATIONS - (NON-REFEREED)**

1. Thornton GF, Weir MR. Extrapulmonary tuberculosis: where and how to find it. Medi guide to Infectious Diseases 1983; 3(3):1-4.
2. Weir MR. An elderly patient undergoing second renal transplantation. No. 3 in a series of case studies. Sandoz Pharmaceuticals 1986.
3. Cohen S, Weir MR, Dagher FJ, Bentley FR, Revie DR, Ordonez J, Chretien P. Effect of cyclosporine on total lymphocyte and T-cell counts in renal-transplant recipients. New England Journal of Medicine 1986; 314:447-448 (letter).
4. Weir MR. Hypertension therapy: avoiding end-organ damage. Urban Practice Today 1988; 2:3-5.
5. Weir MR. The enigma of extrapulmonary tuberculosis (editorial). New York State J Med 1989; 89:251-252.
6. Weir MR. (Moderator), Epstein M, Raij L, Dworkin LD, Hollenberg NH, Curtis JJ. "Perspectives in renal protection: where do ACE inhibitors and calcium channel blockers fit in?" as appearing in Perspectives in Hypertension and Renal Disease. 1989;2:1-34.
7. Weir MR. Impact of blood pressure control on renal function. Current Concepts in Antihypertensive Therapy 1989; 1:56-63.
8. Weir MR. Renal function and its implications for antihypertensive therapy. Practical Cardiology 1990; October: 43-47.
9. Weir MR, Haynie R, Vertes V, Pinson R, Kong BW, Jenkins P, Lavin PT. A comparison of the efficacy and tolerability of enalapril and sustained-release diltiazem in mild to moderate essential hypertension. Clin Ther 1990; 12:473-481.
10. Burris JF, Weir MR, Oparil S, Cady WJ. The effects of thiazides plus calcium channel blockers. JAMA 1990; 264:971-973. (letter)
11. Weir MR. Strategies in treating hypertension: Physiology of pharmacologic intervention to prevent renal insufficiency. Advances in Cardiology 1990; 1:1-10.
12. Weir MR, Li XW, Gomolka D, Peppler R, O'Bryan-Tear CG, Moran MA. Immunosuppressive properties of enisoprost and a 5-lipoxygenase inhibitor (SC-45662). Transplant Proc 1991; 23:1074-1077.
13. Weir MR (Moderator), Sowers JR, Bauer JH, Rostand SG, Bakris GL. Perspectives in renal protection: high-risk hypertensive subpopulations. Perspectives in Hypertension and Renal Disease 1991; 4:1-28.
14. Weir MR, Hise MK. Hypertension in blacks: pathophysiology and therapy. Hypertension: New approaches to drug therapy 1991; 3:2-16.
15. Weir MR. Hypertension and arthritis: coprevalence and implications for therapy. Comorbidity in Cardiovascular Disease 1992; 1:3-9.
16. DeQuattro V, Weir MR. Bisoprolol Fumerate/Hydrochlorothiazide 6.25 mg: a new, low-dose option for first-line antihypertensive therapy. Advances in Therapy 1993; 10:197-206.
17. Weir MR. A new antihypertensive strategy to minimize dose-related side effects: low-dose multi mechanism therapy. Advances in Therapy 1993; 10:293-299.
18. Weir MR. Value of adjunctive calcium channel blockers to broaden the therapeutic index of cyclosporine therapy. Transplantation and Immunology Newsletter 1994; 10:3,11-13.
19. Weir MR. Hypertension - case and comment - multiple problems with multiple solutions. Patient Care 1995;29(11):169-170.
20. Flack JM, Mensah GA, McVeigh GE, Weir MR, Reed JW. Diagnosis, evaluation, and management of hypertension in an ambulatory clinic setting. J of Clinical Outcomes Management 1995;2(5):39-66.
21. Weir MR,. The role of dietary salt in altering the management of hypertension. International Society of Hypertension in Blacks 1995;7-8.
22. Weir MR, Schroeder JS, eds. Primary prevention versus end-stage treatment. U.S. Medical Costs and Values 1995;1-24.
23. Weir MR. Salt sensitivity: defining a major hypertensive subgroup. An interview with Matthew R. Weir, MD. Cardiovascular Horizons 1995; 9-12.
24. Hanes DS, Weir MR. The failing heart and diuretic resistance: adaptation or altruism? Congestive Heart Failure Jan/Feb 1996; 11-16
25. Weir MR. Antihypertensive combination therapy. Drugs of Today 1998; 34:5-9.
26. Weir MR. The effect of dietary salt consumption on blood pressure and cardiovascular risk. Current Practice of Medicine. 1999; 6(2):125-127.
27. Weir MR, Froch L. Weighing the renal effects of NSAIDS and COX-2 inhibitors. Clinical Dilemmas 2000;1:(2):3-15.
28. Weir MR. Do living unrelated transplant recipients require anti-CD25 receptor antibody induction? Clinical Challenges in Transplant Medicine February 2002; 3(2): 7-8.
29. Weir MR. Assessing risk and treating comorbid renal disease. Johns Hopkins University School of Medicine Advanced Studies in Medicine. Vol 5 (10C) – November 2005; S994-S1002.
30. Weir MR. Hypertension and Cardiovascular Risk. US Cardiovascular Disease 2007 (2): 64-66.
31. Weir MR. The Obesity Paradox: Impact of Obesity on the Prevalence and Prognosis of Cardiovascular Diseases. Practice Pearl. January 2009;121(1): 164-165.
32. Weir MR. Leadership message: government and corporate responsibility to work with academia about the obesity epidemic. J Clin Hypertens (Greenwich). 2011 March;13(3):217-8.
33. Weir MR. The author replies. Kidney Int. 2011 June;79(12):1379-80.
34. Gradman A, Nesbitt S, Weir MR. Treating Special Populations with Hypertension: Is a Two-Drug or Fixed-Dose Combination Therapy Appropriate Initial Treatment in Hypertension? Med Roundtable Cardiovasc Ed. 2011;2(4):225–234

**BOOK CHAPTERS**

1. Weir MR, Hise MK. Hypertensive renal damage. In: Saunders E, Brest AN eds. Cardiovascular Diseases in Blacks; Cardiovascular Clinics, F.A. Davis Company, Philadelphia, PA 1991; 21:115-132.
2. Weir MR, Wolfsthal SD. Hypertension and the kidney. In: Boone JL, ed. Primary Care; Clinics in Office Practice. W.B. Saunders Company, Philadelphia, PA, 1991; 18:525-544.
3. Weir MR. Clinical benefits of calcium antagonists in renal transplant recipients. In: Epstein M, ed. Calcium Antagonists in Clinical Medicine. Hanley & Belfus, Inc. Philadelphia, PA, 1992;391-412.
4. Weir MR. Calcium channel blockers. In: Vidt DG, Izzo JL, Black HR, eds. Hypertension Primer. The American Heart Association Press, Dallas, Tx, 1993; 311-313.
5. Weir MR. Antihypertensive therapy: progression of renal injury. In: Hollenberg NK, ed. Hypertension: Mechanisms and Therapy. Atlas of Heart Diseases. Current Medicine, Philadelphia, PA, 1994; 10:1-18.
6. Weir MR, Zachariah PK. Verapamil. In: Messerli FH, ed. Cardiovascular Drug Therapy. W. B. Saunders Co, Philadelphia, PA, 1996; 915-925.
7. Weir MR, Bolli P, Prichard BNC, Weber MA. Bisoprolol. In: Messerli FH, ed. Cardiovascular Drug Therapy. W.B. Saunders Co, Philadelphia, PA, 1996; 557-568.
8. Weir MR, Weber, MA. Quinapril hydrochloride. In: Messerli FH, ed. Cardiovascular Drug Therapy, W.B. Saunders Co., Philadelphia, PA, 1996; 794-801.
9. Weir MR, Bakris GL, Toto RD, Flack JM, Williams B, Neutel JM. Hypertension. In: Gonick H, ed. Current Nephrology, Vol.19. Mosby-Yearbook, Chicago, IL, 1996; 203-241.
10. Weir MR, Bakris GL, Toto RD, Flack JM, Bravo EI. Hypertension. In: Gonick H, ed. Current Nephrology, Vol.20. Mosby-Year Book, Inc., Chicago, IL, 1997; 209-241.
11. Flack JM, Weir MR. Calcium antagonists as antihypertensive agents. In: Epstein M, ed. Calcium Antagonists in Clinical Medicine, 2nd ed. Hanley & Belfus, Inc., Philadelphia, PA, 1998; 291-305.
12. Weir MR. The clinical utility of calcium antagonists in renal transplant recipients. In: Epstein M, ed. Calcium Antagonists in Clinical Medicine, 2nd ed. Hanley & Belfus, Inc., Philadelphia, PA, 1998:467-491.
13. Weir MR. Antihypertensive therapy: progression of renal injury. In: Braunwald E, Hollenberg NK, eds. Atlas of Heart Diseases. Hypertension: Mechanisms and Therapy, 2nd ed, Vol.1. Current Medicine, Inc., Philadelphia, PA, 1998; 10:10.1-10.24.
14. Cohen DJ, Weir MR. Post-transplant in-hospital care. In: Norman DJ, Suki WN, eds. Primer on Transplantation. American Society of Transplant Physicians, Thorofare, NJ, 1998;28:223-228.
15. Ramos E, Weir MR, Klassen DK, Keay S. Donor and Recipient Evaluation. In: Malluche HH, ed. Clinical Nephrology, Dialysis, and Transplantation. Dustri-Verlag, Elmont, NY 1998.
16. Weir MR. Dihydropyridine Calcium Antagonists. In: Izzo and Black, ed. Clinical Management: Sheps SG, Sica DA,Vidt DG. Hypertension Primer. American Heart Association, Second Edition. Baltimore, MD 1998.
17. Weir MR. A patient with non-diabetic renal disease and proteinuria. In: P. Sleight, ed. Clinical cases in hypertension: Specific treatment strategies. 1998.
18. Weir MR. Epidemiology and pathophysiology of hypertension. In: J. Neutel, ed. Cases 11,12,13,14. Cardiology - Pearls and Pitfalls Volume 1, 2, 3; 1998.
19. Weir MR. Initial Choices in the Treatment of Hypertension. In: Oparil and Weber, eds. *Hypertension*: a companion to Brenner and Rector’s *The Kidney*. W.B.Saunders Company, 1999.
20. Ramos ER, Weir MR, Klassen DK, Keay S. Donor and Recipient Transplantation Evaluation. In: *Malluche HH*, ed. Clinical Nephrology, Dialysis and Transplantation Dustri-Verlag, Elmont, NY 1999.
21. Weir MR. Physiology of the Transplanted Kidney. In: Norman DJ, Suki WN, eds. *Primer on Transplantation*. American Society of Transplant Physicians, Thorofare, NJ, 2000
22. Sowers JR, Neutel JM, Weir MR. Diuretics in Hypertensive Therapy. In: Hypertension Medicine. ed. Weber MA. Humana Press, Totowa, NJ 2000; 285-288.
23. Weir MR. Choosing the First Agent. In: *Hypertension Medicine*. ed. Weber MA. Humana Press, Totowa, NJ 2000; 209-221.
24. Dworkin LD, Weir MR. Hypertension in renal parenchymal disease: role in progression. In: *Mechanism and Clinical Management of CRF.* El Nahas AM, Harris KPG, Anderson S, editors. 2nd Edition, Oxford Unviversity Press, Inc. New York, 2000.
25. Immunosuppression. In: *Clinical Management of the Transplant Patient*. Ed. Kuo PC, Schroeder RA, Johnson LB. Oxford University Press, New York, NY 2001; 27-50.
26. Weir MR. Antihypertensive Therapy: Progression of Renal Injury. In: *Atlas of Hypertension*. 4th ed*.* ed. Hollenberg NK. Philadelphia: Current Medicine, Inc., 2003; 209-240.
27. Ramos ER, Drachenburg CB, Portocarrero M, Wali RK, Klassen DK, Fink JC, Farney A, Hirsch H, Papadimitriou JC, Cangro CB, Weir MR, Bartlett ST. BK Virus Nephropathy Diagnosis and Treatment: Experience at the University of Maryland Renal Transplant Program. In: *Clinical Transplants* eds: Cecka and Terasaki. UCLA Immunogenetics Center, Los Angeles 2002.
28. Ramos E, Drachenberg CB, Portocarrero M, Wali R, Klassen DK, Fink JC, Farney A, Hirsch H, Papadimitriou JC, Cangro CB, Weir MR, Bartlett ST. BK virus nephropathy diagnosis and treatment: experience at the University of Maryland renal transplant program. In: *Clinical Transplants*. Cecka JM, Terasaki PI, eds. UCLA Immunogenetics Center 2003; 143-153.
29. Klassen DK, Weir MR. Renal Transplantation. In: *Scientific American Medicine* 2003 Ed. Dale and Federman, eds. Web MD Inc, New York 2003; 2000-2010.
30. Weir MR, Izzo JL Jr. Calcium Antagonists. In. *Hypertension Primer* 3rd Ed. Izzo and Black, Eds. Lippincott Williams & Wilkens: Philadelphia 2003; 433-437.
31. Weir MR, Cangro CB, Klassen DK, Preparing Dialysis Patients for Renal Transplantation. In. *Principles and Practice of Dialysis* 3rd Ed. Henrich, Ed. Lippincott Williams & Wilkens: Philadelphia 2004; 648-661.
32. Weir MR, Hanes D, Klassen DK. Antihypertensive Drugs. In: *Brenner and Rector’s* *The Kidney*. 7th ed. Brenner BM, Ed. Saunders, Philadelphia 2004; 2381-2453.
33. Weir MR. ACE inhibitors and angiotensin receptor blockers in kidney disease: are we denying protection to patients? In: *The Kidney and Hypertension*. Bakris GL, Ed. Martin Dunitz: London and New York, 2004; 105-116.
34. Weir, MR. Future developments in antihypertensive therapy. In: *The Year in Hypertension, 2004*. Gavras H, Ed. Clinical Publishing: Oxford, 2004; 257-263.
35. Klassen DK, Weir, MR. 11 Renal Transplantation. 10 Nephrology. ACP Medicine Online. Dale DC, Federman DD, Eds. Web MD Inc., New York, 2004.
36. Halloran, PF, Gourishankar, S, Vongwiwatana A, Weir, MR: Approaching the Renal Transplant with Deteriorating Function: Progressive Loss of Renal Function is Not Inevitable. In: *Medical Management of Kidney Transplantation*. Pages 389-402. Weir, MR, editor. Lippincott Williams & Wilkins Philadelphia, PA, 2005.
37. Lakkis, J, Weir, MR, Danovitch GM. Waiting List Management. In: *Medical Management of Kidney Transplantation*, Pages 46-52. Weir, MR, editor. Lippincott, Williams & Wilkins Philadelphia, PA, 2005.
38. Weir, MR. Prevention, Detection, and Clinical Presentations of Hypertension. Pages 1-12. Weir, MR, editor. *Hypertension*. American College of Physicians. Philadelphia, PA, 2005.
39. Hanes DS, Weir MR: Initial Evaluation and Follow Up. *Hypertension. A Companion to Brenner and Rector’s: The Kidney.* Pages 543-554. Oparil S and Weber MA, editors. Elsevier Saunders. Philadelphia, PA, 2005.
40. Lakkis J, Weir MR: Diabetes Mellitus and the Cardiovascular Metabolic Syndrome: Reducing Cardiovascular and Renal Events. *Hypertension. A Companion to Brenner and Rector’s: The Kidney.* Pages 543-554. Oparil S and Weber MA, editors. Elsevier Saunders. Philadelphia, PA, 2005.
41. Weir MR: Antihypertensive Therapy: Progression of Renal Injury. *Atlas of Hypertension*. Pages 221-254. N Hollenberg and E Braunwald, editors. Current Medicine LLC. Philadelphia, PA, 2005.
42. Hanes DH, Weir MR: Calcium Agonists. *Hypertension. Principles and Practice.* Pages 517-530. Battegay EJ, Lip GYH, Bakris GL, editors. Taylor & Francis group. NW, D.C. 2005.
43. Klassen DK, Weir MR: Renal Transplantation. *ACP Medicine.* Volume 2. 2006 Edition. A Publication of the American College of Physicians.Pages 2103-2114. Dale DC, Federman DD editors. WebMD Inc. New York, NY, 2006.
44. Briglia AE, Weir MR: Can aggressive control of blood pressure prevent progression of kidney disease? *Therapeutic Strategies in Hypertension*. Pages 125-139. Clinical Publishing. Oxford, 2006.
45. Salzberg DJ, Weir MR. COX-2 Inhibitors and Cardiovascular Risk. Inflammation in the Pathogenesis of Chronic Diseases: The COX-2 Controversy, Subcellular Biochemistry, R. E. Harris (ed) Volume 42, pages159-174.Springer 2007.
46. Weir MR. Calcium Antagonists. Hypertension Primer 2008; 4 (C138): 465-469
47. Weir MR. Efficacy and safety of RAS inhibition in diabetic patients with nephropathy. Renin Angiotensin System in Cardiovascular Medicine. 2007; Vol 3(3): 2-4.
48. Weir MR, Hanes D, Klassen DK. Antihypertensive Drugs. Brenner & Rector’s The Kidney. Phildelphia:Saunder Elsevier, 2008:1596-1645.
49. Salzberg DJ, Weir MR. Recent transplant issues in hypertension. Ed Raymond Townsend, The Year in Hypertension. 2008:7:227-242.
50. Weir MR, Brown EM. What is the optimal treatment in obesity-related hypertension. In: Weir, MR. Evidence-based Management of Hypertension. Tfm Pub Ltd, Castle Hill Barns, Harley, Nr Shrewsbury, UK, 2010. 29-40.
51. Hanes DS, Narakala NK, Weir MR. How Low Should Systolic and Diastolic Blood Pressure Be? In: Clinical Challenges, Hypertension II, ed Toth and Sica. 2010; 51-64.
52. Weir MR, Hanes D, Klassen DK. Antihypertensive Drugs. In: Brenner and Rector’s The Kidney. 9th ed. Brenner BM, Ed. Saunders, Philadelphia 2012; 1824-1867: chap 49.
53. Brown EM, Salzberg DJ, and Weir MR. Renal Consequences of Prostaglandin Inhibition in Heart Failure. In: The Kidney in Heart Failure. George L. Bakris, Editor. Springer. 2012; 117-126
54. Weir MR and Mavanur M. The Use of Angiotensin-Converting Enzyme Inhibitors in the Renal Transplant Recipient. In:ACE Inhibitors Medical Uses, Mechanisms of Action, Potential Adverse Effects and Related Topics 2014;Vol 2:191-202.
55. Karadsheh FF and Weir MR. Hematologic Complications of Chronic Kidney Disease: Leukocyte and Monocyte Function. In: Chronic Renal Disease. Kimmel, PL. and Rosen
56. Weir MR. ACE inhibitors and angiotensin receptor blockers in kidney disease: are we denying protection to patients? In: *The Kidney and Hypertension*. Bakris GL, Ed. Martin Dunitz: London and New York, 2004; 105-116.

## BOOKS

* 1. Weir, MR, editor. *Medical Management of Kidney Transplantation*. Lippincott Williams & Wilkins Philadelphia, PA, 2005.
  2. Weir, MR, editor. *Hypertension*. American College of Physicians. Philadelphia, PA, 2005.
  3. Weir MR, Sica, DA, editors. Contemporary Diagnosis and Management of The Hypertensive Patient. Handbooks in Health Care. Newtown, PA, 2009.
  4. Weir MR. Evidence-based Management of Hypertension. Tfm Pub Ltd, Castle Hill Barns, Harley, Nr Shrewsbury, UK, 2010.

## ABSTRACTS

1. Weir MR, Thornton GF. Extrapulmonary tuberculosis: The experience of a community hospital. American Federation for Clinical Research. October, 1981 (Presented). Clinical Research, 1981; 29: 380A.

2. Kirkman RL, Strom TB, Weir MR, Tilney NL. Late mortality and morbidity in recipients of long-term renal allografts. Proceedings of the American Society of Transplant Surgeons. May, 1982 (Presented). American Society of Transplant Surgeons. Abstract Book, 1982;8.

3. Kirkman RL, Strom TB, Weir MR, Tilney NL. The natural history of long-term renal transplantation. Proceedings of the International Congress of the Transplantation Society. August, 1982 (Presented). International Congress of the Transplantation Society Abstract Book, 1982; 8.

4. Weir MR, Kirkman RL, Strom TB, Tilney NL. Rehabilitation in recipients of long-term renal allografts. Proceedings of the American Society of Nephrology. November, 1982 (Presented). Kidney International, 1983; 23: 297.

5. Weir MR, Cohen DJ, Carpenter CB. Analysis of the alloimmune response of pre-sensitized animals: Compartmentalization of primed clones. American Federation for Clinical Research. May, 1983. Clinical Research, 1983; 31: 356A.

6. Weir MR, Cohen DJ, Carpenter CB. Compartmentalization of the immune response to repetitive stimulation with alloantigen. American Federation for Clinical Research. October, 1983 (Presented). Clinical Research, 1983; 31:690A.

7. Weir MR, Cohen DJ, Carpenter CB. Allograft transplantation subsequent to active and passive enhancement leads to compartmentalization of the immune response. American Federation for Clinical Research. October, 1983 (Presented). Clinical Research, 1983; 31:690A.

8. Weir MR, Kirkman RL, Strom TB, Tilney NL. Chronic liver disease in recipients of long-term renal allografts: Analysis of morbidity and mortality. Proceedings of the American Society of Nephrology. December, 1983 (Presented). Kidney International, 1984; 25:352.

9. Weir MR, Cohen DJ, Carpenter CB. Dissimilar immune responses to varied presentation of identical alloantigens. Proceedings of the International Congress of Nephrology Abstract Book, 1984; 9:267A.

10. Weir MR, Kirkman RL, Strom TB. Long-term effects of hepatitis B virus in renal transplant recipients: Analysis of morbidity and mortality. Proceedings of the International Congress of the Transplantation Society. August, 1984 (Presented). International Congress of the Transplantation Society Abstract Book, 1984; 10:312.

11. Hoopes J, Ryan P, Muncie H, McDermott D, Weir MR, Tenney J. Can serum creatinine be used to estimate accurately measured creatinine clearance in the aged? American Gerontological Society. November, 1984. Abstract Book of American Gerontological Society, 1984.

12. Posner JN, Weir MR, Hall-Craggs M, Shen YS, Alongi SV, Dagher FJ. Prognostic value of peripheral blood and renal biopsy eosinophilia in acute renal allograft rejection. Proceedings of the American Society of Nephrology. December, 1984. Kidney International, 1985, 27:346.

13. Josselson J, Weir MR, Sadler JH. Morbidity and mortality in a twice-weekly maintenance hemodialysis program. Proceedings of the American Society of Nephrology. December, 1984. Kidney International, 1985; 27:164.

14. Weir MR, Josselson J, Sadler JH Bi-weekly vs. thrice-weekly hemodialysis: Five year analysis of morbidity and mortality. Proceedings of the American Society of Nephrology. December, 1984 (Presented). Kidney International, 1985; 27:175.

15. Shen YS, Weir MR, Litkowski LJ, Anthony RL, Welik RA Kosenko, A, Light PD, Dagher FJ, Sadler JH. Diagnosis of transplant rejection and cyclosporine toxicity by measurement of human renal proximal tubular epithelial antigen in the serum. American Society of Transplant Physicians. May, 1985 (Presented). American Society of Transplant Physicians Abstract Book, 1985; 4:39.

16. Kosenko A, Shen SY, Weir MR, Revie D, Ordonez J, Dagher FJ, Sadler JH, Chreitien P. Re-evaluation of T-cell subset monitoring in renal allograft recipients treated with cyclosporine. May, 1985 (Presented). American Society of Transplant Physicians Abstract Book, 1985; 4:10.

17. Weir MR, Zemel S, Shen SY, Welik R, Peppler R, McRoy C, Sadler JH, Leavitt R. Acute effects of hemodialysis on lymphocyte subpopulations and mitogenic response to PHA. American Federation of Clinical Research. September, 1985 (Presented) Clinical Research, 1985; 33:770A.

18. Zemel S, Weir MR, Welik R, Shen SY, Peppler R, McRoy C, Sadler JH. Effects of age and uremia on lymphocyte mitogenic response in end-stage renal disease patients. American Federation of Clinical Research. September, 1985 (Presented) Clinical Research, 1985; 33:770A.

19. Welik R, Urbaitis B, Weir MR, Shen SY, Zemel S, McRoy C, Peppler R, Sadler JH. Intracellular ATP levels in the lymphocytes of dialysis patients as a possible explanation for decreased mitogenic response. American Federation of Clinical Research. September, 1985 (Presented). Clinical Research, 1985; 33:763A.

20. Forrest A, Weir MR, Plaisance K, Drusano G, Caldwell J, Bustamante C, Leslie J, Standford H. Effects of renal dysfunction on pharmaco-kinetics of oral ciprofloxacin. Abstract 1002, Program and Abstracts of the 25th Interscience Conference for Antimicrobial Agents and Chemotherapy. (29 Sept.-2 Oct., 1985). (Presented).

21. Zemel S, Shen SY, Lesko L, Weir MR, Kosenko A, Dagher FJ, Bentley F. Optimal cyclosporine through whole blood level by high pressure liquid chromatography in renal transplants treated with a single daily dose. National Kidney Foundation. December, 1985. American Journal of Kidney Disease, 1985; VI:A25.

22. Welik R, Urbaitis B, Weir MR, Shen SY, Zemel S, McRoy C, Peppler R, Sadler JH. Lymphocyte ATP and mitogenic response in normal and hemodialysis patients. American Society of Nephrology. December, 1985. Kidney International, 1986; 29:327.

23. Weir MR, Josselson J, Hebel R, Yen M, Sadler JH. Mortality risk on maintenance hemodialysis: A five year retrospective analysis. American Society of Nephrology, December, 1985. Kidney International 1986; 29:228.

24. Shen SY, Weir MR, Bentley R, Dagher FJ. Conversion of cyclosporine therapy to azathioprine in renal transplants. American Society of Nephrology. December, 1985. Kidney International 1986; 29:435.

25. Josselson J, Kyser B, Weir MR, Sadler JH. Chronic hepatitis B antigen does not increase morbidity or mortality in hemodialysis patients. American Society of Nephrology. December, 1985. Kidney International 1986; 29:216.

26 Shen SY, Welik R, Zemel S, Weir MR, Sadler JH. Lymphocytic function and status of hepatitis B antigen and antibody in hemodialysis patients. National Kidney Foundation. December, 1985. American Journal of Kidney Diseases 1985; VI:A19.

27. Weir MR, Zemel S, Shen SY, Welik R, Peppler R, McRoy C, Sadler JH, Leavitt R. Acute effects of hemodialysis on lymphocyte subpopulations and mitogenic response to PHA. Joint Session National Kidney Foundation/American Society of Nephrology. December 1985 (Presented). American Journal of Kidney Diseases, 1985; VI:A23.

28. Zemel S, Weir MR, Welik R, Shen SY, Peppler R, McRoy C, Sadler JH, Leavitt R. Effects of age and end-stage renal disease on lymphocyte mitogenic response in hemodialysis patients. American Society of Nephrology. December, 1985 (Presented). Kidney International, 1986; 29:229.

29. Weir MR, Irwin BC, Gemenans G, Maters A, Shen SY, Charache P, Williams GM. High morbidity and mortality associated with the transplantation of a cytomegalovirus-positive kidney into a cytomegalovirus-negative recipient. American Society of Transplant Physicians. May, 1986 (Presented). American Society of Transplant Physicians Abstract Book, 1986; 5:1.

30. Shen SY, Zemel S, Weir MR, Dagher FJ, Bentley FR, Sadler JH. Renal allograft biopsy and conversion of cyclosporine to azathioprine. American Society of Transplant Physicians. May, 1986 (Presented). American Society of Transplant Physicians Abstract Book, 1986; 5:27.

31. Shen, SY, Zemel, S, Weir, MR, Dagher, FJ, Bentley, FR. Renal allograft biopsy at the time of cyclosporine conversion can detect occult rejection and preserve graft function. XI International Congress of the Transplantation Society, August, 1986 (Presented). XI International Congress of the Transplantation Society Abstract Book, 1986, P 33.11.

32. Irwin BC, Weir MR, Maters AW Genemans G, Shen SY., Charache P, Williams GM. Morbid outcome of cytomegalovirus-negative transplant recipients receiving cytomegalovirus-positive kidneys. XI International Congress of the Transplantation Society, August, 1986, (Presented). XI International Congress of the Transplantation Society Abstract Book, 1986, P 37.5.

33. Weir MR, Shen SY, Dagher FJ, Bentley FR, Sadler JH. A short term analysis of the effect of cyclosporine and source leukocyte transfusions on the cytotoxic antibody production of highly sensitized prospective renal transplant recipients. XI International Congress of the Transplantation Society, August, 1986 (Presented). XI International Congress of the Transplantation Society Abstract Book, 1986, P 11.1.

34. Bentley FR, Shen SY, Weir MR, Revie D, Dagher FJ, Chretien P, Sadler JH. Differentiation of acute rejection from acute cyclosporine nephrotoxicity in renal allograft recipients by peripheral blood T-cell subsets counts. International Congress of the Transplantation Society, August, 1986 (Presented). XI International Congress of the Transplantation Society Abstract Book, 1986, P 32.28.

35. Zemel SM, Shen SY, Weir MR, Dagher FJ, Bentley FR. Effects of HLA matching and panel reactive antibodies in the development of rejection after conversion of cyclosporine to azathioprine. XI International Congress of the Transplantation Society, August 1986 (Presented). XI International Congress of the Transplantation Society Abstract Book, 1986, P 33.10.

36. Plaisance K, Drusano G, Forrest A, Weir MR, Standiford H. The effect of renal function on the bioavailability of ciprofloxacin. 26th Interscience Conference for Antimicrobial Agents and Chemotherapy, September, 1986 (Presented).

37. Drusano GL, Weir MR, Forrest A, Plaisance K, Emm T, Standiford H. The pharmacokinetics of intravenous ciprofloxacin in patients with varying degrees of renal dysfunction. 26th Interscience Conference for Antimicrobial Agents and Chemotherapy, September, 1986 (Presented).

38. Weir MR, Peppler R, Handwerger BS. Inhibition of human peripheral blood mononuclear cell function by verapamil. American Society of Nephrology, December, 1986 (Presented). Kidney International 1987;31:471.

39. Josselson J, Weir MR, Hebel JR, Gardner J, Evans D, Sadler JH. Intravenous drug abuse: A marker for reduced success in patients with end-stage renal disease on hemodialysis. American Society of Nephrology, 1986. Kidney International 1987; 32:234.

40. Weir MR, Josselson J, Hebel JR, Sadler JH, Saunders E. End-stage renal disease secondary to hypertension: 5 year analysis of morbidity and mortality. Second International Interdisciplinary Conference on Hypertension in Blacks, Atlanta, Ga., March, 1987;2:45 (Presented).

41. Weir MR, Peppler R, Gomolka D, Handwerger BS. Inhibition of activation and function of human peripheral blood mononuclear cells by verapamil. International Society of Nephrology, London, U.K., July, 1987 (Presented). International Society of Nephrology Abstract Book 1987; 10:605.

42. Weir MR, Peppler R, Gomolka D, Handwerger BS. Additive effects of cyclosporine and verapamil on the inhibition of activation and function of human peripheral blood mononuclear cells. American Society of Transplant Physicians, Chicago, Il., May, 1987 (Presented). American Society of Transplant Physicians Abstract Book 1987; 6:24.

43. Weir MR, Henry ML, Blackmore M, Smith J, First MR, Irwin B, Shen SY, Genemans G, Shield CF, Kittur D, Williams GM, Corry RJ. Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor specific transfusion and living-related donor transplantation. A multi-center evaluation. American Society of Transplant Physicians, Chicago, Il, May, 1987 (Presented). American Society of Transplant Physicians Abstract Book 1987; 6:61.

44. Weir MR, Peppler R, Gomolka D, Handwerger BS. Additive inhibition of human peripheral blood mononuclear function by verapamil and cyclosporine. Second International Conference on Cyclosporine, Washington, D.C., November, 1987. (Presented). Second International Congress on Cyclosporine Abstract Book 1987; 2:284.

45. Weir MR, Peppler R, Gomolka D, Handwerger BS. Inhibitory effect of verapamil on the activation and function of human peripheral blood mononuclear cells is additive with cyclosporine and may occur through calcium independent mechanisms, American Society of Nephrology, Washington, D.C., December 1987 (Presented). Kidney International 1988, 33:455.

46. Weir MR, Klassen DK, Hoover N, Douglas F. Effects of a thromboxane synthetase inhibitor (CGS 13080) on blood pressure, renal hemodynamics and prostaglandin (PG) production in hypertensive humans. 3rd Annual Meeting, American Society of Hypertension, 1988. (Presented) American Journal of Hypertension 1988; 1:69A.

47. Weir MR, Vlachkis ND, DeQuattro V, et al. Efficacy and safety of Nilvadipine in hypertension. 3rd Annual Meeting, American Society of Hypertension, 1988. (Presented) American Journal of Hypertension. 1988; 1:17A.

48. Shen SY, Wood C, Papadimitrou JC, Amin A, Weir MR, Coughlin T. Dermal angiopathy in renal transplants with cyclosporine nephrotoxicity. 7th Annual Meeting, American Society of Transplant Physicians, 1988 and XII International Congress of the Transplantation Society, 1988. (Presented) American Society of Transplant Physicians Abstract Book 1988; 7:83.

49. Shen SY, Weir MR, Coughlin T. Conversion of cyclosporine to azathioprine in renal transplants 7th Annual Meeting, American Society of Transplant Physicians, 1988. (Presented) American Society of Transplant Physicians Abstract Book 1988; 7:107.

50. Weir MR, Klassen DK, Shen SY, Sullivan D, Buddemeyer EU, Handwerger BS, Kowarski AA. The acute effects of intravenous cyclosporine on blood pressure, renal hemodynamics, and urine prostaglandin production of healthy humans. 7th Annual Meeting, American Society of Transplant Physicians, 1988. (Presented) American Society of Transplant Physicians Abstract Book 1988; 7:47.

51. Weir MR, Klassen DK, Shen SY. Effect of verapamil on renal hemodynamics in normotensives. American Heart Association 1988 (Presented) Circulation 1988; 78:1450.

52. Weir MR, Peppler R, Gomolka D, Handwerger BS. Additive inhibitory effect of cyclosporine and verapamil may occur through different mechanisms which may be dependent or independent of the slow calcium channel. (Presented) XII International Congress of the Transplantation Society, 1988; 12:159.

53. Weir MR, Gomolka D, Peppler R, Handwerger BS. Mechanisms of additive inhibition of immunologic responses by cyclosporine and verapamil. 21st meeting of the American Society of Nephrology. (Presented). Kidney International 1989; 35:366.

1. Li XW, Weir MR. Tripterygium Wilfordii inhibits afferent immunologic responses of human peripheral blood

mononuclear cells. 21st meeting of the American Society of Nephrology. Kidney International 1989; 35:353.

55. Weir MR, Saunders E, Kong BW. A comparison of the efficacy of atenolol, captopril and verapamil SR in hypertensive blacks. 4th Annual Meeting of the American Society of Hypertension. (Presented) 1989; 2:21A.

56. Weir MR, Burris JF, Oparil S, Weber M, Cady WJ. A multifactorial evaluation of the antihypertensive efficacy of the combination of diltiazem and hydrochlorothiazide. 4th Annual Meeting of the American Society of Hypertension. (Presented) Am J Hypertens 1989; 2:21A.

57. Weir MR, Gomolka D, Peppler R, Handwerger BS. Mechanisms of additive inhibition of immunological responses by verapamil and cyclosporine. 8th Annual Meeting of the American Society of Transplant Physicians. (Presented) American Society of Transplant Physicians Book 1989; 8:67.

58. Weir MR, Klassen DK, Shen SY, Sullivan D, Buddemeyer EU, Handwerger BS. The acute effects of intravenous cremophor EL on blood pressure, renal hemodynamics and urine prostaglandin production of healthy humans. 8th Annual Meeting of the American Society of Transplant Physicians. (Presented) American Society of Transplant Physicians Book 1989; 8:110.

59. Shen SY, Amin A, Behrens MT, Weir MR, Klassen DK, Coughlin TR. How beneficial is OKT-3 as an immunosuppressive induction agent? 8th Annual Meeting of the American Society of Transplant Physicians. (Presented) American Society of Transplant Physicians Book 1989; 8:88.

60. Weir MR, Klassen DK, Hall PS, Schubert C. Misoprostol minimizes Indomethacin-induced renal dysfunction in healthy women: a preliminary report. 22nd Annual Meeting of the American Society of Nephrology, 1989. Kidney Int 1990; 37:497.

61. Li XW, Weir MR Gomolka D, Peppler R, Moran M, O'Bryan-Tear G. Immunosuppressive properties of enisoprost and a 5-lipoxygenase inhibitor. 22nd Annual Meeting of the American Society of Nephrology, 1989. Kidney Int 1990; 37:421.

62. Klassen DK, Weir MR, Buddemeyer EU. Simultaneous measurements of glomerular filtration rate by radioisotopic methods and creatinine clearance. 22nd Annual Meeting of the American Society of Nephrology, 1989. Kidney Int 1990; 37:277.

63. Li XW, Weir MR, Shen SY. Tripterygium Wilfordii, a chinese herbal medicine with potent immunosuppressive properties. 19th Annual meeting of the National Kidney Foundation, 1989 Am J Kid Dis 1990; 15 (4):A13 (Presented).

64. Weir MR, Josselson J, Ekelund L, Korc M, Pool J, Stein G. Favorable effects of nicardipine on the quality of life during hypertension treatment. 5th Annual Meeting of the American Society of Hypertension. Am J Hypertens 1990; 3:105. (Presented).

65. Weir MR, Gomolka MA, Peppler R. Verapamil has immunosuppressive properties unrelated to its ability to block slow calcium channel. 9th Annual Meeting of the American Society of Transplant Physicians. American Society of Transplant Physicians Book 1990; 9:166. (Presented).

66. Weir MR, Peppler R, Gomolka D, Xue-Wang L, Moran M, O'Bryan-Ter G. Immunosuppressive properties of nisoprost and SC45662 (5-Lipoxygenase Inhibitor). 9th Annual Meeting of the American Society of Transplant Physicians. American Society of Transplant Physicians Book 1990; 9:44. (Presented).

67. Muluk SC, Via SS, Weir MR, Clerici M, Shearer GM. In vitro MHC self-restricted CD4+ T helper cell response to alloantigen correlates with clinical graft status in immunosuppressed kidney transplant recipients. 9th Annual Meeting of the American Society of Transplant Physicians. American Society of Transplant Physicians Book 1990; 9:167. (Presented).

68. Klassen DK, Weir MR, Evans DP, Coughlin TR. Oliguria associated with OKT3 induction immunosuppression in cadaveric renal allografts. 9th Annual Meeting of the American Society of Transplant Physicians. American Society of Transplant Physicians Book 1990; 9:194. (Presented).

69. Muluk SC, Via CS, Weir MR, Clerci M, Shearer G. In vitro MHC self-restricted CDA+T helper cell response to alloantigen correlates with clinical graft status in immunosuppressed kidney transplant recipients XIII International Congress of the Transplantation Society Abstract Book 1990; 78. (Presented).

70. Gomolka D, Weir MR, Peppler R. Immunosuppressive properties of enisoprost and SC45662. XIII International Congress of the Transplantation Society Abstract Book 1990; 290. (Presented).

71. Gomolka D, Weir MR, Peppler R. The antiproliferative effect of verapamil on human peripheral blood lymphocytes is independent of calcium channel inhibitors. J Am Soc Nephrol 1990; 1:748. (Presented).

72. Weir MR, Klassen, DK, Burdick JF, Geiser R, Als A. Suppression of urinary thromboxane does not improve renal function in cyclosporine-treated renal transplant recipients. J Am Soc Nephrol 1990;1:774. (Presented).

73. Gottlieb SS, Robinson S, Weir MR, Fisher M, Kritchen C. Determinants of the renal response to ACE inhibitors in congestive heart failure. Circulation 1990; 82:III-386. (Presented).

74. Weir MR, Peppler R, Gomolka D, Handwerger BS. The antiproliferative effect of verapamil on human peripheral blood mononuclear cells is independent of calcium channel inhibition. Am Soc Transplant Phys Abstract Book 1991; 10:1076. (Presented)

75. Peppler, Weir MR, Gomolka D, Handwerger BS. The antiproliferative effect of verapamil on lymphocytes is related to inhibition of cellular potassium efflux with secondary inhibition of transmembrane calcium flux. J Am Soc Neph 1991; 2:785 (Presented).

76. Weir MR, Bhandaru S, Bakris GL. Inhibition of insulin-mediated mesangial cell proliferation is unrelated to blockade of the voltage-gated slow calcium channel. J Am Soc Neph 1991; 2:470.

77. Weir MR, Behrens MT, Peppler R, Zemel MB. Effects of salt and isradipine on platelet Ca++ in salt sensitive and insensitive hypertensive patients. American Society of Hypertension 1992; 5:66A (Presented).

78. Weir MR, Behrens MT, Zemel MB. Renal hemodynamic and antihypertensive effects on isradipine of salt-insensitive hypertensive patients on high and low sodium diets. NIDDK conference: Kidney Disease and Hypertension in Blacks. Abstract Book 1991; 12 (Presented).

79. Weir MR, Behrens MT, Hall PS, Zemel MB. Differing hemodynamic responses to sodium intake in black and white hypertensives. Clinical Research 1992; 40:286A (Presented).

80. Gottlieb SS, Weir MR, Robinson SW, Krichten CM, Fisher ML. Does the effect of ACE inhibition on renal function depend on dosing frequency? Clinical Research 1992; 40:233A (Presented).

81. Weir MR, Peppler R, Gomolka D, Handwerger BS. Mechanisms responsible for inhibition of lymphocyte activation by agents which block membrane calcium or potassium channels. Am Soc Transplant Physicians Abstract Book 1992; 11:199 (Presented).

82. Behrens MT, Weir MR, Hall PS, Zemel MB. Higher sodium intake in salt resistant black and white hypertensives does not lead to alterations in renal hemodynamics. J Am Soc Neph 1992; 3:558.

83. Schulick RD, Weir MR, Cohen DJ, Miller MW, Shearer GM. Time-dependents changes of in vitro CD4+ T helper function in renal transplant patients. 1992 National Kidney Foundation Annual Meeting (Presented).

84. Schoenberger JA, Weir MR, Wolfsen PM, Fishman WH, Cargo PH, Lefkowitz MP, Targum SL, Weber MA. A placebo controlled study of verapamil in the treatment of hypertension in the elderly. Am J Hypertens 1993; 6:123A (Presented)

85. Weir MR, Gomolka D, Handwerger BS. Inhibition of lymphocyte activation by drugs that block calcium and potassium channels. Further insight into mechanisms of action. American Society of Transplant Physicians Abstract Book 1993; 12:311. (Presented).

86. Keay S, Baldwin B, Weir MR. Inhibition of CMV replication in vitro by the immunosuppressive agents Cyclosporine A, FK-506, and RS-61443. American Society of Transplant Physicians Abstract Book 1993; 12:238. (Presented).

87. Weir MR, Behrens MT. Increased sodium intake in hypertensives results in hyperfiltration fraction and increased microalbuminuria. J Am Soc Neph 1993; 4:590.

88. Weir MR, Houston MC, Grey JM. Effects of NSAIDs on blood pressure controlled by verapamil. J Am Soc Neph 1993; 4:542 (presented).

89. Nicholson PG, Raval DT, Behrens MT, Weir MR. A prospective crossover trial to compare the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemia in organ transplant recipients. J Am Soc Neph 1993; 4:952 (presented).

90. Weir MR, Hall PS, Behrens MT. Greater Antihypertensive response to the calcium antagonist isradipine in salt-sensitive vs. salt-resistant hypertensives. Am J Hypertens 1994; 7:8A.

91. Houston MC, Weir MR, Gray JM. Effects of NSAIDS on blood pressure controlled by verapamil. Am J Hypertens 1994; 7:105A.

92. Weir MR, Behrens MT. Sodium sensitivity, independent of race, predicts higher filtration fraction and microalbuminuria in hypertensives on higher sodium intake. Am J Hypertens 1994; 7:131A.

93. Weir MR. A pilot study to assess the influence of isradipine therapy on proteinuria in hypertensive patients with Type II diabetes. Am J Hypertens 1994; 7:131A.

94. Klassen DK, Weir MR, Nicholson RD, Schweitzer E, Bartlett ST. Isolated pancreas graft rejection in combined kidney pancreas transplantation; clinical results of percutaneous pancreas biopsy in 40 consecutive cases. Am Soc Transplant Physicians Abstract Book 1994; 13:60 (Presented).

95. Oldach D, Constantine N, Zhang Y, Abdel-Hamid M, Zhang X, Weir MR, Bartlett ST, Styuver L. Renal transplant donor and recipient HCV type characterization: Evidence for establishment of donor virus type viremia (superinfection) in recipients with prior HCV infection. 2nd International Meeting on Hepatitis C and Related Viruses (In Press).

96. Prisant LM, Weir MR, Papademetriou V, Adegbile A, Alemayehu D, Lefkowitz MP, Carr AA, Weber MA. Novel first line therapy for hypertension: Low dose combination drug therapy. Am Coll Clinical Pharmacol (In Press).

97. Oldach D, Constantine N, Zhang X, Abdel-Hamid M, Weir MR, Bartlett ST, Stuyver L. Hepatitis C virus transmission by renal transplant from a viremic donor into a receipient with prior infection (super-infection). J Am Soc Nephrol 1994;5:1028. (Presented).

98. Koya I, Doyle B, Dengel D, Weir MR. Influence of donor kidney race on post-transplantation blood pressure and renal function. J Am Soc Nephrol 1994; 5:115. (Presented).

99. Klassen DK, Weir MR, Johnson L, Schweitzer EJ, Bartlett ST. Isolated pancreas graft rejection in combined kidney pancreas transplantation: Clinical results of percutaneous pancreas biopsy. J Am Soc Nephrol 1994; 5:118. (Presented)

100. Weir MR, Malinow L, Klassen DK, Schweitzer EJ, Bartlett ST. A comparison of the incidence of delayed renal allograft function with OKT3, intra-operatively or post-operatively, vs polyclonal antilymphocyte globulin. J Am Soc Nephrol 1994; 5:1043 (presented).

101. Weir MR, Robinson S, Fisher ML, Krichten C, Gottlieb SS. 24 hour blood pressure monitoring to assess the role of hypotension in the renal deterioration associated with ACE inhibition in CHF. J Am Soc Nephrol 1994; 5:615.

102. Walker J, Weir MR, Klassen DK, Dunston R, Schweitzer EJ, Bartlett ST. Late pancreatic rejection: Inadequacy of current laboratory screening and importance of cyclosporine (CSA) levels. J Am Soc Nephrol 1994; 5:1043.

1. Klassen DK, Papadimitriou JC, Drachenberg CB, Mayuga RS, Walker JA, Hooper FJ, Hoehn-Saric EW,

Schweitzer EJ,Bartlett ST, Weir MR. A proposed histologic grading system for acute pancreas allograft rejection: A

predictor of graft survival. Am Soc Transplant Physicians Abstract Book 1995; 14:111 (presented).

1. Oldach D, Constatine N, Schweitzer EJ, Weir MR, Bartlett ST, Abdel-Hamid M, Zhang X, Keay S, Stuyver L. Clinical
2. Virologic outcomes in Hepatitis C Virus (HCV) infected renal transplant recipients. Am Soc Transplant Physicians Abstract Book 1995;14:98 (presented).
3. Walker JA, Klassen DK, Hoehn-Saric EW, Hooper FJ, Schweitzer EJ, Johnson LB, Bartlett ST, Weir MR. Acute pancreas
4. allograft rejection after the first year: Predisposing factors. Am Soc Transplant Physicians Abstract Book 1995;14:155. (presented).
5. Hoehn-Saric EW, Wiland A, Weir MR, Klassen DK, Schweitzer EJ, Johnson LB, Bartlett ST. Initial experience with tacrolimus as rescue therapy for refractory pancreatic allograft rejection. Am Soc Transplant Physicians Abstract Book 1995; 14:155. (presented)
6. Wiland A, Schweitzer EJ, Johnson LB, Anderson L, Klassen DK, Weir MR, Bartlett ST. Omission of anti-thymocyte globulin (ATG) induction in haplo-and non-identical living donor transplants prolongs initial hospitalization. Am Soc Transplant Physicians Abstract Book 1995; 14:178. (presented)
7. Weir MR, Saunders E and the Trandolapril Multicenter Study Group. Differing mechanisms of action of angiotensin converting enzyme inhibition in black and white hypertensives. Am J Hypertens 1995; 8:138A (presented).
8. Moy E, Bartman B, Weir MR. Effects of income, insurance and source of care on hypertensive care. Am J of Hypertension 1995; 8:79. (presented)
9. Weir MR, Prisant LM, Papademetriou V, Weber MA, Adegbile IA, Alemayehu D, Lefkowitz MP. Correlation of prior antihypertensive therapy, current therapy (amlodipine, bisoprolol/HCTZ, enalapril), adverse events and blood pressure reduction with changes in quality of life. Am J Hypertens 1995; 8:132A. (presented)
10. Weir MR, Dengel DR, Behrens MT, Goldberg AP. Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. Am J Hypertens 1995; 8:156A. (presented)
11. Dailey G, Boden G, Creech R, D'Elia J, Johnson D, Kennedy F, Weir MR. Weekly pulsatile IV insulin treatments appear to slow progression of diabetic nephropathy. American Diabetes Association Annual Meeting 1995. Diabetes 1995; 44:24A.
12. Stewart D, DeForge B, Moy E, Tijani T, Weir MR. Similarities and differences between working poor and unemployed poor hypertensives. Abstract Book of the International Society of Hypertension in Blacks, 1995. (presented)
13. Shearer GM, Grady RW, Schulick RD, Muluk S, Miller MW, Weir MR, Ohler L, Miller JA, Kimmel PL, Clerici M. Direct versus Indirect Antigen Presentation. Abstract book of the XIIIth International Congress of Nephrology. (presented)
14. Weir MR, Dengel DR, Mayuga RS, Goldberg AP. Insulin resistance, elevated glomerular filtration fraction and renal injury. Council for High Blood Pressure Research 49 th Annual Fall Conference and Scientific Sessions. Hypertension 1995; 25:16, P2. (presented)
15. Wiland A, Schweitzer EJ, Anderson LM, Johnson LB, Kuo P, Weir MR, Klassen DK, Hoehn-Saric EW, Bartlett ST. The benefits of CD3 monitoring during ATGAM administration. Am Soc Transplant Physicians Abstract Book May 1996; P-74:191(A).
16. Keay S, Oldach D, Wiland A, Abruzzo L, Kumar D, Weir MR, Klassen DK, Hoehn-Saric EW, Schweitzer EJ, Johnson LB, Kuo P, Bartlett ST. Early onset post-transplant lymphoproliferative disorder associated with OKT3 in EBV-seropositive pancreas transplant recipients. Am Soc Transplant Physicians Abstract Book May 1996; 160:124(A).

118. Hadley GA, Bartlett ST, Gomolka DM, Rostapshova EA, Weir MR. A major subpopulation of human alloreactive CD8 cells express E integrin. Am Soc Transplant Physicians Abstract Book May 1996; 283:155(A).

119. White M, Hanes D, Wiland A, Klassen DK, Hoehn-Saric EW, Schweitzer EJ, Kuo P, Johnson LB, Bartlett ST, Weir MR. Long-term treatment of hyperlipidemia in transplant recipients with pravastatin and gemfibrozil. Am Soc Transplant Physicians Abstract Book May 1996; P-270:240(A).

120. Drachenberg D, Klassen DK, Papdimitriou J, Weir M, Hoehn-Saric E, Light P, Ramos E, Kuo P, Schweitzer E, Johnson L, Hanes D, Bartlett S. Histologic findings in islets of pancreatic allografts: Lack of evidence for recurrent cell mediated diabetes mellitus (DM). Am Soc Transplant Physicians Abstract Book May 1996; 154:123(A).

121. Oldach DW, Pfundstein J, Morris JG, Keay S, Schwalbe RS, Qaiyumi SQ, Weir M, Klassen D, Johnson L, Schweitzer E, Bartlett ST. A randomized trial of surgical antimicrobial prophylaxis with and without vancomycin in kidney and pancreas transplant recipients. Am Soc Transplant Physicians Abstract Book 1996 (In Press).

122. Johnson L, Weir MR, Kuo P, Schweitzer E, Ridge L, Hoehn-Saric E, Klassen D, Bartlett S. Stable renal function in recipients of double renal allografts from marginal donors. Am Soc Transplant Physicians Abstract Book May 1996; 307:161(A).

123. Johar B, Brechemin L, Klassen DK, Hoehn-Saric EW, Schweitzer EJ, Anderson L, Allen E, Bartlett S, Weir MR. Tertiary hyperparathyroidism in renal transplant (Tx) patients. Am Soc Transplant Physicians Abstract Book May 1996; P-271:241(A).

124. Hoehn-Saric EW, Wiland A, Klassen DK, Anderson L, Schweitzer EJ, Johnson L, Kuo P, Bartlett S, Weir MR. The efficacy of short term FK506 therapy in treating refractory pancreas rejection. Am Soc Transplant Physicians Abstract Book May 1996;250:147(A).

125. Klassen DK, Weir MR, Hoehn-Saric E, Anderson L, Kuo P, Johnson L, Schweitzer E, Bartlett ST. Cyclosporine vs. Tacrolimus as maintenance immunosuppression in simultaneous kidney pancreas (SPK) transplantation: preliminary results. Am Soc Transplant Physicians Abstract Book 1996 (In Press).

126. Klassen DK, Hoehn-Saric EW, Weir MR, Light P, Schweitzer E, Johnson L, Kuo P, Bartlett ST, Papadimitriou JC, Drachenberg C. Occult kidney rejection in simultaneous kidney pancreas transplantation (SPK). Am Soc Transplant Physicians Abstract Book May 1996; 155:123(A).

127. Schweitzer E, Anderson L, Johnson L, Kuo P, Weir MR, Klassen DK, Hoehn-Saric EW, Bartlett ST. Safe pancreas transplantation in diabetics with ischemic heart disease. Am Soc Transplant Physicians Abstract Book 1996.

128. Weir MR, Saunders E. Racial similarity in response to the angiotensin converting enzyme inhibitor trandolapril. Am J Hypertens 1996; 9(4):174A.

129. Weir MR. Efficacy and safety of losartan versus calcium channel blockers in hypertension.

130. Weir MR. Antagonism of angiotensin II: new understandings about the interrelationship with dietary salt and blood pressure reduction.

131. Bakris GL, Weir MR, DeQuattro V, Rosendorff C, McMahon G. Renal hemodynamic and antiproteinuric response to an ACE inhibitor, Trandolopril (T) or calcium antagonist, verapamil (V) alone or in fixed dose combination in patents with diabetic nephropathy: A randomized multicenter study. J Amer Soc Nephr A1470:1546. 1996.

132. Yoon SW, Evans D, Jaekels J, Schweitzer EJ, Johnson LB, Kuo P, Weir MR, Klassen D, Hoehn-Saric E, Bartlett ST. Increased living donor volunteer rates with a formal recipient family education program. Am Soc Transplant Physicians Abstract Book May 1996;P-297:247(A).

133. Weir MR, Weder A, for the MIST Study Group. Influence of race and dietary salt on blood pressure (BP) responses in salt sensitive hypertensives. AJH 1997; 10:19A.

134. Weir MR, Reisin E, Falkner B, Hutchinson HG, Anzalone D, Tuck M for the TROPHY Study Group. Effect of lisinopril (L), hydrochlorothiazide (H) and dipper/non-dipper status on 24-hour ambulatory blood pressure (ABP) in obese hypertensives. AJH 1997; 10:77A.

135. Weir MR, Cargo PH, Colasante D, McDevitt JT, Oparil S. Differential effects of calcium channel blockers on heart rate in women. AJH 1997; 10:106A.

136. Weir MR. Therapeutic approaches to patients with special indications. AJH 1997; 10:228A.

137. Weir MR. Hypertension progressing to renal failure: is there a way out? AJH 1997; 10:233A.

138. Weir MR. The rationale for combination therapies vs. single entities in hypertension. AJH 1997; 10:241A.

139. Weir MR. Efficacy and safety of losartan versus calcium channel blockers in hypertension. AJH 1997; 10:243A.

140. Fink JC, Roghmann M, Gabregiorgish K, Antonopoulos G, Maker T, Weir MR, Polish LB, Morris JG, Light PD. Vancomycin resistant enterococcus in patients on hemodialysis: risk factors and outcomes. J Amer Soc Nephr 1997; A1081:235A.

141. Fink JC, Stehman-Breen CO, Kufera JL, Weir MR, Hooper FJ. Patients from the same dialysis unit are not independent observations: estimation of within center correlations in the USRDS. J Amer Soc Nephr 1997; A1301:283A.

142. Song H, Papadimitriou J, Drachenberg C, Weir MR, Wei C. Presentation and localization of renal endothelin-1 (ET), ET receptors and ET converting enzyme expression in human renal biopsy with rejection after kidney transplantation. J Amer Soc Nephr 1997; A1559:339A.

143. Song H, Papadimitriou J, Drachenberg C, Weir MR, Wei C. Increase the expression of natriuretic peptides and cGMP in rejected human renal graft. J Amer Soc Nephr 1997; A1886:407A.

144.Wei C, Song H, Papadimitriou J, Drachenberg C, Weir MR. Protein expression of apoptosis related-gene in human renal graft rejection. J Amer Soc Nephr 1997; A1994:430A.

145.Wei C, Song H, Papadimitriou J, Drachenberg C, Weir MR. Increase transforming growth factor- and its receptors in human renal tissue with rejection. J Amer Soc Nephr 1997;;A3354:722A.

146. Wei C, Song H, Papadimitriou J, Drachenberg C, Weir MR. Nitric oxide synthase in human renal graft rejection after kidney transplantation. J Amer Soc Nephr 1997; A3355:722A.

147. Drachenberg CB, Fink JC, Klassen DK, Hoehn-Saric EW, Anderson L, Brechemin L, Bartlett ST, Weir MR, Papadimitriou JC. Transplant glomerulopathy: relationship with long term arterial hypertension. Am Soc Transplant Physicians Abstract Book 1997;104:110A.

148. Maddox L, McCarter R, Kumar D, Weir MR, Bartlett ST, Keay S, Oldach D. Transplant esophagitis: microbiological, pathological, and clinical correlates in a series of 97 episodes in kidney and pancreas Tx precipients. Am Soc Transplant Physicians Abstract Book 1997;109:112A.

149. Nogueira J, Drachenberg CB, Papadimitriou JC, Fink JC, Hoehn-Saric E, Klassen DK, Cangro CB, Bartlett ST, Weir MR. Prognostic significance of eosinophils on renal allograft biopsy with acute rejection. Am Soc Transplant Physicians Abstract Book 1997;161:125A.

150. Weir MR, Anderson L, Fink JC, Schweitzer E, Hoehn-Saric E, Klassen D, Cangro CM, Kuo P, Johnson L, Lim J, Bartlett ST. A new approach to the treatment of chronic allograft nephropathy. Am Soc Transplant Physicians Abstract Book 1997; 398:184A.

151. Oldach D, Constantine N, Schweitzer E, Madayag R, Bartlett S, Weir MR, Yang Q, Rowe J, Foung S, Hadlock K. Prevalence and significance of hepatitis viruses C & G in allograft recipients. Am Soc Transplant Physicians Abstract Book 1997; 562:225A.

152. Madayag R, Johnson L, Bartlett ST, Schweitzer E, Constantine N, McCarter R, Kuo P, Weir MR,

Oldach D. Use of allografts from donors positive for hepatitis B core antibody confer minimal risk for subsequent

development of hepatitis B virus (HBV) infection. Am Soc Transplant Physicians Abstract Book 1997; 565:226A

1. Weir MR, Fink JC, Hanes DS, et al. Chronic allograft nephropathy effect of cyclosporine reduction and addition of mycophenolate on progression of renal disease. Transplantation 1999;67:S82.
2. Klassen DK, Fink J, Blahut S, Weir MR. Delayed function after pancreas transplantation: effects on allograft rejection and survival. Transplantation 1999; 67:S171.
3. Drachenberg CB, Klassen DK, Wiland A, Weir MR. Islet cell damage associated with tacrolimus and cyclosporine morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 67:S209.
4. Drachenberg CB, Beskow CO, Papadimitriou JC, Cangro CB, Rocca M, Klassen DK, Weir MR. Human polyoma virus infected cells (POVIC): incidence in renal biopsies (BX), urine cytology and correlation with clinical presentation. Transplantation 1999;67:S217.
5. Hanes DS, Wali R, Fink JC, Klassen DK Cangro CB, Bartlett ST, Weir MR. Comparison of the incidence of acute rejection in simultaneous pancreas-kidney transplant recipients receiving either tacrolimus (FK506) or cyclosporine microemulsion (Neoral) in combination with mycophenolate mofetil (MMF) and corticosteroids. Transplantation 1999; 67:S224.
6. Weir MR, Traver M, Blahut SA, Klassen DK, et al. The long-term impact calcineurin inhibitor reduction or discontinuation in patients with declining kidney function due to chronic allograft nephropathy. Transplantation 2000; 69:S163.
7. Weir MR, Ward M, Blahut S, Klassen DK, et al. The influence of blood pressure, serum cholesterol and glucose on the rate of loss of renal function in renal transplant recipients with chronic allograft nephropathy after calcineurin inhibitor dose reduction. J Am Soc Nephrol 2000; 11: 712A.
8. Weir MR, Ward M, Klassen DK, et al. The role of blood pressure and metabolic factors in predicting graft loss in patients with chronic allograft nephropathy (CAN) after calcineurin inhibitor reduction or cessation. J Am Soc Nephrol 2000; 11: 712A
9. Salmanullah M, Blahut S, Sawyer R, Fink JC, Weir MR, Henrich, WL. Hise M. Patterns of Creatinine Elevation in a VA Hospital. J Am Soc Nephrol 2000; 11:164A
10. Salmanullah M, Sawyer R, Henrich WL, Weir MR, Fink JC, Hise MK. The natural history of an elevated creatinine in a VA population. J Am Soc Nephrol 2000; 11:164A
11. Salmanullah M, Sawyer R, Henrich WL, Weir MR, Fink JC, Hise MK. Control of clinical parameters (CP) in a subspeciality setting. J Am Soc Nephrol 2000; 11:164A.

Stopped listing in 2000 due to space constraints.

**PRESENTATIONS, SPEECHES AND GRAND ROUNDS**

1. Weir MR, Cohen, D.J., Carpenter, C.B. Compartmentalization of the immune response to repetitive stimulation with alloantigen. American Federation for Clinical Research. October, 1983.
2. Weir MR, Cohen, D.J., Carpenter, C.B. Allograft transplantation subsequent to active and passive enhancement leads to compartmentalization of the immune response. American Federation for Clinical Research. October, 1983.
3. Weir MR, Kirkman, R.L., Strom, T.B., Tilney, N.L. Chronic liver disease in recipients of long-term renal allografts: Analysis of morbidity and mortality. American Society of Nephrology. December, 1983.
4. Weir MR, Cohen, D.J., Carpenter, C.B. Dissimilar immune responses to varied presentation of identical alloantigens. International Society of Nephrology. June, 1984.
5. Weir MR, Kirkman, R.L., Strom, T.B. The long-term effects of hepatitis B virus in renal transplant recipients: Analysis of morbidity and mortality. International Congress of the Transplantation Society. August, 1984.
6. Weir MR, Josselson, J., Sadler, J.H. Bi-weekly vs. thrice-weekly hemodialysis: Five year analysis of morbidity and mortality. American Society of Nephrology. December, 1984.
7. Medical Grand Rounds: Maryland General Hospital. "Use of Cyclosporine in Transplantation Today." September, 1983.
8. Nephrology Grand Rounds: Baltimore City Hospital. "Use of HLA-typed apheresis byproducts as alloenhancing agents in prospective renal transplant recipients." December, 1983.
9. Medical Grand Rounds: Waterbury Hospital, CT. "Use of Cyclosporine in Renal Transplantation." January, 1984.
10. Nephrology Grand Rounds: Yale-New Haven Hospital. "Cyclosporine as an immunomodulatory of the mixed lymphocyte reaction." January, 1984.
11. Medical Grand Rounds: Southern Maryland Hospital. "Newer agents in the treatment of hypertension." May, 1984.
12. Nephrology Grand Rounds: The Johns Hopkins Hospital. "Rat model of Cyclosporine Nephrotoxicity." May, 1984.
13. Medical Grand Rounds: Southern Maryland Hospital. "Newer agents in the treatment of hypertension." May, 1984.
14. Medical Grand Rounds: Perry Point V.A. Hospital. "Hypertension Update: 1984." September, 1984.
15. Nephrology Grand Rounds: Francis Scott Key Hospital. "Comparison Study of Bi-weekly vs. thrice-weekly hemodialysis." November, 1984.
16. Medical Grand Rounds: Union Memorial Hospital. "Controversies in Anti-hypertensive Therapy." December, 1984.
17. Medical Grand Rounds: Rutgers/New Jersey Medical School. "Immunologic Basis of Action of Cyclosporine." December, 1984.
18. WBJC Radio. Discussion of the use of cyclosporine in renal transplantation. January 1985.
19. Medical Grand Rounds: Church Home Hospital. "Newer agents in the treatment of hypertension." February, 1985.
20. Medical Housestaff Conference: Prince George's General Hospital. "Management of Hypertension in 1985." February, 1985.
21. Medical Grand Rounds: Mercy Hospital. "Use of Cyclosporine in Organ Transplantation." March 1985.
22. Medical Grand Rounds: Doctor's Hospital. "Electrolyte Disorders." May, 1985.
23. Housestaff Medical Conference: Greater Baltimore Medical Center. "Acid-Base Disorders." June, 1985.
24. 11th Annual Family Medicine Review Course, Ocean City, Maryland. "Are Thiazides Still Appropriate for Hypertension." June, 1985.
25. Medical Grand Rounds: Harford Memorial Hospital. "Treatment of Hypertension in the Elderly." August, 1985.
26. Medical Staff Basic Science Lecture: Greater Baltimore Medical Center. "Pathogenesis and treatment of hypertension in the elderly." August, 1985.
27. Housestaff Medical Conference: Mercy Hospital. "Renal Transplantation and Immunosuppression." September, 1985.
28. Invited Speech at Semiannual Meeting of the Medical and Chirurgical Faculty of Maryland. "Extrapulmonary Tuberculosis in a Community Hospital Experience." Bermuda, September, 1985.
29. Medical Grand Rounds: Kirk Army Hospital. "Treatment of hypertension in the elderly." September, 1985.
30. Cyclosporine Symposium: Practical, Clinical and Economic issues in the cyclosporine-treated patient. Panelist and speaker. Chicago, IL. September, 1985.
31. Medical Grand Rounds: Fallston General Hospital. "Newer Agents in the Treatment of Hypertension." September, 1985.
32. Medical Grand Rounds: Mercy Hospital, "Extrapulmonary Tuberculosis." October, 1985.
33. Medical Grand Rounds: St. Joseph's Hospital. "Are Thiazides Still Relevant in Treatment of Hypertension." October,1985.
34. Invited Panelist in National Conference: "Clinical Management of the Renal Transplant Recipient Treated with Cyclosporine." Palm Beach Florida, November, 1985.
35. Medical Grand Rounds: Peninsula General Hospital. "Newer Agents in the Treatment of Hypertension." November, 1985.
36. Invited Speaker: Symposium on Medical Update, Harford Memorial Hospital. "Organ Transplantation: Update." November, 1985.
37. Weir MR "Acute Effects of Hemodialysis on Lymphocyte Subpopulations and Response to PHA." Presentation at Joint Session National Kidney Foundation American Society of Nephrology, December, 1985.
38. Medical Grand Rounds: Waterbury Hospital Health Center. "Newer Developments in the Treatment of Hypertension." December, 1985.
39. Housestaff Medical Conference: Mercy Hospital. "Hypertension Update, 1986." January, 1986.
40. Invited Speaker: Constant Care Medical Center. "Evaluation and Treatment of Hypertension." March, 1986.
41. Invited Visiting Professorship and Medical Grand Rounds, Hahnemann University Hospital, Philadelphia, Pennsylvania. "Never Insights into Immunosuppressive Therapy in Organ Transplantation." March, 1986.
42. Invited Speaker: AMA of Southern New Jersey. "Calcium Channel Blockers and their use in hypertension today." March, 1986.
43. Columbus, Eldersburg, MD. "Hypertension Evaluation and Detection." March, 1986.
44. Medical Grand Rounds: Perry Point VA Hospital. "Hypertension Update-Transcutaneous Delivery Systems." May, 1986.
45. Weir MR Incidence of cytomegalovirus disease in cyclosporine-treated renal transplant recipients based on donor/recipient pre-transplant immunity. American Society of Transplant Physicians, Chicago, IL. May, 1986.
46. Medical Conference: Greater Baltimore Medical Center. "Hypertension Update-Transcutaneous Delivery Systems." June, 1986.
47. Medical Grand Rounds: Howard University Hospital, Washington D.C. "Update in Hypertension, 1986." June, 1986.
48. Medical Conference: Pentagon Army Medical Clinic. "Update in Hypertensive Therapy-Focus on Blood Lipids." August, 1986.
49. Weir MR, Irwin, B.C., Maters, A.W., Genemans, G., Shen, S.Y., Charache, P., Williams G.M. Morbid outcome of cytomegalovirus-negative transplant recipients receiving cytomegalovirus-positive kidneys. XI International Congress of the Transplantation Society, August, 1986, Helsinki, Finland (Presented).
50. Weir MR, Shen, S.Y., Dagher, F.J., Bentley, F.R., Sadler, J.H. A short term analysis of the effect of cyclosporine and source leukocyte transfusions on the cytotoxic antibody production of highly sensitized prospective renal transplant recipients. XI International Congress of the Transplantation Society, August, 1986 Helsinki, Finland (Presented).
51. Invited Presentation: Annual Meeting of the Virginia Academy of Family Practice, Vienna, Virginia. "Newer Strategies in Anti-hypertensive Therapy: 1986." September, 1986.
52. WNTR Radio. Discussion about What's New in Transplantation. September, 1986.
53. Medical Conference: University of Louisville, Louisville, KY. "Importance of Quality of Life and Side Effects in Anti-Hypertensive Therapy." October, 1986.
54. Medical Conference: Eastern Shore Hospital, Cambridge, MD. "Acid-Base and Electrolyte Disorders," October, 1986.
55. Visiting Professor of the People to People Citizen Ambassador Program to the People's Republic of China. Conferences and Lectures on organ transplantation and treatment of hypertension at: the Beijing Friendship Hospital, Peking Union Medical College in Beijing, and the Jinling Hospital in Nanjing. October, 1986.
56. Medical Conference and Visiting Professor at the University of Iowa Hospital, Iowa City, IA. "The effects of Calcium Channel Blockade on Lymphocyte Activation and Function." November, 1986.
57. Invited Speaker: Investigator's Meeting for the "Verapamil vs Captopril vs Atenolol in Hypertensive Blacks," study at Hilton Head, S.C. "Hemodynamic effects of Verapamil, Captopril and Atenolol in Hypertensives." November, 1986.
58. Medical Conference: Physician's Memorial Hospital, LaPlata, MD. "Acid-Base and Electrolyte Disorders." November, 1986.
59. Weir MR, Peppler, R., Handwerger, B.S., Inhibition of human peripheral blood mononuclear cell function by Verapamil. American Society of Nephrology, Washington, D.C., December, 1986.
60. Medical Grand Rounds: Union Hospital, Cecil, MD. "Update in Organ Transplantation." January, 1987.
61. Research Conferences and Visiting Professor: Wayne State University, Detroit, MI "Use of calcium channel blockers in organ transplantation" and "A physiologic approach to the control of blood pressure while maintaining organ perfusion," February, 1987.
62. Medical Grand Rounds: Beltsville Hospital, Laurel, MD. "Update in anti-hypertensive therapy, 1987." February, 1987.
63. Medical Grand Rounds: Mercy Hospital, Baltimore, MD. "A physiologic approach to the control of blood pressure while maintaining organ perfusion." March, 1987.
64. Research Conferences and Visiting Professor: University of Cincinnati Medical Center, Cincinnati, OH. "Use of calcium channel blockers in hypertension and as immunomodulatory agents." March, 1987.
65. Research Conferences and Visiting Professor: The Cleveland Clinic Foundation, Cleveland, OH. "Use of calcium channel blockers in hypertension and as immunomodulatory agents." March, 1987.
66. Weir MR, Josselson, J., Hebel, J.R., Sadler, J.H., Saunders, E. "End-stage Renal Disease secondary to hypertension: 5 year analysis of morbidity and mortality." Presentation at the Second International Interdisciplinary Conference on Hypertension in Blacks. March, 1987.
67. Invited speaker at Symposium preceding American College of Cardiology, Tulane University School of Medicine. "Expanding Options in Hypertension Therapy: Calcium Channel Blockers." New Orleans, La. March, 1987.
68. Invited speaker at symposium of Maryland Academy of Family Practice: "Use of ACE Inhibitor and calcium channel blockers in the treatment of hypertension." Easton, MD, March, 1987.
69. Medical Grand Rounds: Riverside Hospital, Newport News, Va. "A physiologic approach to the control of blood pressure while maintaining organ perfusion." April, 1987.
70. Medical Grand Rounds: Doctor's Hospital, Prince George, MD. "Electrolyte Disorders a simplified approach." April, 1987.
71. Medical Research Conference: Cedars-Sinai Medical Center, Miami, FL. "Physiology of anti-hypersensitivity and how to achieve blood pressure control." May, 1987.
72. Moderator and speaker, Symposium: "Focus on Ace Inhibitors." Baltimore, MD, May, 1987.
73. Weir MR Presentation at American Society of Transplant Physicians, Chicago, IL: "Additive effect of cyclosporine and verapamil on the inhibition of the activation and function of human peripheral blood mononuclear cells." May, 1987.
74. Weir MR Presentation of the American Society of Transplant Physicians, Chicago, IL: "Incidence and morbidity of cytomegalovirus disease in a seronegative recipient of seropositive donor specific transfusion and living relative donor transplantation: a multi-center evaluation." May, 1987.
75. Medical Grand Rounds: Altoona V. A. Hospital, Altoona, Pa. "Newer approaches to the treatment of hypertension." June, 1987.
76. Weir, MR. Presentation at International Society of Nephrology, London U.K. "Additive inhibition of verapamil and cyclosporine on lymphocyte activation." July, 1987.
77. Invited Speaker: American Academy of Family Practice Annual Meeting. "Managing hypertension in modern family practice." San Francisco, CA, September, 1987.
78. Invited Speaker: Church Home Hospital. "Renal-Electrolyte Disorders." October 1987.
79. Invited Speaker: Broward General Hospital Medical Grand Rounds, Miami, FL. "Use of calcium antagonists in the treatment of hypertension." October, 1987.
80. Invited Speaker: Waynesboro Hospital Grand Rounds, Waynesboro, PA. "Update in Organ Transplantation." October, 1987.
81. Weir MR, Presentation at Second International Congress on Cyclosporine, Washington, D.C. "Additive Inhibition of human peripheral blood mononuclear cell-function by verapamil and cyclosporine." November, 1987.
82. Invited Speaker: Latrobe Area Hospital Medical Grand Rounds, Latrobe, PA. Hypertension update: "Prevention of End-Organ Damage." November, 1987.
83. Weir MR Presentation at the American Society of Nephrology 20th Annual Meeting. "Inhibition of verapamil and the activation and function of human peripheral blood mononuclear cells in additive with cyclosporine and may occur through calcium independent mechanisms." December 1987.
84. Visiting Professor: Parkland Memorial Hospital, Dallas, TX. Medical Research Conferences: "Subcellular effects of verapamil and cyclosporine on calcium metabolism in lymphocytes" and "A physiologic approach to the control of blood pressure from a nephrologist's standpoint." January, 1988.
85. Invited Speaker: Symposium preceding the American College of Cardiology. Topic: "Impact of high blood pressure on the kidney." Atlanta, Georgia. March, 1988.
86. Plenary Session Speech: International Interdisciplinary Conference on Hypertension in Blacks. Topic: "Implication of high blood pressure on renal function." Baltimore, MD. April, 1988.
87. Invited Speaker: Symposium on: "Newer aspects of cardiovascular therapy." Sponsored by The University of Massachusetts. "Renal aspects of antihypertensive therapy." Boston, MA. May, 1988.
88. Weir MR Presentation at the American Society of Transplant Physicians 7th Annual Meeting. "Acute effects of cyclosporine on blood pressure, renal hemodynamics and urine prostaglandin production in healthy humans." Chicago, IL. May, 1988.
89. Visiting Professor: Oregon Health Sciences University, Portland, OR. Medical Research Conferences: "Subcellular effects of verapamil and cyclosporine on calcium metabolism in lymphocytes" and "A physiologic approach to the control of blood pressure from a nephrologist's standpoint." June, 1988.
90. Weir MR Presentation at the American Society of Hypertension 3rd Annual Meeting. "Effect of the thromboxane synthetase inhibitor CGS 13080 on blood pressure, renal hemodynamics and prostaglandin production in hypertensive humans" and "Efficacy and safety of nilvadipine in hypertension." New York, N.Y. June, 1988.
91. Weir MR Research Lecture at the University of Mississippi Medical Center. "Impact of antihypertensive agents on renal hemodynamics: can they arrest the progression of renal disease?" July, 1988.
92. Weir MR Medical Grand Rounds: St. Joseph's Hospital, Yonkers, N.Y. "A physiologic approach to the control of blood pressure: can it offer target organ protection?" July, 1988.
93. Weir MR Medical Grand Rounds: Richmond V.A. Hospital, Richmond, Va. "Impact of antihypertensive therapy on target organ protection." August, 1988.
94. Weir MR Two presentations at the XII International Congress of the Transplantation Society in Sydney, Australia. "Additive inhibitory effect of cyclosporine and verapamil may occur through independent mechanisms which may be dependent or independent of the slow calcium channel" and "The acute effects of intravenous cyclosporine on renal function in healthy humans." August, 1988.
95. Weir MR Medical Grand Rounds: Maryland General Hospital, Baltimore, Maryland. "Evolving goals in the treatment of hypertension." September, 1988.
96. Weir MR Presentation at a symposium at the American Academy of Family Practice, New Orleans, LA. "Target organ protection: impact of antihypertensive therapy on the kidney." October, 1988.
97. Weir MR Medical Grand Rounds: Harrisburg Hospital, Harrisburg, PA. "Evolving goals in the treatment of hypertension with focus on target organ protection." October, 1988.
98. Weir MR Medical Grand Rounds: Bedford V.A. Hospital, Bedford, MA. "Evolving goals in the treatment of hypertension." October, 1988.
99. Weir MR Symposium: Sponsored by the Cleveland Clinic, Cleveland, OH. "Impact of antihypertensive therapy on the kidney: target organ protection." November, 1988.
100. Weir MR Presentation at the 61st American Heart Association Meeting, Washington, D.C. "Effect of verapamil on renal hemodynamics in normotensives." November, 1988.
101. Weir MR. Presentation at the 21st Annual Meeting of the American Society of Nephrology, San Antonio, Tx. "Mechanisms of additive inhibition of immunologic responses of cyclosporine and verapamil." December, 1988.
102. Weir MR Medical Grand Rounds: Bronx VA Hospital, Bronx, N.Y. "Physiology of blood pressure control: focus on target organ protection." January, 1989.
103. Weir MR Visiting Professor and Research Conferences: Miami VA Hospital and Jackson Memorial Hospital. "Impact of the effect of ACE inhibitors and calcium antagonists on target organ protection in the kidney."
104. Weir MR Research Conference: Albert Einstein Medical Center, Bronx, N.Y. "Physiology of blood pressure control: focus on target organ protection."
105. Weir MR Medical Grand Rounds: Oakland Naval Hospital, Oakland, CA. "Can we prevent target organ damage to the kidney." March, 1989.
106. Weir MR Medical Conference: Bethesda Naval Hospital, Bethesda, MD. "A physiologic approach to blood pressure control while maintaining organ perfusion." March, 1989.
107. Weir MR Medical Grand Rounds: Wilkes-Barre VA Hospital, Wilkes Barre, PA. "Magnesium deficiency: clinical implications." March, 1989.
108. Weir MR Medical Grand Rounds: St. Joseph's Hospital, Pontiac, MI. "Target organ damage in hypertension: can we prevent it?" March, 1989.
109. Medical Grand Rounds: Letterman Army Hospital, San Francisco, CA. "A physiologic approach to blood pressure control while maintaining organ perfusion," May, 1989.
110. Weir MR Presentation at the 4th Annual Meeting of the American Society of Hypertension. "Comparison of the efficacy of atenolol, captopril and verapamil SR in hypertensive blacks." New York, N.Y., May, 1989.
111. Weir MR Presentation at the 4th Annual Meeting of the American Society of Hypertension. "A multifactorial evaluation of the antihypertensive efficacy of the combination of diltiazem and hydrochlorothiazide." New York, N.Y., May, 1989.
112. Weir MR Presentation at the 8th Annual Meeting of the American Society of Transplant Physicians. "Mechanisms of additive inhibition of immunological responses by verapamil and cyclosporine." Chicago, IL., May, 1989.
113. Weir MR Presentation at the 8th Annual Meeting of the American Society of Transplant Physicians. "The acute effects of intravenous cremophor EL on blood pressure, renal hemodynamics and urine prostaglandin production of healthy humans." Chicago, IL., May, 1989.
114. Invited Speaker: Maryland Academy of Family Practice Annual Meeting: Ocean City, Maryland. "Physiologic Approach to blood pressure control while maintaining organ perfusion." May, 1989.
115. Weir MR Medical Grand Rounds: Washington Adventist Hospital, Washington, D.C. "A physiologic approach to blood pressure control while maintaining organ perfusion." June, 1989.
116. Invited Speaker: "Hypertension Symposium," "Race as a variable factor in the management of hypertension." Hilton Head, S.C., June, 1989.
117. Weir MR Medical Grand Rounds: National Rehabilitation Hospital, Washington, D.C. "Physiologic approach to blood pressure control while maintaining organ perfusion." June, 1989.
118. Invited Speaker: National Medical Association Annual Meeting, Orlando, FL. "Physiology of blood pressure control in black hypertensives; impact on renal protection." July, 1989.
119. Invited Speaker: Medical Grand Rounds, Sinai Hospital, Baltimore, MD: "The physiologic approach to blood pressure control while maintaining organ perfusion," September, 1989.
120. Invited Speaker: Satellite Symposium of the American Academy of Family Practice. "Physiology of blood pressure control: implication for renal protection," Los Angeles, CA, September 1989.
121. Invited Speaker: Medical Grand Rounds, Southern Maryland Hospital, LaPlata, MD: The physiology of blood pressure control." September, 1989.
122. Invited Speaker: Medical Grand Rounds, Cumberland Memorial Hospital: "The physiologic approach to blood pressure control while maintaining organ perfusion," Cumberland, MD 1989.
123. Invited Speaker: Renal Grand Rounds, Georgetown University: "The impact of blood pressure control on renal protection." October, 1989.
124. Invited Speaker: Medical Grand Rounds, Liberty Medical Center: "Impact of blood pressure control on renal function." October, 1989.
125. Invited Speaker: Renal Grand Rounds, Francis Scott Key Medical Center: "Impact of blood pressure control on renal function." November, 1989.
126. Visiting Professor: UCLA, Los Angeles, CA. UCLA Nephrology Society: "The use of calcium antagonists in organ transplantation," Medical Grand Rounds,
127. Sepulveda VA Hospital: "The physiologic approach to blood pressure control while maintaining organ perfusion," Nephrology Research Conference, Wadsworth VA Hospital: "Acid base and electrolyte disorders." November 1989.
128. Invited Speaker: Nephrology Grand Rounds, University of Louisville, Louisville, KY: "Implications of blood pressure control on renal function." November 1989.
129. Invited Speaker: Medical Grand Rounds, Monmouth Medical Center, Monmouth, N.J: "The physiologic approach to blood pressure control while maintaining organ perfusion." November 1989.
130. Weir MR Presentation at the 22nd Annual Meeting of the American Society of Nephrology, Washington, D.C: "Immunosuppressive properties of enisoprost and SC-45662 (5-lipoxygenase inhibitor). December 1989.
131. Weir MR Presentation at the 22nd Annual Meeting of the American Society of Nephrology, Washington D.C: "Tripterygium Wilfordii, a chinese herbal medicine with potent immunosuppressive properties." December 1989.
132. Invited Speaker: Medical Grand Rounds, Brooke Army Medical Center, San Antonio, Tx: "Impact of blood pressure control in renal function." December 1989.
133. Invited Speaker: Medical Grand Rounds, D.C., General Hospital, Washington, D.C.: "The physiologic approach to blood pressure control while maintaining organ perfusion." December 1989.
134. Invited Speaker: Cardiology Grand Rounds, Yale New Haven Medical Center, New Haven, CT: "The physiology of blood pressure control: impact on vascular disease." January, 1990.
135. Invited Speaker: Toronto General Hospital, Toronto, Canada: "Impact of blood pressure control on renal function." January 1990.
136. Invited Speaker: Nephrology Research Conference, Vanderbilt University, Nashville, TN: "Impact of calcium channel blockade and inhibition of prostaglandin synthesis on the activation and function of peripheral blood lymphocytes." January, 1990.
137. Invited Speaker: Nephrology Grand Rounds, Miami VA Hospital, Miami, Florida: "Calcium channel
138. blockers in organ transplantation: Implications for therapy." February, 1990
139. Invited Speaker: Medical Grand Rounds, Flushing Hospital, Flushing, N.Y.: "Hypertension in the elderly: an important concern," March, 1990.
140. Invited Speaker: Interfaith Medical Center, Brooklyn N.Y: "Hypertension in the elderly."
141. March, 1990.
142. Invited Speaker: Satellite Symposium preceding the American College of Cardiology: "The impact of calcium blockade on lymphocyte activation and function. March, 1990.
143. Invited Speaker: Research Grand Rounds, University of Indiana, Indianapolis, Indiana: "Impact of blood pressure control on renal function." April, 1990.
144. Invited Speaker: Annual Meeting of the North Carolina Academy of Rheumatology, Raleigh, N.C: "Musculoskeletal symptomatology in dialysis and transplant patients." April, 1990.
145. Invited Speaker: Medical Grand Rounds, University of Tennessee, Knoxville, TN. "The physiologic approach to blood pressure control while maintaining organ perfusion." April, 1990.
146. Invited Speaker: Medical Grand Rounds, St. Joseph's Hospital, Towson, MD: "The implications of renal prostanoid synthesis on renal function." April, 1990.
147. Invited Speaker: Medical Grand Rounds, Good Samaritan Hospital, Lebanon, PA, "The physiology of blood pressure control," April, 1990.
148. Invited Speaker, plenary program, International Society of Hypertension in Blacks Annual Meeting, Long Beach, CA. "Quality of Life, the cornerstone of antihypertensive management," May 1990.
149. Weir MR Presentation at the 5th Annual Meeting of the American Society of Hypertension. "Favorable effects of nicardipine on the quality of life during hypertension treatment," May 1990.
150. Invited Speaker: Medical Grand Rounds, University of Arkansas Medical Center, Little Rock, AR. "Antihypertensive therapy and the kidney: Is renal protection possible," May 1990.
151. Invited Speaker: Medical Grand Rounds, Henry Ford Hospital, Detroit, MI. "Prostaglandins and the kidney," May 1990.
152. Invited Speaker, plenary program, American Society of Transplant Physicians Annual Meeting, Chicago, IL. "The use of calcium antagonists in Organ Transplantation," May 1990.
153. Weir MR Presentation at the 9th Annual Meeting of the American Society of Transplant Physicians. "Verapamil has immunosuppressive properties unrelated to its ability to block slow calcium channel," June 1990.
154. Weir MR Presentation at the 9th Annual Meeting of the American Society of Transplant Physicians. "Immunosuppressive properties of enisoprost and SC45662 (5-Lipoxygenase Inhibitor)," June 1990.
155. Medical Grand Rounds, Philadelphia Naval Hospital, Philadelphia, PA. "Prostaglandins and the kidney," July 1990.
156. Medical Grand Rounds, St. Joseph's Hospital, Atlanta, GA. "Prostaglandins and the kidney, August, 1990.
157. Invited Speaker: Medical Grand Rounds, York Hospital, PA. "Prostaglandins and the kidney," August, 1990.
158. Invited Speaker, Plenary Session, 9th Annual Meeting of the American Society of Transplant Physicians, San Francisco. "Immunosuppressive properties of enisoprost and SC45662 (5-Lipoxygenase Inhibitor)," August, 1990
159. Invited Speaker: Transplantation Grand Rounds/Research Conference University of Wisconsin Medical Center, Madison, WI. "Newer immunosuppressive agents." August, 1990.
160. Invited Speaker: Medical Symposium, Delaware County Medical Society, Philadelphia, PA. "Antihypertensive therapy and the kidney," October, 1990.
161. Invited Speaker: Research Conference, East Carolina University Medical Center, Greenville, N.C. "Newer immunosuppressive agents," October, 1990.
162. Invited Speaker: Medical Grand Rounds, St. John's Hospital, Detroit, MI. "A physiologic approach to blood pressure control," October, 1990.
163. Invited Speaker: Medical Grand Rounds, Harford Memorial Hospital, Havre de Grace, MD. "Antihypertensive agents and the kidney," October, 1990.
164. Invited Speaker: American College of Clinical Pharmacy Symposium, Atlanta, GA. "A physiologic approach to blood pressure control," November, 1990.
165. Invited Speaker, Medical Grand Rounds & Teaching Sessions, The Reading Hospital, Reading, PA. "Prostaglandins and the kidney," November, 1990.
166. Medical Grand Rounds, Vassar Brothers Hospital, Poughkeepsie, N.Y. "The physiology of blood pressure control," December, 1990.
167. Invited Speaker, American Society of Nephrology Satellite Symposium, Washington, D.C. "Hypertensive renal injury in blacks: Implications for therapy," December, 1990.
168. Weir MR. Presentation at the American Society of Nephrology Symposium, Washington, D.C. "The antiproliferative effect of verapamil on human peripheral blood lymphocytes is independent of calcium channel inhibitors, December, 1990.
169. Weir MR. Presentation at the American Society of Nephrology Symposium, Washington, D.C. "Suppression of urinary thromboxane does not improve renal function in cyclosporine-treated renal transplant recipients," December, 1990.
170. Invited Speaker, Research Conference and Visiting Professor, Miami VAH, Miami, FL. "Prostaglandins and the kidney, December, 1990.
171. Invited Speaker: Medical Grand Rounds, Univ of Illinois, Chicago, IL. "The physiology of blood pressure control: implications for target organ protection," May, 1991.
172. Invited Speaker: America Heart Assoc Forum. Chicago, IL. "The genesis of cyclosporine-mediated hypertension." May, 1991.
173. Weir MR. Presentation at the 10th Annual Meeting of the American Society of Transplant Physicians, Chicago, IL. "The antiproliferative effect of verapamil on human peripheral blood mononuclear cells in independent of calcium channel inhibition." May, 1991.
174. Moderator & Presenter, Postgraduate Course of the American Society of Transplant Surgeons, Chicago, IL. "The emerging role of calcium antagonists in Organ Transplantation," May, 1991.
175. Invited Speaker: Medical Grand Rounds, Harper Hospital-Wayne State Univ., Detroit, MI. The immunosuppressive effects of calcium antagonists in organ transplantation," January, 1991.
176. Invited Speaker: UCSD Course: Advanced nephrology for the consultant. "Newer aspects of inductive immunotherapy "and" cyclosporine and the kidney," February, 1991.
177. Invited Speaker: Florida Academy of Family Physicians Orlando, FL. "Renal considerations with antihypertensive therapy," February, 1991.
178. Invited Speaker: American College of Cardiology Satellite Symposium, Kona HI. "Physiologic approach to blood pressure control: Implications for target organ protection," February, 1991.
179. Invited Speaker: Medical Grand Rounds, Portsmouth Naval Hospital, Portsmouth, VA. "Hypertension and the Kidney," February, 1991
180. Invited Speaker: Medical Grand Rounds: The Hoag Hospital, Newport Beach, CA. "The physiology of blood pressure control: implications for target organ protection," March, 1991.
181. Invited Speaker: UCSD symposium on "Recent advances in geriatric medicine." Presentation on: "Diabetic hypertension: a special problem," March, 1991.
182. Invited Speaker: Medical Grand Rounds, Division of Family Medicine, EVMS, Norfolk, VA. "Demographic issues in blood pressure management," March, 1991.
183. Invited Speaker: Medical Grand Rounds, Andrews AFB Hospital." Secondary causes of hypertension: Focus on the kidney," March, 1991.
184. Invited Speaker: Jefferson Medical College Symposium on Diabetes, Philadelphia, PA. "Hypertension and Diabetes: Physiologic Approaches," March, 1991.
185. Invited Speaker/Visiting Professor: Southern Illinois School of Medicine, Springfield, IL. Medical Grand Rounds, "The physiology of blood pressure control: Implications for target organ protection," April, 1991.
186. Invited Speaker: AHA Symposium on "Cardiovascular Diseases: Drug therapy," Baltimore, MD presentations on: "The Blockers" and "Therapeutic approaches to blood pressure control in minorities," May, 1991.
187. Invited Speaker: American Society of Gerontology, Chicago, IL. "Hypertension and the kidney," May, 1991.
188. Invited Speaker: Renal Grand Rounds at Francis Scott Key Medical Center, Baltimore, MD. "Calcium Antagonists in Organ Transplantation," May, 1991.
189. Invited Speaker: Transplant Grand Rounds at Washington Hospital Center, Washington, D.C. "In vitro methods for monitoring immunosuppression in organ transplant recipients," May 1991.
190. Invited Speaker: AHA Forum, Univ. of Chicago, Chicago IL. "Cyclosporine and the kidney," May 1991.
191. Weir MR: Presentation at the American Society of Transplant Physicians, Chicago, IL. "The antiproliferative effect of verapamil on human peripheral blood mononuclear cells is independent of calcium channel inhibition." May 1991.
192. Chairman of Symposium. 1991 American Society of Transplant Surgeons, Chicago, IL. "The clinical use of calcium antagonists in renal transplant recipients." May, 1991.
193. Invited Speaker: Medical Grand Rounds, Moses-Cone Community Hospital, Greensboro, NC. "Diabetes and Hypertension: Accelerated risk for renal injury." July, 1991.
194. Invited Speaker: NC Academy of Family Practice, Atlantic Beach, NC. "Acute Renal Failure." July, 1991.
195. Invited Speaker: Medical Grand Rounds, Medical Center of Delaware, Christiana, DE. "The physiology of blood pressure control: Implications for target organ protection." July 1991.
196. Invited Speaker: National Medical Association Meeting, Indianapolis, IN. "Hypertension and Renal Injury in Blacks," and "Update on Clinical Immunosuppression in Organ Transplantation." July 1991.
197. Invited Speaker: Illinois Academy of Family Practice, Chicago, IL. "Update in Organ Transplantation," August, 1991.
198. Invited Speaker: Medical Grand Rounds, Union Memorial Hospital, Baltimore, MD. "The Physiology of Blood Pressure Control: Implications for Target Organ Protection." August, 1991.
199. Invited Speaker: Medical Grand Rounds, Home Medical Center, Erie, PA. "The Physiology of Blood Pressure Control: Implications for Target Organ Protection." August, 1991.
200. Invited Speaker: Univ of Connecticut Nephrology Grand Rounds, St Francis Hospital, Hartford, CT. "Hypertensive Nephropathy: Is it preventable?" September, 1991.
201. Invited Speaker: Research Conference. Baystate Medical Center, Springfield, MA. "Newer approaches for inductive immunosuppression." September, 1991.
202. Invited Speaker: Medical Grand Rounds, Harlem Hospital Center, New York, NY. "Hypertension and Kidney Disease in Blacks," October, 1991.
203. Invited Speaker: Medical Grand Rounds, St. Agnes Hospital, Baltimore, MD. "The physiology of blood pressure control: Implications for Target Organ Protection." October, 1991.
204. Invited Speaker: Medical Grand Rounds, E. Orange VA Medical Center, Orange, NJ. "The physiology of blood pressure control: Implications for Target Organ Protection." October, 1991.
205. Weir MR. Presentation at the NIDDK Conference: Kidney Disease and Hypertension in Blacks. "Renal hemodynamic and antihypertensive effects on isradipine of salt-insensitive hypertensive patients on high and low sodium diets." November, 1991.
206. Invited Speaker: Medical Grand Rounds, East Carolina Univ, Greenville, NC. "The physiology of blood pressure control: Implications for target organ protection." December 1991.
207. Invited Speaker: Medical Grand Rounds, Oak Knoll Navel Hospital, Oakland CA. "The physiology of blood pressure control: Implications for renal protection." January, 1992.
208. Invited Speaker: Medical Grand Rounds, Livermore VAH, Livermore, CA. "The physiology of blood pressure control: Implications for renal protection." January 1992.
209. Invited Speaker: Medical Grand Rounds, Liberty Medical Center, Baltimore MD. "Diabetes and Hypertension: Accelerated risk for renal injury." January, 1992.
210. Invited Speaker: Medical Grand Rounds, Harford Memorial Hospital, Havre de Grace, MD. "The physiology of blood pressure control: Implications for target organ protection. February, 1992.
211. Invited Speaker: Medical Grand Rounds, Martin Luther King Hospital, Los Angeles, CA. "Race, Diabetes, and Hypertension. "Accelerated risk for renal injury." February, 1992.
212. Invited Speaker: Rheumatology Research Conference, Northwestern University Hospital, Chicago, IL "Non-steroidal Renal Syndromes." March, 1992.
213. Invited Speaker: Florida Academy of Family Practice Annual Meeting,
214. Perdicho Beach, FL. "Non-steroidal renal syndromes. " March, 1992.
215. Invited Speaker: Medical Grand Rounds, Sacred Heart Hospital, Spokane, WA. "The physiology of blood pressure control: Implications for target organ protection." March, 1992.
216. Invited Speaker: Nephrology Conference, Thomas Jefferson University Hospital, Philadelphia, PA. "The physiology of blood pressure control: implications for renal protection." March, 1992.
217. Invited Speaker: Research Conference, University of South Florida, Tampa, FL. "Ion flux and lymphocyte activation." April, 1992.
218. Weir MR. Presentation at the 5th Annual Meeting of American Society of Hypertension, New York, NY. "Effects of salt and isradipine on platelet Ca++ in salt sensitive and insensitive hypertensive patients." May, 1992.
219. Invited Speaker: Satellite Symposium of the 5th Annual Meeting of the American Society of Hypertension, New York, NY. "Is reducing proteinuria an important goal in the hypertensive diabetic?" May, 1992.
220. Invited Speaker: Medical Grand Rounds, University of New Mexico, Albuquerque, NM. "The physiology of blood pressure control: Implications for target organ protection." May 1992.
221. Invited Speaker: Nephrology Research Conference, University of Virginia, Charlottesville, VA. "Diabetes and Hypertension: Accelerated risk for renal injury." May 1992.
222. Weir MR. Presentation at the 11th Annual Meeting of the American Society of Transplant Physicians, Chicago, IL. "Mechanisms responsible for inhibition of lymphocyte activation by agents which block membrane calcium on potassium channels." May, 1992.
223. Invited Speaker: Canadian Consensus Conference on Renal/Endocrine Medical Problems, "Diabetes and Hypertension: Accelerated risk for Renal Injury." Calgary, Alberta. May, 1992.
224. Invited Speaker: Medical Grand Rounds, York Hospital, York, PA. "Non-steroidal renal syndromes." June 1992.
225. Invited Speaker: Satellite Symposium at National Medical Association Meeting, San Francisco, CA. "Influence of Race on the risk for hypertensive renal injury." August 1992.
226. Weir MR. Mechanisms responsible for inhibition of lymphocyte activation by agents which block membrane calcium or potassium channels. Presentation at International Congress of the Transplantation Society, Paris, France. August, 1992.
227. Invited Speaker: Medical Grand Rounds, Frederick Memorial Hospital, Frederick, MD "Hypertension and Diabetes: Accelerated risk for renal injury." August, 1992.
228. Invited Speaker: Geriatrics Research Conference and Department of Internal Medicine Symposium on "Health Issues in the Elderly," University of Iowa Hospital and Clinics, Iowa City, IA. "Influence of Aging and Hypertension on Renal Function in the elderly." September, 1992.
229. Invited Speaker: Kansas University Nephrology Society: "Update in Newer Therapeutic Modalities in Organ Transplantation." October. 1992.
230. Invited Speaker: American Dietetic Association National Meeting, Washington, DC. Influence of Non-pharmacologic/Pharmacologic interventions of the rate of progression of renal disease. October, 1992.
231. Invited Speaker: Medical Grand Rounds, Southern Maryland Medical Center, Clinton, MD. "The physiology of blood pressure control: Implications for target organ protection." November, 1992.Invited Session Chairman/Speaker at the National Kidney Foundation Annual Meeting, Baltimore, MD. Session: Special Considerations in Antihypertensive Therapy. "Hypertensive Nephropathy: Will a more physiologic approach to blood pressure control reduce the risk for renal injury?" November, 1992.
232. Invited Speaker: Grand Rounds, Beth Israel Medical Center, New York, NY. "Hypertensive Renal Injury: Can it be prevented?" January 1993.
233. Panelist, Lifetime Medical Television. "A review of JNC V." January, 1993.
234. Invited Speaker: Research Conference, University of Massachusetts, Worcester, MA." Calcium antagonists in organ transplantation." January 1993.
235. Invited Speaker: Research Conference, Wayne State University School of Medicine. "Importance of ion flux on lymphocyte activation." March 1993.
236. Invited Speaker: Grand Rounds, Roosevelt Hospital, New York, NY. "The physiology of blood pressure control." March, 1993.
237. Invited guest speaker on Television: "Health Today" for Howard County Community College. "Life style adjustments important for blood pressure control." April, 1993.
238. Invited Speaker: Grand Rounds, Methodist Hospital, Indianapolis, IN. "Prevention of target injury." April, 1993.
239. Visiting Professor, University of Texas Medical School, Houston, TX. "Research Conference: "Importance of ion flux on lymphocyte activation." May, 1993.
240. Visiting Professor, Baylor University College of Medicine, Houston, TX. Grand Rounds: "Hypertensive renal injury, can it be prevented?" May, 1993.
241. Invited Speaker: Grand Rounds, Washington VA Medical Center, Washington, D.C.: "Physiology of blood pressure control," June 1993.
242. Weir MR, Gomolka D, Handwerger BS. "Inhibition of lymphocyte activation by drugs that block calcium and potassium channels. Further insight into mechanisms of action." American Society of Transplant Physicians Abstract Book 1993; 12:311. Presented May, 1993
243. Keay S, Baldwin B, Weir MR. "Inhibition of CMV replication in vitro by the immunosuppressive agents Cyclosporine A, FK-506, and RS-61443." American Society of Transplant Physicians Abstract Book 1993;12:238. Presented May, 1993.
244. Invited Speaker: Renal Grand Rounds, Robert Wood Johnson Medical School, New Brunswick, NJ. "Update on Organ Transplantation," September 1993.
245. Invited Speaker: Renal Grand Rounds, Bowman-Gray School of Medicine, Winston Salem, NC. Progression of Renal Disease," October 1993.
246. Invited Speaker: Renal Grand Rounds, Duke University Medical Center, Durham, N.C. "Calcium Antagonists in Organ Transplantation," October 1993.
247. Invited Speaker: Renal Grand Rounds, Medical College of Virginia, Richmond, VA. "Calcium Antagonists in Organ Transplantation," November 1993.
248. Invited Speaker: Satellite symposium at the American Heart Association, Atlanta, GA. "Calcium-independent Antiproliferative effects of Calcium Antagonists," November 1993.
249. Invited Speaker: Research Conference at University of Alabama, Birmingham AL. "Calcium-independent antiproliferative effects of calcium antagonists," November 1993.
250. Invited Speaker: Plenary Session at National Kidney Foundation Annual Meeting, Boston, MA. "Hypertensive Nephropathy in African-Americans," November 1993.
251. Invited Speaker: Plenary Session at American Society of Nephrology Annual Meeting, Boston, MA.

"Delayed Allograft Function," November 1993.

1. Invited Speaker: American Society of Nephrology Clinical Program. "Hypertensive Nephropathy," November 1993.
2. Weir MR, Houston MC, Grey JM. Effects of NSAIDS on blood pressure controlled by verapamil. 26th Annual Meeting of the American Society of Nephrology, Boston MA.
3. Visiting Professor: Hahnemann University, Philadelphia, PA. "Renal protection: Where do ACE inhibitors and calcium channel blockers fit in?" January 1994.
4. Visiting Professor: University of South Carolina, Columbia, SC. "Influence of dietary sodium and insulin resistance on the risk for hypertensive renal injury." April 1994.
5. Renal Grand Rounds: George Washington University Hospital, Washington, D.C. "Influence of dietary sodium and insulin resistance on the risk for hypertensive renal injury." May 1994.
6. Weir MR, Hall PS, Behrens MT. Greater Antihypertensive response to the calcium antagonist isradipine in salt-sensitive vs. salt-resistant hypertensives. Am Soc Hypertens (Presented May 1994)
7. Weir MR, Behrens MT. Sodium sensitivity, independent of race, predicts higher filtration fraction and microalbuminuria in hypertensives on higher sodium intake. Am Soc Hypertens (Presented May 1994)
8. Weir MR. A pilot study to assess the influence of isradipine therapy on proteinuria in hypertensive patients with Type II diabetes. Am Soc Hypertens (Presented May 1994)
9. Invited Speaker: Symposium at American Society of Hypertension Annual Meeting. "Newer approaches for antihypertensive therapy." New York, NY, May 1994.
10. Invited Speaker: Association of Black Cardiologists Meeting. "Effects of angiotensin II on hypertensive vascular injury." Orlando, FL, July 1994.
11. Invited Speaker: National Medical Association Annual Meeting. "Influence of dietary sodium and insulin resistance on the risk for hypertensive renal injury in African-Americans." Orlando, FL, July 1994.
12. Invited Speaker: Southeastern Dialysis and Transplantation Association Annual Meeting. "Salutory influences of calcium channel blockers in the cyclosporine-treated organ transplant recipients." Memphis, TN, August 1994.
13. Invited Speaker: Nephrology Grand Rounds at the University of Miami Medical Center. "Influence of dietary salt and insulin resistance on the risk for hypertension and injury. February, 1995.
14. Invited Speaker: Nephrology Grand Rounds at State University of New York.
15. Invited Speaker: "Influence of dietary salt and insulin resistance on the risk for hypertension and injury." Syracuse, NY, April 1995.
16. Walker JA, Klassen DK, Hoehn-Saric EW, Hooper FJ, Schweitzer EJ, Johnson LB, Bartlett ST, Weir MR. Acute Pancreas allograft rejection after the first year: Predisposing factors". Am Soc Transplant Physicians. (Presented May 1995).
17. Weir MR, Saunders E, and the Tandolapril Multicenter Study Group. Differing mechanisms of action of angiotensin converting enzyme inhibition in black and white hypertensives. American Society of Hypertension (Presented May 1995).
18. Weir MR, Prisant LM, Papadimitriou, Weber MA, Adegbile IA, Alemayehu D, Lefkowitz MP. Correlation of prior antihypertensive therapy current therapy (amlodipine, bisoprolol/HCTZ, enalapril), adverse events and blood pressure reduction with changes in quality of life. American Society of Hypertension (Presented May 1995).
19. Weir MR, Dengel DR, Behrens MT, Goldberg AP. Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. (Presented May 1995).
20. Invited speaker: Southern Medical Association on "Influence of dietary salt and insulin resistance on the risk for hypotensive renal injury. Orlando, FL, November 1995.
21. Medical Grand Rounds. Diabetic Nephropathy, North Shore Hospital
22. National Kidney Foundation Symposium at Annual Meeting. “Hypertension in African Americans” 1996
23. Grand Rounds. “Medical Complication in Renal Transplant Recipients” Howard University Hospital., 1996.
24. University of Michigan Visiting Professor - Research Conference, Medical Grand Rounds. “Hypertension in African Americans”, 1996
25. Visiting Professor, Bowman-Gray School of Medicine. Research Conference, Medical Grand Rounds. “Implications of Salt Sensitivity and Cardiovascular Risk, 1996
26. National Kidney Foundation Annual Meeting: Symposium Chairman/Speaker. “Hypertension and the Kidney”., 1996
27. University Program: South African Cardiology Society. Capetown, Johannesburg, Multiple lectures on Hypertensive Renal Injury in all major teaching hospitals. 1997
28. Turkish Nephrology and Hypertension Society. Instanbul, Turkey - “Angiotensin Receptor Blockers and the Kidney”. 1997
29. Duke University Medical Center. Medical Grand Rounds/Research Conference. Hypertension, Salt Sensitivity and Renal Injury.” 1997
30. Plenary Speaker International Congress in ACE inhibition, Hong Kong. Is it the drug or blood pressure reduction which results in renal protection?” (Presented 1997).
31. Society of Hypertension Plenary Program - Annual Meeting: Therapeutic approaches for patients with renal disease. New York. 1997
32. Albert Einstein College of Medicine Research Conference: Salt Sensitivity and Renal Injury, 1997.
33. Sattelite Symposium of American Society of Nephrology Meeting in San Antonio, Chairman/Speaker. How low should yo go and with which drugs?” 1997
34. University of Virginia Transplant Research Conference “New treatments for chronic allograft nephropathy.” 1998
35. University of Minnesota Transplant Conference. “Chronic Allograft Nephropathy: New Insight into an old problem”. 1998
36. Maryland Academy of Family Practice Annual Meeting. “Prevention of Hypertensive Cardiovascular Disease”. 1998
37. International Congress of the Transplant Society, Montreal, Canada. “New insight into the treatment of chronic allograft nephropathy”. 1998
38. European Society of Cardiology, Vienna, Austria. “How to prevent diabetic nephropathy”. 1998
39. Visiting Professor, Massachusetts General Hospital. Two conferences: Transplant Clinical Conference and Research Conference. Both on Chronic deterioration of renal disease in transplant patients. 1998
40. New England Deaconess Hospital Surgical Grand Rounds: Chronic Allograft Nephropathy. 1998
41. Medical Grand Rounds, Ohio State University. Hypertensive Renal Disease in African Americans. 1998
42. Medical Grand Rounds. National Naval Medical Center. “Salt Sensitivity and Progressive Renal Injury”. 1999
43. Visiting Professor. Shanghai University, China - Chronic Allograft Nephropathy: New Strategies. 1999
44. Plenary Symposium. Annual Meeting American Society of Hypertension. “Is it the drug or blood pressure reduction which is important for renal protection. 1999
45. Visiting Professor. Dalhousie University, Nova Scotia. “New strategies in chronic allograft nephropathy”. 1999
46. Visiting Professor Western University, London, England. “New strategies in chronic allograft nephropathy”. 1999
47. University of Alabama, Birmingham Research Conference. “Hypertension and the kidney”. 1999
48. Satellite Symposium American Society of Nephropathy Annual Meeting. “New strategies in diabetic nephropathy, Miami, FL 1999.
49. Endocrine Grand Rounds. George Washington University Hospital. Washington, D.C., “Diabetic Nephropathy”. 1999
50. Plenary Speaker. Southeast Asia Endocrine Society. Bangkok, Thailand. Update in diabetic nephropathy. 1999
51. Hahnemann University Medical Grand Rounds. “Hypertension and the kidney” 1999

Stopped listing in 1999 due to space constraints.